Chimeric antigen receptors and use methods thereof

Genetically engineered lymphocytes with enhanced chimeric antigen receptors and antibody secretion capabilities address the limitations of existing CARs by effectively targeting tumor antigens and overcoming immune suppression, improving cancer treatment outcomes.

JP2024163140AActive Publication Date: 2024-11-21DANA FARBER CANCER INSTITUTE INC
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2024147204
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2015-11-06
Filing Date
2024-08-29
Publication Date
2024-11-21
Estimated Expiration
2035-12-21

AI Technical Summary

Technical Problem

Existing cancer treatments using chimeric antigen receptors (CARs) face challenges in effectively targeting tumor-associated antigens, overcoming immunosuppressive microenvironments, and inducing sustained activation of cytotoxic T cells, leading to limited efficacy against solid tumors.

Method used

Genetically engineered lymphocytes, such as T cells, are equipped with chimeric antigen receptors (CARs) that include extracellular ligand binding domains, transmembrane domains, and intracellular signaling domains, optionally with costimulatory molecules, to enhance tumor-specific targeting and activation, and are engineered to secrete antibodies like anti-PD-L1 to overcome immune checkpoints.

Benefits of technology

The engineered lymphocytes effectively target tumor-associated antigens, evade immune escape mechanisms, and enhance cytotoxicity, leading to improved antitumor responses and reduced T cell exhaustion, thereby increasing treatment efficacy against solid tumors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024163140000023
    Figure 2024163140000023
  • Figure 2024163140000024
    Figure 2024163140000024
  • Figure 2024163140000025
    Figure 2024163140000025
Patent Text Reader

Abstract

To provide chimeric antibodies, nucleic acids encoding the same, and cells that express the chimeric antigen receptors.SOLUTION: The invention provides a chimeric antigen receptor comprising an intracellular signaling domain, a transmembrane domain, and an extracellular domain, where the intracellular signaling domain comprises a CD3 zeta chain, the transmembrane domain comprises CD28, the chimeric antigen receptor further comprises one or more additional co-stimulatory molecule of CD28, 4-1BB, ICOS or OX40 positioned between the transmembrane domain and the intracellular signaling domain, and the extracellular domain comprises an antibody such as a scFV that is specific to BCMA, CD138, CCR4, PD-1, PDL-1, D-L2, CXCR4, GITR, SARS virus, flavivirus, MERS virus, influenza virus or CAIX. The invention also provides a nucleic acid that encodes the chimeric antigen receptor and a cell that expresses the chimeric antigen receptor.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Related Applications This application claims priority to and benefit of U.S. Provisional Application No. 62 / 094,625, filed December 19, 2014, and U.S. Provisional Application No. 62 / 252,083, filed November 6, 2015, the contents of each of which are incorporated by reference in their entirety.

[0002] INCORPORATION-BY-REFERENCE TO SEQUENCE LISTING The contents of the text file entitled "Omnibus Sequence Listing for filing with DFCI-102_001WO_ST25," created on December 21, 2015, are incorporated herein by reference in their entirety.

[0003] FIELD OF THE INVENTION The present invention relates generally to chimeric antigen receptor cells for the treatment of cancer and other disorders and methods of using same for the treatment of cancer and other disorders.

[0004] Government Interests This invention was made with government support under [] awarded by []. The government has certain rights in this invention. [Background technology]

[0005] Background of the Invention T lymphocytes recognize individual antigens through the interaction of short peptides presented by major histocompatibility complex (MHC) class I or II molecules with the T cell receptor (TCR). For initial activation and clonal expansion, naive T cells are dependent on professional antigen-presenting cells (APCs), which provide additional costimulatory signals. Activation of the TCR in the absence of costimulation can result in unresponsiveness and clonal anergy. To circumvent immune responses, various approaches have been developed to induce cytotoxic effector cells with specific recognition specificities. Chimeric antigen receptors (CARs) have been constructed, consisting of binding domains derived from natural ligands or antibodies specific for cell surface components of the TCR-bound CD3 complex. Upon antigen binding, such CARs link to the effector cell's endogenous signaling pathways, generating activation signals similar to those initiated by the TCR complex. Since the first report of chimeric antigen receptors, this concept has been steadily refined, and the molecular design of chimeric receptors has been optimized. Advances in recombinant antibody technology have also aided in the creation of chimeric antigen receptors that target a wide variety of antigens on the surface of cancer cells and cells infected with the human immunodeficiency virus (HIV). Summary of the Invention

[0006] Summary of the Invention In various aspects, the present invention provides a chimeric antigen receptor (CAR) having an intracellular signaling domain, a transmembrane domain, and an extracellular domain.

[0007] In some aspects, the transmembrane domain further comprises a stalk region located between the extracellular domain and the transmembrane domain. The transmembrane domain comprises CD28. In another aspect, the CAR further comprises one or more additional costimulatory molecules located between the transmembrane domain and the intracellular signaling domain. The costimulatory molecule is CD28, 4-1BB, ICOS, or OX40. The intracellular signaling domain is, for example, the CD3 zeta chain. The extracellular domain is an antibody, for example, Fab or scFV. Preferably, the antibody is specific to BCMA, CA-9, CD138, CCR4, or influenza virus.

[0008] The present invention also encompasses nucleic acids encoding the CAR of the present invention, which further comprise a nucleic acid encoding a polypeptide located after the intracellular signaling domain. The polypeptide is an antibody, such as an scFV. Preferably, the antibody is specific to CCR4, PD-1, PDL-1, PD-L2, CXCR4, or GITR. The present invention also encompasses vectors containing the nucleic acids according to the present invention and cells containing the vectors.

[0009] In yet a further aspect, the present invention provides a genetically engineered cell that expresses and retains the chimeric antigen receptor of the present invention on its cell surface membrane. The cell is a T cell or an NK cell. The T cell is a CD4 + or CD8 + The cells are CD4 + cells and CD8 cells + The cells are further engineered to express and secrete a polypeptide, such as an antibody.

[0010] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which this invention belongs. In carrying out the present invention, methods and materials similar or equivalent to those described herein can be used, but suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are expressly incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples described herein are illustrative only and are not intended to be limiting.

[0011] [The present invention 1001] Chimeric antigen receptors (CARs) contain an intracellular signaling domain, a transmembrane domain, and an extracellular domain. [The present invention 1002] 1001. The CAR of the present invention, wherein the transmembrane domain further comprises a stalk region located between the extracellular domain and the transmembrane domain. [The present invention 1003] 1001. A CAR of the present invention, wherein the transmembrane domain comprises CD28. [The present invention 1004] The CAR of the present invention 1001, further comprising one or more additional costimulatory molecules located between the transmembrane domain and the intracellular signaling domain. [The present invention 1005] 1004. A CAR of the present invention, wherein the costimulatory molecule is CD28, 4-1BB, ICOS, or OX40. [The present invention 1006] 1001. A CAR of the present invention, wherein the intracellular signaling domain comprises a CD3 zeta chain. [The present invention 1007] 1001. A CAR of the present invention, wherein the extracellular domain is an antibody. [The present invention 1008] 1007. A CAR of the present invention, wherein the antibody is a Fab or scFV. [The present invention 1009] 1007. The CAR of the present invention, wherein the antibody is specific to BCMA, CD138, CCR4, PD-1, PDL-1, PD-L2, CXCR4, GITR, SARS virus, flavivirus, MERS virus, influenza virus, or CAIX. [The present invention 1010] A nucleic acid encoding any of the CARs of the present invention, further comprising a nucleic acid encoding a polypeptide located after the intracellular signaling domain. [The present invention 1011] The nucleic acid of the invention 1010, wherein the polypeptide is an antibody. [The present invention 1012] 1011. The nucleic acid of the invention, wherein the antibody is an scFV. [The present invention 1013] 1012. The nucleic acid of the invention, wherein the antibody is specific for BCMA, CD138, CCR4, PD-1, PDL-1, PD-L2, CXCR4, GITR, SARS virus, flavivirus, MERS virus, influenza virus, or CAIX. [The present invention 1014] A vector comprising any one of the nucleic acids of the present inventions 1011 to 1013. [The present invention 1015] A cell comprising the vector of the present invention. [The present invention 1016] A genetically engineered cell that expresses any one of the chimeric antigen receptors of the present inventions 1001 to 1009 and retains it on the cell surface membrane. [The present invention 1017] The genetically engineered cell of the present invention 1016, which is a T cell or an NK cell. [The present invention 1018] T cells are CD4 + or CD8 + The genetically engineered cell of the present invention. [The present invention 1019] CD4 + cells and CD8 cells + The genetically engineered cells of the present invention, comprising a mixed population of 1018 cells. [The present invention 1020] The cell of the invention 1016, further engineered to express and secrete a polypeptide. [The present invention 1021] 1020. The cell of the present invention, wherein the expressed and secreted polypeptide is anti-PDL-1. Other features and advantages of the present invention will be apparent from and are encompassed by the following detailed description and the appended claims. [Brief explanation of the drawings]

[0012] [Figure 1] ADCC of CAIX-specific Ab. 1 μg / ml of CAIX-specific scFv-Fc minibody was added to target tumor cells in the presence of human PBMC (E:T 25:1). Similar results were obtained in two experiments. Irrelevant anti-SARS scFv-Fc (11A) and anti-CCR4 scFv-Fc (48) minibodies were used as negative controls. A, CAIX+ sk-rc-09 cells; B, CAIX+ sk-rc-52 cells; C, CAIX- sk-rc59 cells. [Figure 2A]Construction and expression of CAIX-specific CARs. A. Construction: The first-generation CAR, scFv-CD8-TCRζ (CD8 CAR), consists of a specific anti-CAIX scFv linked to a truncated human CD8α extracellular domain, hinge (H), transmembrane (TM), and intracellular regions, and then to the signaling domain of human TCRζ. The second-generation CAR, scFv-CD28-TCRζ (CD28 CAR), contains an anti-CAIX scFv fused to the human CD28 extracellular, TM, and intracellular signaling domains, and fused to TCRζ. Both anti-CAIX CARs were cloned into a bicistronic self-inactivating (SIN) lentiviral vector, expression of which is driven by the internal eF1-α promoter. The CAR control construct contains an irrelevant anti-HIV CCR5-specific A8 scFv substitution. B. FACS analysis: The reporter gene ZsGreen was used to quantify the transduction efficiency of primary T cells with the lentiviral CAR constructs. Additionally, anti-CAIX scFv CARs were stained with CAIX-Fc fusion protein, and the C9 tag (TETSQV APA) was stained with 1D4 antibody. Untransduced activated T cells, LAKs alone, served as unstained cell controls (i) or stained with secondary antibodies (ii. PE-anti-human IgG and iii. APC-anti-mouse IgG). C. Western blot: Monomeric / dimeric structures of anti-CAIX (clone G36) CD28 and anti-CCR5 (clone A8) CD28 CARs and the molecular size of the endogenous TCR ζ chain of untransduced T cells were shown. [Figure 2B] See legend to Figure 2A. [Figure 2C] See legend to Figure 2A. [Figure 3A]Effector function of CAIX-specific CART cells. A. Cytokine secretion. Anti-CAIX CART, irrelevant CART, or activated control T cells (LAK) were cocultured overnight with the renal carcinoma cell lines sk-rc-52 (CAIX+) and sk-rc-59 (CAIX-) for cytokine production. One representative sample is shown. B. ELISPOT. G36 CART or control A8 CART cells were added to tumor cells overnight. IFN-γ- or granzyme B-secreting T cells were detected by ELISPOT. Similar results were obtained in two to three experiments. C. Specific antitumor cytotoxicity of CAIX-specific CART cells. Control A8 CART cells or LAK cells were incubated with different amounts of target tumor cells at the indicated ratios in a 4-hour cytotoxicity assay. One representative sample is shown. Clone 4-1 is an in vivo-passaged subclone of sk-rc-52. [Figure 3B] See legend to Figure 3A. [Figure 3C] See legend to Figure 3A. [Figure 4A] Clonal expansion of CART cells after tumor challenge. A. Expansion. CAR-transduced or non-transduced T cells (LAK) were plated weekly with irradiated tumor cells (CAIX+ sk-rc-52 & CAIX- sk-rc-59) at three different tumor-to-T cell ratios as indicated. T cell numbers were counted in triplicate in two separate wells every 3-4 days. Similar results were obtained in two experiments. B. Clonality enrichment. In tumor stimulation experiments, cultures derived from CART- and LAK cells were assayed for CART and T cell subset expression by flow cytometry at 1 and 2 weeks. One representative result is shown. [Figure 4B] See legend to Figure 4A. [Figure 4C] See legend to Figure 4A. [Figure 5]Regression of human RCC xenografts formed by CART cells. Athymic null mice were inoculated subcutaneously in the left and right flanks with 7.5 x 10 sk-rc-52 and 5 x 10 sk-rc-59 RCC tumor cells, respectively. Six days after tumor implantation, mice were intravenously injected with 50 x 10 G36 CD28 CART cells, A8 CD28 CART cells (≥20% CAR+), LAK, or PBS alone. High-dose IL-2 (1 x 10 U / ml) was injected every 2–3 days. Tumor size was measured every 2–3 days using calipers. Experiment 1, n = 7; Experiment 2, n = 8. Tumor sizes from these two experiments are shown separately. +, p<0.05; *, p<0.01; **, p<0.001 for the G36 tandem-treated mice vs. the control non-T cell-treated mice group in these two studies. Other statistical calculations are reported in the text. [Figure 6A]In vivo antitumor activity of CAR+ T cells. A. ZsGreen expression by CART cells is shown in the upper panel. CART cells were prestained with Far Red dye, cytospun, and examined by fluorescence microscopy (lower panel). B. In situ staining of G36 CD28 CART cells in regressing tumors. CART cells were injected intravenously into RCC-forming mice, and tumor tissues were collected on days 1–3. Tumor cell apoptosis was measured using a TUNNEL assay with PE-Cy5 dye (shown in red) using confocal microscopy. Transduced T cells were visualized with ZsGreen. Nuclei were counterstained with DPAI. Two representative slides show tumor cell apoptosis at the tumor edge (upper panel) and within the tumor bed (middle panel), respectively. The magnified image (lower panel) shows that CART cells interacted with multiple tumors, resulting in the death of some surrounding tumor cells. C. Granzyme B+ T cells and tumor necrosis. After treatment with CART cells, regressing CAIX+ sk-rc-52 tumors were stained with granzyme B antibody (brown) and H&E. Higher magnification images (middle and lower panels of sections a and b in the upper panel) show the location of granzyme B+ T cells (indicated by arrows), and the corresponding H&E slides show tumor necrosis (indicated by n). Granzyme B+ T cells are distributed at the tumor edge (middle panel) and within the tumor (lower panel). [Figure 6B] See legend to Figure 6A. [Figure 6C] See legend to Figure 6A. [Figure 7] CAIX-sk-rc-52 tumors treated with control LAK cells showed negative granzyme B staining (left) (bottom panel), and the corresponding histology is shown by H&E (right). [Figure 8] Low background staining of granzyme B in CAIX- sk-rc-59 tumors treated with G36 CD28z CART cells. [Figure 9] Low background staining of granzyme B in CAIX-sk-rc-59 tumors treated with LAK cells. [Figure 10] A positive control for granzyme B staining was performed in sk-rc-52 tumors locally injected with G36 CD28z CART cells (left), and tumor morphology is shown by H&E (right). [Figure 11] Expression of αCAIX CAR and αPD-L1 scFv-Fc in 293T cells transiently transfected with αCAIX CAR and αPD-L1 scFv-Fc. 10 293T cells were transfected with or without lentiviral pHAGE-EF1αG36-C9 tag-CD28-CD3 zeta-IRES-anti-PDL1 scFv-Fc(IgG4)-WPRE or control pHAGE-EF1α-A716-C9 tag-CD28-CD3 zeta-IRES-ZsGreen-WPRE plasmids. Cells and supernatants were collected 24 and 48 hours after transfection. Left: Purified CAIX(ECD)-Fc-biotin and streptavidin-APC were used for cell staining and flow cytometry analysis. Right: Total human IgG in the supernatant was quantified using a human IgG quantification kit. [Figure 12A] (A) Total PBMCs from four donors were stimulated with 50 ng / ml SEB and treated with 10 μg / ml anti-PDL1 (#42) sIgG4 or anti-influenza sIgG4. Recovery of IFNγ (top) or TNFα (bottom) production was measured. [Figure 12B] (B) The parental anti-CCR4 antibody, c1567IgG, inhibited Treg chemotaxis toward CCL22. [Figure 12C] (C) CD4+CD25- T cells were CFSE-labeled and incubated with Tregs at a 10:1 ratio, followed by stimulation with anti-CCR4 mAb and control mAb in the presence of anti-CD3 / 28 costimulation. After 3 and 7 days, cells were collected and analyzed by flow cytometry. The percentage of fluorescently positive CD4+CD25- T cells and counting beads was calculated. Proliferation rates were normalized to CD4+CD25- T effector cells on day 0. Data shown were calculated from two independent experiments. Bars represent the mean ± SD. [Figure 12D](D) IFNγ ELISPOT analysis of CD4+CD25− Teff cells treated with mAb2-3 and control antibody. Data represent quantitation from three separate experiments using three different donor blood. [Figure 12E] (E) Left: CFSE-labeled Teffs (5x104) and unlabeled Tregs (5x103) were co-incubated with 20 μg / ml PHA in a 96-well plate for 5 days. CFSE-labeled Teffs were collected, and CFSE intensity was analyzed by flow cytometry. Teff proliferation was only observed when the co-culture was incubated with anti-GITR mAb. Right: IFNγ production in the same culture was further measured by MSD. CFSE-labeled Teffs (5x104) and unlabeled Tregs (5x103) were co-incubated with 20 μg / ml PHA in a 96-well plate for 5 days. CFSE-labeled Teffs were collected, and CFSE intensity was analyzed by flow cytometry. Teffs proliferated after 5 days of incubation with PHA, but not in the Teff / Treg co-culture. Left: IFNγ production in the same culture was measured by MSD. [Figure 13] 1A-1C illustrate various CART configurations according to the present invention. [Figure 14] 1A-1C illustrate various armed CART configurations according to the present invention. [Figure 15] 1A-1C are further diagrams illustrating various armed CART configurations according to the present invention. [Figure 16-1]This is a series of figures and graphs showing chimeric antigen receptor (CAR) constructs for transduction of CD8+ T cells. (A) Schematic diagram of the second-generation pHAGE lentiviral vector containing CD28 as the costimulatory domain. To express the CAR-binding domain, anti-carbonic anhydrase IX (CAIX) or (as a negative control) anti-B cell maturation antigen (BCMA) scFv was inserted after the eIFα promoter. The second cassette, following the internal ribosome entry site (IRES) sequence, encodes soluble anti-PD-L1 IgG1 or IgG4 isotype or anti-severe acute respiratory syndrome (SARS) coronavirus IgG1. To produce this lentivirus, the pHAGE vector, along with packaging plasmids (Gag, Rev, Tat, and VSVG), was transfected into 293T LentiX cells using polyethylenimine. Two days after transfection, the virus was harvested, purified, and concentrated using a LentiX Concentrator (Clontech™) according to the manufacturer's instructions. LTR: long terminal repeat; eIFα: eukaryotic translation initiation factor alpha; scFv: single-chain variable fragment; C9 tag: C9 peptide TETSQVAPA; IRES: internal ribosome entry site; WPRE: woodchuck hepatitis virus posttranscriptional regulatory element. (B) This lentivirus was used to transduce T cells to generate anti-CAIX CART cells that can recognize CAIX-positive RCC and release anti-PD-L1 IgG1 or IgG4 in the tumor microenvironment to prevent PD-1 / PD-L1-induced T cell exhaustion. (C) The percentage of CART cells 14 days after transduction demonstrates stable, long-term expression of the integrated lentiviral CAR in CD8+ T cells. CD8+ T cells were selected using the Dynabeads™ CD8 Positive Isolation Kit (Life Technologies) and activated using Dynabeads™ Human T Cell Activator CD3 / CD28 (Life Technologies) in the presence of 50 U / mL IL-21. IL-21 was added to the culture medium every 2 days.After 14 days, CART cells were incubated with human CAIX-Fc or BCMA-Fc, followed by APC-conjugated anti-human Fc IgG, and analyzed by FACS. (D) The concentration of IgG secreted into the medium of transduced T cells was assessed using a Human IgG ELISA Quantitation Set (Bethyl Laboratories). (E) The concentration of anti-PD-L1 antibodies in the supernatants of 293T cells transduced with lentiviruses containing anti-CAIX or anti-BCMA CAR and anti-PD-L1 IgG1, anti-PD-L1 IgG4, or nonspecific anti-SARS IgG1 sequences. Antibodies in the supernatants were purified using Protein A Sepharose beads (GE Healthcare) and biotinylated using EZ-Link Sulfo-NHS-LC-Biotin (Thermo Scientific™). These antibodies were incubated with 5 μg / mL human PD-L1 pre-immobilized on a 96-well MaxiSorp plate (Nunc™). Biotinylated antibodies were detected by incubating with streptavidin-HRP for 1 hour and developing with TMB. Absorbance was read at λ=450 nm. *P<0.001 compared to anti-BCMA / anti-SARS IgG1 and anti-CAIX / anti-SARS IgG1. **P<0.05 compared to anti-CAIX / anti-PD-L1 IgG1. (F and G) Clonal expansion of CD8+ CART cells. (F) Concentration of CART cells versus days in the presence of skrc-52 CAIX+ / PD-L1- cells. *P<0.05 compared to all CARS against anti-BCMA / anti-SARS IgG1. (G) Percentage of transduced T cells versus days in the presence of skrc-52 CAIX-positive cells. *P<0.05 compared to all CARS against anti-BCMA / anti-SARS IgG1.CD8+ CART cells were transduced with anti-CAIX CARs capable of expressing anti-PD-L1 IgG1 (anti-CAIX / anti-PD-L1 IgG1), IgG4 (anti-CAIX / anti-PD-L1 IgG4), or a nonspecific anti-SARS Ab (anti-CAIX / anti-SARS IgG1), or with anti-BCMA CARs (negative control) capable of expressing a nonspecific anti-SARS Ab (anti-BCMA / anti-SARS IgG1), pre-cultured for 5 days, and activated with Dynabeads™ Human T Activator CD3 / CD28 (Life Technologies) in the presence of 50 U / mL IL-21. The beads were removed, and the CART cells were cultured with skrc52 CAIX+ PD-L1- and IL-21 (50 U / mL) added to the culture medium every 2 days for 21 days. Results represent the mean ± SD of three donors performed in duplicate. [Figure 16-2] See description of Figure 16-1. [Figure 16-3] See description of Figure 16-1. [Figure 17-1]Figure 1 is a series of graphs showing the effector function of CART cells. Viability of (A) Skrc59 CAIX+ / PD-L1+ cells or (B) Skrc52 CAIX- / PD-L1- cells incubated overnight (ON) with CART cells anti-CAIX / anti-PD-L1 IgG1, anti-CAIX / anti-PD-L1 IgG4, anti-CAIX / anti-SARS IgG1, or anti-BCMA / anti-SARS IgG1. These CART cells were used 4 days after lentiviral transduction. Cell viability was assessed by MTT (Molecular Probes™). *P<0.05 for all CART cells compared to anti-BCMA / anti-SARS IgG1. IL2 released by CART cells after overnight contact with (C) Skrc59 CAIX+ / PD-L1+ cells or (D) Skrc52 CAIX- / PD-L1- cells. IL-2 secretion was assessed using the Human IL-2 ELISA Ready-SET-Go Kit (eBioscience™). *P<0.001 for all CART cells compared with anti-BCMA / anti-SARS IgG1. IFNγ released by CART cells after overnight contact with (E) Skrc59 CAIX+ / PD-L1+ or (F) Skrc52 CAIX- / PD-L1- cells. IFNγ secretion was assessed using the Human IFNγ ELISA Ready-SET-Go Kit (eBiosciences™). *P<0.05 for all CART cells compared with anti-BCMA / anti-SARS IgG1. Antibody-dependent cell-mediated cytotoxicity of (G) skrc59 CAIX+ / PD-L1+ or (H) skrc52 CAIX- / PD-L1- after incubation with CART cell supernatants (SN) containing 500 ng / mL of anti-PD-L1 IgG1, anti-PD-L1 IgG4, or anti-SARS IgG1. To obtain antibodies, CART cells were incubated with Dynabeads™ Human T Activator CD3 / CD28 (Life Technologies) in the presence of 50 U / mL IL-21 for 6 days.After 7 days, the mAb-containing medium was collected, and NK cells were purified using the EasySep™ Human NK Cell Enrichment Kit (StemCell™ Technologies). The RCC cell lines Skrc59 CAIX+ PD-L1+ and Skrc52 CAIX- PD-L1- were used as target cells, plated at 1.5 x 103 cells / well in a 96-well plate. RCC cells were incubated with 50µL of CART cell supernatant containing 500ng / mL of each Ab (anti-PD-L1 IgG1, anti-PD-L1 IgG4, or anti-SARS IgG1) at 37°C for 1 hour. After incubation, the cells were washed with medium and then incubated with NK cells at 12.5:1, 25:1, or 50:1 ratios for 4 hours at 37°C. Culture supernatants were collected by centrifugation, and LDH in the supernatants was measured at 490 nm by CytoTox 96® Non-Radioactive Cytotoxicity Assay (Promega™). The results represent the mean ± SD of three donors performed in duplicate. [Figure 17-2] See description of Figure 17-1. [Figure 18-1]Figure 1 is a series of graphs showing CART cell expression of exhaustion markers. (A) Lag3, (B) Tim3, and (C) PD-1 expression. *P<0.05 compared to anti-CAIX / anti-SARS IgG1 and anti-BCMA / anti-SARS IgG1. CD8+ CART cells were selected using the Dynabeads™ CD8 Positive isolation Kit (Life Technologies), activated with Dynabeads™ Human T Activator CD3 / CD28 (Life Technologies), and transduced with the following CARs: anti-CAIX / anti-PD-L1 IgG1, anti-CAIX / anti-PD-L1 IgG4, anti-CAIX / anti-SARS IgG1, or anti-BCMA / anti-SARS IgG1. These cells were cultured for 5 days in the presence of 50 U / mL of IL-21 and Dynabeads™ Human T Activator CD3 / CD28. After this period, CART cells were cocultured with Skrc-59 CAIX+ PD-L1+ for 2 days to stimulate exhaustion. CART cells were stained with FITC-conjugated anti-human PD-1, PE-conjugated anti-human Tim3, and PerCP / Cy5.5 anti-human Lag3 and analyzed by FACS. (D) Viability of Skrc59 CAIX+ / PD-L1+ cells after incubation with exhausted CART cells. Cell viability was assessed by MTT (Molecular Probes). *P<0.05 compared to both anti-CAIX / anti-SARS IgG1 and anti-BCMA / anti-SARS IgG1. **P<0.05 compared to anti-CAIX / anti-PD-L1 IgG1. These results represent the mean ± SD of three donors. [Figure 18-2] See description of Figure 18-1. [Figure 18-3] See description of Figure 18-1. [Figure 19A]This is a series of images and graphs showing the effect of CART cells in an orthotopic model of human RCC. (A) NSG mice (N=35) were injected with 5.0x104 skrc-59 CAIX-positive, PD-L1-positive, and luciferase-positive RCC cells. One week later, mice were injected IV with 1.0x107 CART or untransduced T cells (day 0). CART cells were pre-transduced with the following lentiviral sequences: anti-BCMA CAR / anti-SARS IgG1, anti-CAIX CAR / anti-SARS IgG1, anti-CAIX CAR / anti-PD-L1 IgG1, and anti-CAIX CAR / anti-PD-L1 IgG4 (N=6 mice per group). Tumor bioluminescence was quantified using IVIS after a 5-minute IP injection of luciferin. Images of tumors before CART injection (day 0) and 7, 14, 23, and 30 days after the first CART cell injection. A second injection of 2.5x106 cells was administered on day 17. (B) Images of tumors after resection on day 30. Scale bar = 1 cm. (C) Tumor growth curve. *P<0.05 when comparing anti-PD-L1 IgG1 and IgG4 groups with anti-BCMA / anti-SARS IgG1 and **P<0.05 when comparing anti-PD-L1 IgG1 and IgG4 groups with anti-CAIX / anti-SARS IgG1. (D) Tumor weight 30 days after treatment. *P<0.05 compared to anti-BCMA / anti-SARS IgG1 CAR. **P<0.05 compared to anti-CAIX / anti-SARS IgG1. [Figure 19B] See legend to Figure 19A. [Figure 19C] See legend to Figure 19A. [Figure 19D] See legend to Figure 19A. [Figure 20A]A series of graphs and histological images show antitumor activity from CART cells. (A) Expression of exhaustion markers in tumor-infiltrating lymphocytes (TILs). Kidney tumors from all mice were divided into two halves, and one halve was fragmented into small pieces and digested with collagenase and DNAse to extract TILs. CART cells were analyzed for exhaustion markers PD-1, Tim-3, and Lag3. *P<0.05 compared to untransduced, anti-BCMA / anti-SARS IgG1 CAR and anti-CAIX / anti-SARS IgG1. (B) Detection of Ki67 and granzyme B as tumor cell proliferation markers for analysis of CART cell activity in tissue. Four-micrometer sections of formalin-fixed, paraffin-embedded tissue were dewaxed and rehydrated in a decreasing ethanol series. Endogenous peroxidase activity was quenched using 3% hydrogen peroxide. Antigen retrieval was performed in citrate buffer (pH = 6.0) at 123°C and 15 PSI for 45 seconds using a pressure cooker. The tissue sections were incubated for 45 minutes with rabbit anti-human Ki67 polyclonal antibody (Vector, VP-K451) at 1:2000, mouse anti-human PD-L1 mAb (clone 405.9A11) developed by Dr. Gordon Freeman (Boston, MA) at 10.4 μg / mL, biotinylated CAIX-Fc protein (produced in our laboratory) at 17 μg / mL, rabbit anti-human granzyme B polyclonal antibody (Abcam, ab4059) at 1:100, or rabbit anti-human NCAM (CD56) mAb at 1:100 (Abcam, ab133345), followed by secondary HRP-conjugated anti-rabbit antibody or HRP-avidin. Slides were developed with 3,3'-diaminobenzidine (DAB) and counterstained with hematoxylin. Images were acquired on an Olympus BX51 microscope using a DP71 digital camera (Olympus) and analyzed with DP Controller Software (Olympus™). Scale bars represent the magnification of images in each column [500 μm (40X), 100 μm (200X), or 50 μm (400X)]. (C) Serial images show quantification of the percentage of TILs that stained positive for granzyme B, PD-L1-IHC, and Ki67.(C) also shows the Ki67-DAB pixel counts of TILs. [Figure 20B] See legend to Figure 20A. [Figure 20C-1] See legend to Figure 20A. [Figure 20C-2] See legend to Figure 20A. [Figure 20C-3] See legend to Figure 20A. [Figure 20C-4] See legend to Figure 20A. [Figure 21]A series of graphs showing the evaluation of IL-2 versus IL-21 on CD8+ CART cell proliferation. A and B. Proliferation of CART-transduced cells in the presence of IL-2 or IL-21 assessed 48, 72, and 120 hours after lentiviral transduction. (A) Anti-CAIX CART cells or (B) nonspecific anti-BCMA CART cells (both with ZsGreen in the second cassette). CD8+ T cells were selected using Dynabeads™ CD8 Positive isolation Kit (Life Technologies) and activated with Dynabeads™ Human T Activator CD3 / CD28 (Life Technologies) in the presence of IL2 or IL-21 50 U / mL (Peprotech™). CART cell transduction was assessed by ZsGreen expression using FACS. Data represent the mean ± SD of two donors. *p<0.05 for IL-21 compared to untreated control (Ctr). **p<0.05 comparing IL21 to IL-2. C and D. Viability of RCC cells treated with CD8+ CART cells cultured in the presence of IL-2 or IL-21. Viability was assessed by MTT after overnight incubation of CART cells, anti-BCMA, anti-CAIX, or untransduced T cells with (C) Skrc-59 CAIX+ / PD-L1+ and (F) Skrc-52 CAIX- / PD-L1- RCC cells. CART cells were previously cultured for 120 hours in the presence of 50 U / mL of IL2 or IL-21. These results represent the mean ± SD of two donors performed in triplicate. *P<0.05 comparing anti-CAIX CARs to anti-BCMA CARs or untransduced T cells. [Figure 22]A series of flow cytometry graphs showing PD-1 and CAIX expression in renal cell carcinoma (RCC) lines: (A) negative control, (B) Skrc52 CAIX- PD-L1-, (C) Skrc52 CAIX+ PD-L1-, and (D) Skrc59 CAIX+ PD-L1+. Cells were stained with anti-human CAIX antibody developed with APC anti-human Fc IgG and biotinylated anti-human PD-L1 antibody developed with PE-avidin. Analysis was performed by FACS. [Figure 23] This is a series of graphs showing the characterization of CART cells. (A) Proliferation of total CD8+ T cells 2 or 4 days after transduction with anti-CAIX CAR / anti-PD-L1 IgG1), (anti-CAIX CAR / anti-PD-L1 IgG4), anti-CAIX CAR / anti-SARS IgG1), or anti-BCMA CAR / anti-SARS IgG1. CD8+ T cells were selected using Dynabeads™ CD8 Positive isolation Kit (Life Technologies) and activated with Dynabeads™ Human T Activator CD3 / CD28 (Life Technologies) in the presence of IL-21 50 U / mL. IL-21 was added to the culture medium every two days. Proliferation was assessed by FACS using Counting Beads (Molecular Probes). (B) Concentration of CAR-transduced T cells 2 and 4 days after transduction. CART cells were incubated with human CAIX-Fc or BCMA-Fc, followed by incubation with APC-conjugated anti-human Fc IgG, and analyzed by FACS. (C) Percentage of CART cells 2 and 4 days after transduction. Results represent the mean ± SD of three donors performed in duplicate. [Figure 24A]This is a series of graphs showing the effect of CART cells in an orthotopic model of human RCC. (A) Comparison of tumor size, as detected by bioluminescence, over time in the CART cell groups. NSG mice (N=35) were injected into the kidney capsule with 5.0x104 skrc-59 CAIX+, PD-L1+, and luciferase+ RCC cells. One week later, the mice were injected IV with 1.0x107 CART or untransduced T cells. CART cells were previously transduced with the following lentiviral sequences: anti-BCMA CAR / anti-SARS IgG1, anti-CAIX CAR / anti-SARS IgG1, anti-CAIX CAR / anti-PD-L1 IgG1, and anti-CAIX CAR / anti-PD-L1 IgG4 (N=6 mice per group). Tumor bioluminescence was quantified using IVIS 5 minutes after IP injection of luciferin. On day 17, an additional 2.5x106 CART cells were injected. *P<0.05 compared to anti-BCMA CART cells. **P<0.05 compared to untransduced T cells, ***P<0.05 compared to anti-CAIX / anti-SARS IgG1. (B) Percentage of T cells in mouse blood 8 days after treatment. *P<0.05 compared to untransduced T cells. **P<0.05 compared to all anti-CAIX CARs. Red blood cells were lysed using ACK Lysing Buffer (Lonza™), and the remaining cells were stained with Pacific Blue-conjugated anti-human CD45 and analyzed by FACS. (C) Total tumor-infiltrating lymphocytes (TILs) 30 days after CART cell treatment. Tumors and kidneys from all mice were divided into two halves, and one half was fragmented into small pieces and digested with collagenase and DNAse to extract TILs. Cells were stained with Pacific Blue-conjugated anti-human CD45 and analyzed by FACS. [Figure 24B] See legend to Figure 24A. [Figure 24C] See legend to Figure 24A. [Figure 25A]A series of graphs and histological images show human natural killer (NK) cells in tumors treated with anti-CAIX CART cells releasing anti-PD-L1 IgG1 Ab. (A) Percentage of CD56+ cells (NK marker) in tumors. Two mice from each group were injected with 4.5 x 106 NK cells one day before euthanasia. Kidney tumors from all mice were divided into two halves, and one half was fragmented into small pieces and digested with collagenase and DNAse to extract NK cells. NK cells present in the tumor were stained with APC-anti-CD56 Ab and analyzed by FACS. *P<0.05. (B) CD56+ cells in excised tumors detected by IHC and quantified using the IHC Profiler Plugin in ImageJ Software. Four-micrometer sections of formalin-fixed, paraffin-embedded tissue were dewaxed and rehydrated in a decreasing ethanol series. Endogenous peroxidase activity was quenched using 3% hydrogen peroxide. Antigen retrieval was performed in citrate buffer (pH = 6.0) using a pressure cooker at 123°C and 15 PSI for 45 seconds. The tissue sections were incubated with rabbit anti-human CD56 mAb 1:100 (Abcam, ab133345) for 45 minutes, followed by secondary HRP-conjugated anti-rabbit or anti-mouse Abs. Slides were developed with 3,3'-diaminobenzidine (DAB) and counterstained with hematoxylin. Images were acquired on an Olympus BX51 microscope using a DP71 digital camera (Olympus) and analyzed with DP Controller Software (Olympus™). Quantitation was performed using the IHC Profiler Plugin in ImageJ Software (23). Scale bars represent image magnification (400X). *P < 0.05 compared to untransduced; **P < 0.05 compared to untransduced and anti-BCMA / anti-SARS IgG1. [Figure 25B] See legend to Figure 25A. DETAILED DESCRIPTION OF THE INVENTION

[0013] Detailed Description of the Invention The present invention relates to chimeric antigen receptors (CARs) adapted to immune cells, particularly for use in immunotherapy.

[0014] In one embodiment, a dual immunotherapy strategy based on blocking T cell exhaustion using anti-PD-L1 antibodies secreted by targeted anti-CAIX CAR T cells combined in a single lentiviral construct is described to improve the treatment of cancer.

[0015] A novel mechanism implicated in the progression of RCC and other tumors is the immune checkpoint pathway, which exists in cellular interactions that prevent excessive T cell activation under normal conditions and render T cell function self-limiting. As an evasion mechanism, many tumors can stimulate the expression of immune checkpoint molecules and induce an anergic phenotype of T cells that cannot suppress tumor progression. Emerging clinical data highlight the importance of an inhibitory ligand and receptor pair: programmed death ligand 1 (PD-L1; B7-H1 and CD274) and programmed death receptor 1 (PD-1; CD279) as an immune checkpoint in preventing cytotoxic T lymphocytes from killing cancer cells. The PD-1 receptor is expressed by many cell types and host tissues, including T cells, B cells, and natural killer cells (NK). PD-L1-expressing tumors and antigen-presenting cells (APCs) can block T cell receptor (TCR) signaling of cytotoxic T lymphocytes through binding to the receptor PD-1, thereby reducing cytokine production and T cell proliferation. Overexpression of PD-L1 can be found in many tumor types, and it also mediates immunosuppressive functions through its interactions with other proteins, including CD80 (B7.1), which blocks their ability to activate T cells through binding to CD28.

[0016] Genetically engineering human lymphocytes to express tumor-specific chimeric antigen receptors (CARs) can generate antitumor effector cells that circumvent tumor immune escape mechanisms due to abnormalities in protein-antigen processing and presentation. Furthermore, these transgenic receptors can target tumor-associated antigens that are not derived from proteins. In certain embodiments of the present invention, lymphocytes (CARTS) are engineered to contain at least one CAR, and in certain embodiments of the present invention, one CAR targets two or more antigens. In preferred embodiments, CARTS are further engineered to express and secrete one or more polypeptides, such as antibodies or cytokines. Such CARTS are referred to herein as armed CARTS. Armed CARTS enable simultaneous secretion of polypeptides locally at the target site (i.e., tumor site).

[0017] Engineered TCRs, called chimeric antigen receptors (CARs), contain single-chain variable antibody fragments (scFvs) preselected for high affinity to specific tumor-associated antigens. The scFvs present in the CARs are linked to an intracellular signaling block containing CD3ζ to induce T cell activation and subsequent antigen binding. This architecture, characteristic of first-generation CARs, has evolved into second-generation CARs that link the signaling and costimulatory endodomains of CD28, 4-1BB, or OX40 to CD3, or third-generation CARs that link both endodomains in tandem to CD3ζ. These endodomains are required for full T cell activation upon TCR recognition by antigen-presenting cells (APCs) and improve cytokine production and proliferation of CAR T cells. Due to the difficulty of discovering unique tumor-associated antigens, inefficient T cell homing to tumor sites, poor T cell persistence in the body, and the immunosuppressive microenvironment of solid tumors, CAR T cell efficacy has been limited in the treatment of solid tumors.

[0018] In certain instances, the lymphocyte comprises a receptor that is chimeric, non-natural, and at least partially engineered by human hands. In certain instances, the engineered chimeric antigen receptor (CAR) has one, two, three, four, or more elements, and in some embodiments, one or more elements facilitate targeting or binding of the lymphocyte to one or more tumor antigen-containing cancer cells.

[0019] A CAR according to the present invention generally comprises at least one transmembrane polypeptide comprising at least one extracellular ligand binding domain and one transmembrane polypeptide comprising at least one intracellular signaling domain, which polypeptides combine to form a chimeric antigen receptor.

[0020] As used herein, the term "extracellular ligand-binding domain" is defined as an oligopeptide or polypeptide capable of binding to a ligand. Preferably, this domain will be capable of interacting with a cell surface molecule. For example, the extracellular ligand-binding domain may be selected to recognize a ligand that functions as a cell surface marker on target cells associated with a particular disease state.

[0021] In particular, the extracellular ligand-binding domain may comprise an antigen-binding domain derived from an antibody directed against a target antigen.

[0022] By way of non-limiting example, target antigens include tumor-associated surface antigens, such as ErbB2 (HER2 / neu), carcinoembryonic antigen (CEA), epithelial cell adhesion molecule (EpCAM), epidermal growth factor receptor (EGFR), EGFR variant III (EGFRvIII), CD19, CD20, CD30, CD40, disialoganglioside GD2, ductal epithelial mucin, gp36, TAG-72, glycosphingolipids, glioma-associated antigens, beta-human chorionic gonadotropin, alpha-fetoprotein (AFP), lectin-reactive AFP, thyroglobulin, RAGE-1, MN-CA IX, human telomerase reverse transcriptase, RU1, RU2 (AS), intestinal carboxylesterase, mut hsp70-2, M-CSF, prostase, prostase-specific antigen (PSA), PAP, NY-ESO-1, LAGA-1a, p53, prostein, PSMA, survival and telomerase, prostate cancer tumor antigen-1 (PCTA-1), MAGE, ELF2M, neutrophil elastase, ephrin B2, CD22, insulin growth factor (IGF1)-I, IGF-II, IGF1 receptor, mesothelium, major histocompatibility complex (MHC) molecules presenting tumor-specific peptide epitopes, 5T4, ROR1, Nkp30, NKG2D, tumor stromal antigen, extra domain A (EDA) and extra domain B (EDB) of fibronectin and A1 domain of tenascin-C (TnC) A1) and fibroblast-associated proteins (fap); lineage- or tissue-specific antigens such as CD3, CD4, CD8, CD24, CD25, CD33, CD34, CD133, CD138, CTLA-4, B7-1 (CD80), B7-2 (CD86), endoglin, major histocompatibility complex (MHC) molecules, BCMA (CD269, TNFRSF 17) or virus-specific surface antigens such as HIV-specific antigens (e.g. HIV gp120); EBV-specific antigens, CMV-specific antigens, HPV-specific antigens, Lassa Virus-specific antigens, influenza virus-specific antigens and any derivatives or variants of these surface markers.

[0023] Preferably, the CAR is specific for BMCA, CAIX, CCR4, PD-L1, PD-L2, PD1, glucocorticoid-induced tumor necrosis factor receptor (GITR), severe acute respiratory syndrome (SARS), influenza, flavivirus, or Middle East respiratory syndrome (MERS).

[0024] In a preferred embodiment, the extracellular ligand-binding domain comprises a light chain (V) of a target antigen-specific monoclonal antibody connected by a flexible linker. L ) and heavy chain (V H ) single chain antibody fragments (scFv) containing variable fragments.

[0025] In more preferred embodiments, the scFv antibody is specific for BMCA, CAIX, CCR4, PD-L1, PD-L2, PD1, GITR, SARS, influenza, flavivirus, or MERS.

[0026] Exemplary antibodies useful in constructing CARs in accordance with the present invention include, for example, those disclosed in WO / 2005 / 060520, WO / 2006 / 089141, WO / 2007 / 065027, WO / 2009 / 086514, WO / 2009 / 079259, WO / 2011 / 153380, WO / 2014 / 055897, WO 2015 / 143194, WO 2015 / 164865, WO 2013 / 166500 and WO 2014 / 144061, PCT / US2015 / 054202, PCT / US2015 / 054010 and 62 / 144,729, the contents of which are incorporated herein by reference in their entireties.

[0027] PDL1(68) Exemplary anti-PDL1 antibodies include a VH nucleotide sequence having SEQ ID NO: 1485 and a VL nucleotide sequence having SEQ ID NO: 1487, a VH nucleotide sequence having SEQ ID NO: 1485 and a VL nucleotide sequence having SEQ ID NO: 1487, a VH nucleotide sequence having SEQ ID NO: 1489 and a VL nucleotide sequence having SEQ ID NO: 1491, a VH nucleotide sequence having SEQ ID NO: 1493 and a VL nucleotide sequence having SEQ ID NO: 1495, a VH nucleotide sequence having SEQ ID NO: 1497 and a VL nucleotide sequence having SEQ ID NO: 1499, a VH nucleotide sequence having SEQ ID NO: 1501 and a VL nucleotide sequence having SEQ ID NO: 1503, a VH nucleotide sequence having SEQ ID NO: 1505 and a VL nucleotide sequence having SEQ ID NO: 1507, a VH nucleotide sequence having SEQ ID NO: 1509 and a VL nucleotide sequence having SEQ ID NO: 1509 the VH nucleotide sequence having SEQ ID NO: 1529 and a VL nucleotide sequence having SEQ ID NO: 1531; the VH nucleotide sequence having SEQ ID NO: 1533 and a VL nucleotide sequence having SEQ ID NO: 1535; the VH nucleotide sequence having SEQ ID NO: 1537 and a VL nucleotide sequence having SEQ ID NO: 1539; the VH nucleotide sequence having SEQ ID NO: 1521 and a VL nucleotide sequence having SEQ ID NO: 1523; the VH nucleotide sequence having SEQ ID NO: 1525 and a VL nucleotide sequence having SEQ ID NO: 1527; the VH nucleotide sequence having SEQ ID NO: 1529 and a VL nucleotide sequence having SEQ ID NO: 1531; the VH nucleotide sequence having SEQ ID NO: 1533 and a VL nucleotide sequence having SEQ ID NO: 1535; the VH nucleotide sequence having SEQ ID NO: 1537 and a VL nucleotide sequence having SEQ ID NO: 1539.

[0028] Exemplary anti-PDL1 antibodies include a VH amino acid sequence having SEQ ID NO:970 and a VL amino acid sequence having SEQ ID NO:971, a VH amino acid sequence having SEQ ID NO:1486 and a VL polypeptide sequence having SEQ ID NO:1488, a VH amino acid sequence having SEQ ID NO:1490 and a VL polypeptide sequence having SEQ ID NO:1492, a VH amino acid sequence having SEQ ID NO:1494 and a VL polypeptide sequence having SEQ ID NO:1496, a VH amino acid sequence having SEQ ID NO:1498 and a VL polypeptide sequence having SEQ ID NO:1500, a VH amino acid sequence having SEQ ID NO:1502 and a VL polypeptide sequence having SEQ ID NO:1504, a VH amino acid sequence having SEQ ID NO:1506 and a VL polypeptide sequence having SEQ ID NO:1508, a VH amino acid sequence having SEQ ID NO:1510 and a VL polypeptide sequence having SEQ ID NO:1512, The antibodies include an antibody having a VH amino acid sequence having SEQ ID NO:1514 and a VL polypeptide sequence having SEQ ID NO:1516, a VH amino acid sequence having SEQ ID NO:1518 and a VL polypeptide sequence having SEQ ID NO:1520, a VH amino acid sequence having SEQ ID NO:1522 and a VL polypeptide sequence having SEQ ID NO:1524, a VH amino acid sequence having SEQ ID NO:1526 and a VL polypeptide sequence having SEQ ID NO:1528, a VH amino acid sequence having SEQ ID NO:1530 and a VL polypeptide sequence having SEQ ID NO:1532, a VH amino acid sequence having SEQ ID NO:1534 and a VL polypeptide sequence having SEQ ID NO:1536, a VH amino acid sequence having SEQ ID NO:1538 and a VL polypeptide sequence having SEQ ID NO:1540.

[0029] In other embodiments, the anti-PDL1 antibody comprises a heavy chain having three CDRs comprising the amino acid sequences SEQ ID NOs: 1541, 1554, 1569, respectively, and a light chain having three CDRs comprising the amino acid sequences 1584, 1599, 1610, respectively, or a heavy chain having three CDRs comprising the amino acid sequences 1543, 1556, 1571 and a light chain having three CDRs comprising the amino acid sequences 1586, 1600, 1612, or a heavy chain having three CDRs comprising the amino acid sequences 1544, 1557, 1572 and a light chain having three CDRs comprising the amino acid sequences 1587, 1601, 1613, or a heavy chain having three CDRs comprising amino acid sequences 1545, 1558, 1573 and a light chain having three CDRs comprising amino acid sequences 1588, 1602, 1614, or a heavy chain having three CDRs comprising amino acid sequences 1546, 1559, 1574 and a light chain having three CDRs comprising amino acid sequences 1589, 1603, 1615, or a heavy chain having three CDRs comprising amino acid sequences 1547, 1560, 1575 and a light chain having three CDRs comprising amino acid sequences 1590, 1604, 1616, or a heavy chain having three CDRs comprising amino acid sequences 1548, 1561, 1576 and a light chain having three CDRs comprising amino acid sequences 1591, 1605, 1617, or a heavy chain having three CDRs comprising amino acid sequences 1541, 1562, 1577 and a light chain having three CDRs comprising amino acid sequences 1592, 1599, 1618, or a heavy chain having three CDRs comprising amino acid sequences 1549, 1563, 1578 and a light chain having three CDRs comprising amino acid sequences 1593, 1606, 1619, or an amino acid sequence 1550, a heavy chain having three CDRs comprising amino acid sequences 1564, 1579 and a light chain having three CDRs comprising amino acid sequences 1594, 1607, 1620, or a heavy chain having three CDRs comprising amino acid sequences 1551, 1565, 1580 and a light chain having three CDRs comprising amino acid sequences 1595, 1599, 1621, or a heavy chain having three CDRs comprising amino acid sequences 1542, 1566, 1581 and a light chain having three CDRs comprising amino acid sequences 1596, 1599, 1622, or an amino acid sequence 1552, 1567,A heavy chain having three CDRs containing amino acid sequences 1553, 1568, and 1583 and a light chain having three CDRs containing amino acid sequences 1598, 1609, and 1624.

[0030] SARS(26) Exemplary SARS neutralizing antibodies include a VH nucleotide sequence having SEQ ID NO:1626 and a VL nucleotide sequence having SEQ ID NO:1628, a VH nucleotide sequence having SEQ ID NO:1630 and a VL nucleotide sequence having SEQ ID NO:1639, a VH nucleotide sequence having SEQ ID NO:1634 and a VL nucleotide sequence having SEQ ID NO:1640, a VH nucleotide sequence having SEQ ID NO:1632 and a VL nucleotide sequence having SEQ ID NO:1641, a VH nucleotide sequence having SEQ ID NO:1633 and a VL nucleotide sequence having SEQ ID NO:1642, a VH nucleotide sequence having SEQ ID NO:1634 and a VL nucleotide sequence having SEQ ID NO:1643, a VH nucleotide sequence having SEQ ID NO:1635 and a VL nucleotide sequence having SEQ ID NO:1644, a VH nucleotide sequence having SEQ ID NO:1636 and a VL nucleotide sequence having SEQ ID NO:1645, The antibody includes an antibody having a VL nucleotide sequence having SEQ ID NO:1645, a VH nucleotide sequence having SEQ ID NO:1637, and a VL nucleotide sequence having SEQ ID NO:1646.

[0031] CXCR4(33) Exemplary anti-CXCR4 antibodies include antibodies having a VH amino acid sequence having SEQ ID NO:771 and a VL amino acid sequence having SEQ ID NO:779, a VH amino acid sequence having SEQ ID NO:772 and a VL amino acid sequence having SEQ ID NO:780, a VH amino acid sequence having SEQ ID NO:773 and a VL amino acid sequence having SEQ ID NO:781, a VH amino acid sequence having SEQ ID NO:774 and a VL amino acid sequence having SEQ ID NO:782, a VH amino acid sequence having SEQ ID NO:775 and a VL amino acid sequence having SEQ ID NO:783, a VH amino acid sequence having SEQ ID NO:776 and a VL amino acid sequence having SEQ ID NO:784, a VH amino acid sequence having SEQ ID NO:777 and a VL amino acid sequence having SEQ ID NO:785, or a VH amino acid sequence having SEQ ID NO:778 and a VL amino acid sequence having SEQ ID NO:786.

[0032] In other embodiments, the anti-CXCR4 antibody comprises a heavy chain having three CDRs comprising the amino acid sequences SEQ ID NOs: 803, 804, 805, respectively, and a light chain having three CDRs comprising the amino acid sequences 806, 807, 808, respectively; or a heavy chain having three CDRs comprising the amino acid sequences 809, 810, 811, respectively, and a light chain having three CDRs comprising the amino acid sequences 812, 813, 814, respectively; or a heavy chain having three CDRs comprising the amino acid sequences 815, 816, 817, respectively, and a light chain having three CDRs comprising the amino acid sequences 818, 819, 820, respectively; or It has a heavy chain having three CDRs comprising amino acid sequences 827, 828, and 829, and a light chain having three CDRs comprising amino acid sequences 830, 831, and 832, respectively; or a heavy chain having three CDRs comprising amino acid sequences 833, 834, and 835, respectively, and a light chain having three CDRs comprising amino acid sequences 836, 837, and 838, respectively; or a heavy chain having three CDRs comprising amino acid sequences 839, 840, and 841, respectively, and a light chain having three CDRs comprising amino acid sequences 842, 843, and 844, respectively.

[0033] Carbonic anhydrase IX (40) Exemplary anti-CA IX antibodies include a VH amino acid sequence having SEQ ID NO:845 and a VL amino acid sequence having SEQ ID NO:846, a VH amino acid sequence having SEQ ID NO:847 and a VL amino acid sequence having SEQ ID NO:868, a VH amino acid sequence having SEQ ID NO:848 and a VL amino acid sequence having SEQ ID NO:869, a VH amino acid sequence having SEQ ID NO:849 and a VL amino acid sequence having SEQ ID NO:870, a VH amino acid sequence having SEQ ID NO:850 and a VL amino acid sequence having SEQ ID NO:871, a VH amino acid sequence having SEQ ID NO:851 and a VL amino acid sequence having SEQ ID NO:872, a VH amino acid sequence having SEQ ID NO:852 and a VL amino acid sequence having SEQ ID NO:873, a VH amino acid sequence having SEQ ID NO:853 and a VL amino acid sequence having SEQ ID NO:874, a VH amino acid sequence having SEQ ID NO:854 and a VL amino acid sequence having SEQ ID NO:875, a VH amino acid sequence having SEQ ID NO:855 and a VL amino acid sequence having SEQ ID NO:876, a VH amino acid sequence having SEQ ID NO:856 and a VL amino acid sequence having SEQ ID NO:877, a VH amino acid sequence having SEQ ID NO:857 and a VL amino acid sequence having SEQ ID NO:878, a VH amino acid sequence having SEQ ID NO:858 and a VL amino acid sequence having SEQ ID NO:879, a VH amino acid sequence having SEQ ID NO:859 and a VL amino acid sequence having SEQ ID NO:880, a VH amino acid sequence having SEQ ID NO:860 and a VL amino acid sequence having SEQ ID NO:881, a VH amino acid sequence having SEQ ID NO:861 and a VL amino acid sequence having SEQ ID NO:882, a VH amino acid sequence having SEQ ID NO:862 and a VL amino acid sequence having SEQ ID NO:883 a VL amino acid sequence having SEQ ID NO:883, a VH amino acid sequence having SEQ ID NO:863 and a VL amino acid sequence having SEQ ID NO:884,These antibodies include an antibody having a VH amino acid sequence having SEQ ID NO:864 and a VL amino acid sequence having SEQ ID NO:885, a VH amino acid sequence having SEQ ID NO:865 and a VL amino acid sequence having SEQ ID NO:886, a VH amino acid sequence having SEQ ID NO:866 and a VL amino acid sequence having SEQ ID NO:887, and a VH amino acid sequence having SEQ ID NO:867 and a VL amino acid sequence having SEQ ID NO:888.

[0034] In other embodiments, the anti-CA IX antibody comprises a heavy chain having three CDRs comprising the amino acid sequences SEQ ID NOs: 803, 804, 805, respectively, and a light chain having three CDRs comprising the amino acid sequences 806, 807, 808, respectively, or a heavy chain having three CDRs comprising the amino acid sequences 899, 915, 909 and a light chain having three CDRs comprising the amino acid sequences 905, 906, 952, or a heavy chain having three CDRs comprising the amino acid sequences 899, 915, 909 and a light chain having three CDRs comprising the amino acid sequences 935, 943, 953 ... a heavy chain having three CDRs and a light chain having three CDRs comprising amino acid sequences 935, 906, and 954, or a heavy chain having three CDRs comprising amino acid sequences 910, 916, and 923 and a light chain having three CDRs comprising amino acid sequences 936, 944, and 955, or a heavy chain having three CDRs comprising amino acid sequences 899, 915, and 909 and a light chain having three CDRs comprising amino acid sequences 936, 944, and 956, or a heavy chain having three CDRs comprising amino acid sequences 911, 917, and 924 and a light chain having three CDRs comprising amino acid sequences 9 a heavy chain having three CDRs comprising amino acid sequences 899, 915, 909 and a light chain having three CDRs comprising amino acid sequences 935, 946, 958; a heavy chain having three CDRs comprising amino acid sequences 899, 915, 909 and a light chain having three CDRs comprising amino acid sequences 938, 946, 959; or a heavy chain having three CDRs comprising amino acid sequences 899, 915, 909 and a light chain having three CDRs comprising amino acid sequences 905, 946, 960. or a heavy chain having three CDRs comprising amino acid sequences 899, 918, 925 and a light chain having three CDRs comprising amino acid sequences 937, 947, 955, or a heavy chain having three CDRs comprising amino acid sequences 899, 918, 926 and a light chain having three CDRs comprising amino acid sequences 937, 945, 957, or a heavy chain having three CDRs comprising amino acid sequences 912, 919, 927 and a light chain having three CDRs comprising amino acid sequences 937, 943, 961, ora heavy chain having three CDRs comprising amino acid sequences 928 and a light chain having three CDRs comprising amino acid sequences 937, 906, and 960, or a heavy chain having three CDRs comprising amino acid sequences 899, 918, and 928 and a light chain having three CDRs comprising amino acid sequences 937, 906, and 960, or a heavy chain having three CDRs comprising amino acid sequences 913, 920, and 929 and a light chain having three CDRs comprising amino acid sequences 939, 948, and 962, or a heavy chain having three CDRs comprising amino acid sequences 899, 918, and 930 and a light chain having three CDRs comprising amino acid sequences 935, 944, and 955, or a heavy chain having three CDRs comprising amino acid sequences 899, 921, and 931 and an amino acid sequence 93 941, 950, 964, or a heavy chain having three CDRs comprising amino acid sequences 912, 919, 932 and a light chain having three CDRs comprising amino acid sequences 940, 949, 963; or a heavy chain having three CDRs comprising amino acid sequences 899, 915, 909 and a light chain having three CDRs comprising amino acid sequences 935, 943, 960; or a heavy chain having three CDRs comprising amino acid sequences 914, 922, 933 and a light chain having three CDRs comprising amino acid sequences 941, 950, 964; or a heavy chain having three CDRs comprising amino acid sequences 912, 918, 934 and a light chain having three CDRs comprising amino acid sequences 942, 951, 965.

[0035] CC chemokine receptor 4 (CCR4) (048) Exemplary CC chemokine receptor 4 (CCR4) antibodies include antibodies having a VH nucleotide sequence having SEQ ID NO:969 and a VL nucleotide sequence having SEQ ID NO:971; and antibodies having a VH nucleotide sequence having SEQ ID NO:969 and a VL nucleotide sequence having SEQ ID NO:972.

[0036] Exemplary CCR4 antibodies include an antibody having a VH amino acid sequence having SEQ ID NO:970 and a VL amino acid sequence having SEQ ID NO:971.

[0037] In other embodiments, the CCR4 antibody has a heavy chain with three CDRs comprising the amino acid sequences SEQ ID NOs: 973, 974, 975, respectively, and a light chain with three CDRs comprising the amino acid sequences 976, 977, 978, respectively.

[0038] Middle East Respiratory Syndrome Coronavirus (MERS-CoV) (85) Exemplary anti-Middle East Respiratory Syndrome coronavirus (MERS-CoV) antibodies include antibodies having a VH nucleotide sequence having SEQ ID NO:677 and a VL nucleotide sequence having SEQ ID NO:679, a VH nucleotide sequence having SEQ ID NO:681 and a VL nucleotide sequence having SEQ ID NO:683, a VH nucleotide sequence having SEQ ID NO:685 and a VL nucleotide sequence having SEQ ID NO:687, a VH nucleotide sequence having SEQ ID NO:689 and a VL nucleotide sequence having SEQ ID NO:692, a VH nucleotide sequence having SEQ ID NO:693 and a VL nucleotide sequence having SEQ ID NO:695, a VH nucleotide sequence having SEQ ID NO:697 and a VL nucleotide sequence having SEQ ID NO:699, and a VH nucleotide sequence having SEQ ID NO:701 and a VL nucleotide sequence having SEQ ID NO:703.

[0039] Exemplary anti-Middle East Respiratory Syndrome coronavirus (MERS-CoV) antibodies include antibodies having VL amino acid sequences having the VH amino acid sequences SEQ ID NO:678 and SEQ ID NO:680, VL amino acid sequences having the VH amino acid sequences SEQ ID NO:682 and SEQ ID NO:684, VL amino acid sequences having the VH amino acid sequences SEQ ID NO:686 and SEQ ID NO:688, VL amino acid sequences having the VH amino acid sequences SEQ ID NO:690 and SEQ ID NO:692, VL amino acid sequences having the VH amino acid sequences SEQ ID NO:694 and SEQ ID NO:696, VL amino acid sequences having the VH amino acid sequences SEQ ID NO:698 and SEQ ID NO:700, and VL amino acid sequences having the VH amino acid sequences SEQ ID NO:702 and SEQ ID NO:704.

[0040] In other embodiments, the anti-Middle East Respiratory Syndrome coronavirus (MERS-CoV) antibody comprises a heavy chain having three CDRs comprising the amino acid sequences of 705, 706, and 707 and a light chain having three CDRs comprising the amino acid sequences 722, 723, and 724; a heavy chain having three CDRs comprising the amino acid sequences of 708, 709, and 710 and a light chain having three CDRs comprising the amino acid sequences 725, 726, and 727; a heavy chain having three CDRs comprising the amino acid sequences of 711, 712, and 713 and a light chain having three CDRs comprising the amino acid sequences 728, 729, and 730; and a light chain having three CDRs comprising amino acid sequences 731, 732, and 733; a heavy chain having three CDRs comprising amino acid sequences 711, 735, and 716 and a light chain having three CDRs comprising amino acid sequences 737, 738, and 739; a heavy chain having three CDRs comprising amino acid sequences 717, 718, and 719 and a light chain having three CDRs comprising amino acid sequences 736, 742, and 743; and a heavy chain having three CDRs comprising amino acid sequences 714, 720, and 721 and a light chain having three CDRs comprising amino acid sequences 740, 729, and 741.

[0041] GITR(93) Exemplary anti-human GITR antibodies include a VH nucleotide sequence having SEQ ID NO: 1361 and a VL nucleotide sequence having SEQ ID NO: 1363, a VH nucleotide sequence having SEQ ID NO: 1365 and a VL nucleotide sequence having SEQ ID NO: 1367, a VH nucleotide sequence having SEQ ID NO: 1369 and a VL nucleotide sequence having SEQ ID NO: 1371, a VH nucleotide sequence having SEQ ID NO: 1381 and a VL nucleotide sequence having SEQ ID NO: 1375, a VH nucleotide sequence having SEQ ID NO: 1377 and a VL nucleotide sequence having SEQ ID NO: 1379, a VH nucleotide sequence having SEQ ID NO: 1381 and a VL nucleotide sequence having SEQ ID NO: 1383, a VH nucleotide sequence having SEQ ID NO: 1385 and a VL nucleotide sequence having SEQ ID NO: 1387, a VH nucleotide sequence having SEQ ID NO: 1389 and a VL nucleotide sequence having SEQ ID NO: 1389 The antibodies include antibodies having a VL nucleotide sequence having SEQ ID NO:1391, a VH nucleotide sequence having SEQ ID NO:1393 and a VL nucleotide sequence having SEQ ID NO:1395, a VH nucleotide sequence having SEQ ID NO:1397 and a VL nucleotide sequence having SEQ ID NO:1398, or a VH nucleotide sequence having SEQ ID NO:1401 and a VL nucleotide sequence having SEQ ID NO:1403.

[0042] Exemplary anti-human GITR antibodies include a VH amino acid sequence having SEQ ID NO: 1362 and a VL amino acid sequence having SEQ ID NO: 1364, a VH amino acid sequence having SEQ ID NO: 1366 and a VL polypeptide sequence having SEQ ID NO: 1368, a VH amino acid sequence having SEQ ID NO: 1371 and a VL amino acid sequence having SEQ ID NO: 1372, a VH amino acid sequence having SEQ ID NO: 1382 and a VL amino acid sequence having SEQ ID NO: 1376, a VH nucleotide sequence having SEQ ID NO: 1378 and a VL nucleotide sequence having SEQ ID NO: 1380, a VH amino acid sequence having SEQ ID NO: 1382 and a VL polypeptide sequence having SEQ ID NO: 1384, a VH amino acid sequence having SEQ ID NO: 1386 and a VL amino acid sequence having SEQ ID NO: 1388, a VH amino acid sequence having SEQ ID NO: 1390 and a VL nucleotide sequence having SEQ ID NO: 1391, The antibodies include antibodies having a VL amino acid sequence having SEQ ID NO:1392, a VH amino acid sequence having SEQ ID NO:1394 and a VL polypeptide sequence having SEQ ID NO:1396, a VH amino acid sequence having SEQ ID NO:1399 and a VL amino acid sequence having SEQ ID NO:1400, or a VH amino acid sequence having SEQ ID NO:1402 and a VL amino acid sequence having SEQ ID NO:1404.

[0043] In other embodiments, the anti-human GITR antibody comprises a heavy chain having three CDRs comprising amino acid sequences 1405, 1406, and 1407, respectively, and a light chain having three CDRs comprising amino acid sequences 1408, 1409, and 1410; a heavy chain having three CDRs comprising amino acid sequences 1411, 1412, and 1413, respectively, and a light chain having three CDRs comprising amino acid sequences 1414, 1415, and 1416; a heavy chain having three CDRs comprising amino acid sequences 1417, 1418, and 1419, respectively, and a light chain having three CDRs comprising amino acid sequences 1420, 1421, and 1422; a light chain having three CDRs comprising the sequences 1420, 1421 and 1422; a heavy chain having three CDRs comprising the amino acid sequences 1423, 1424 and 1425, respectively, and a light chain having three CDRs comprising the amino acid sequences 1426, 1427 and 1428; a heavy chain having three CDRs comprising the amino acid sequences 1429, 1430 and 1431, respectively, and a light chain having three CDRs comprising the amino acid sequences 1432, 1433 and 1434, respectively, and three CDRs comprising the amino acid sequences 1435, 1436 and 1437; and a light chain having three CDRs comprising amino acid sequences 1438, 1439, and 1440, respectively; a heavy chain having three CDRs comprising amino acid sequences 1441, 1442, and 1443, respectively, and a light chain having three CDRs comprising amino acid sequences 1444, 1445, and 1446, respectively; a heavy chain having three CDRs comprising amino acid sequences 1447, 1448, and 1449, respectively, and a light chain having three CDRs comprising amino acid sequences 1450, 1451, and 1452, respectively; and 1455 and a light chain having three CDRs comprising amino acid sequences 1456, 1457, and 1458, respectively; a heavy chain having three CDRs comprising amino acid sequences 1459, 1460, and 1461, respectively, and a light chain having three CDRs comprising amino acid sequences 1462, 1463, and 1464, respectively; or a heavy chain having three CDRs comprising amino acid sequences 1465, 1466, and 1467, respectively, and a light chain having three CDRs comprising amino acid sequences 1468, 1469, and 1470, respectively.

[0044] Flavivirus (73) Exemplary anti-West Nile virus envelope protein E (WNE) antibodies include antibodies having a VH nucleotide sequence having the VH amino acid sequence having SEQ ID NO:1224 and a VL amino acid sequence having SEQ ID NO:1226.

[0045] Exemplary anti-West Nile virus envelope protein E (WNE) antibodies include antibodies having a VH nucleotide sequence having SEQ ID NO:1225 and a VL nucleotide sequence having SEQ ID NO:1227.

[0046] In other embodiments, the anti-West Nile virus envelope protein E (WNE) antibody has a heavy chain with three CDRs comprising amino acid sequences 1244, 1245, and 1246, and a light chain with three CDRs comprising amino acid sequences 1247, 1248, and 1249, respectively.

[0047] CCR4(65) Exemplary anti-CC chemokine receptor 4 (CCR4) antibodies include antibodies having a VH nucleotide sequence having SEQ ID NO:1329 and a VL nucleotide sequence having SEQ ID NO:1331, a VH nucleotide sequence having SEQ ID NO:1333 and a VL nucleotide sequence having SEQ ID NO:1335, a VH nucleotide sequence having SEQ ID NO:1337 and a VL nucleotide sequence having SEQ ID NO:1192, a VH nucleotide sequence having SEQ ID NO:1341 and a VL nucleotide sequence having SEQ ID NO:1343, or a VH nucleotide sequence having SEQ ID NO:1357 and a VL nucleotide sequence having SEQ ID NO:1359.

[0048] An exemplary anti-CC chemokine receptor 4 (CCR4) antibody is V having SEQ ID NO:1330. H V having the amino acid sequence SEQ ID NO: 1332 L V having the amino acid sequence SEQ ID NO:1334 HV having the amino acid sequence SEQ ID NO: 1336 L V having the amino acid sequence SEQ ID NO:1338 H V having the amino acid sequence SEQ ID NO: 1340 L V having the amino acid sequence SEQ ID NO:1342 H V having the amino acid sequence SEQ ID NO: 1344 L V having the amino acid sequence SEQ ID NO: 1358 H V having the amino acid sequence SEQ ID NO: 1360 L It includes an antibody having an amino acid sequence.

[0049] In other embodiments, the anti-CC chemokine receptor 4 (CCR4) antibody comprises a heavy chain having three CDRs comprising amino acid sequences 1203, 1208, and 1211, respectively, and a light chain having three CDRs comprising amino acid sequences 1207, 1209, and 1216, or a heavy chain having three CDRs comprising amino acid sequences 1204, 1208, and 1212, respectively, and a light chain having three CDRs comprising amino acid sequences 1207, 1209, and 1217, or a heavy chain having three CDRs comprising amino acid sequences 1204, 1208, and 1213, respectively, and a light chain having three CDRs comprising amino acid sequences 1207, 1209, and 1217. a heavy chain having three CDRs comprising the amino acid sequences 1205, 1208, and 1214, respectively, and a light chain having three CDRs comprising the amino acid sequences 1207, 1209, and 1218, or a heavy chain having three CDRs comprising the amino acid sequences 1206, 1208, and 1210, respectively, and a light chain having three CDRs comprising the amino acid sequences 1207, 1209, and 1220, or a heavy chain having three CDRs comprising the amino acid sequences 1202, 1208, and 1210, respectively, and a light chain having three CDRs comprising the amino acid sequences 1207, 1209, and 1219.

[0050] Human immunoglobulin heavy chain variable region germline gene VH1-69(57)

[0051] Exemplary anti-human immunoglobulin heavy chain variable region germline gene VH1-69 antibodies include antibodies having a VH nucleotide sequence having SEQ ID NO:1153 and a VL nucleotide sequence having SEQ ID NO:1155, or a VH nucleotide sequence having SEQ ID NO:1163 and a VL nucleotide sequence having SEQ ID NO:1155.

[0052] An exemplary anti-human immunoglobulin heavy chain variable region germline gene VH1-69 antibody is the VH1-69 antibody having SEQ ID NO:1154. H V having the amino acid sequence SEQ ID NO: 1156 L V having the amino acid sequence SEQ ID NO:1164 H V having the amino acid sequence SEQ ID NO: 1156 L It includes an antibody having an amino acid sequence.

[0053] In other embodiments, the anti-human immunoglobulin heavy chain variable region germline gene VH1-69 antibody has a heavy chain with three CDRs comprising amino acid sequences 1157, 1158, and 1159, and a light chain with three CDRs comprising amino acid sequences 1160, 1161, and 1162, respectively.

[0054] Influenza (49) Exemplary anti-influenza antibodies include a VH nucleotide sequence having SEQ ID NO:981 and a VL nucleotide sequence having SEQ ID NO:983, a VH nucleotide sequence having SEQ ID NO:985 and a VL nucleotide sequence having SEQ ID NO:989, a VH nucleotide sequence having SEQ ID NO:987 and a VL nucleotide sequence having SEQ ID NO:991, a VH nucleotide sequence having SEQ ID NO:993 and a VL nucleotide sequence having SEQ ID NO:997, a VH nucleotide sequence having SEQ ID NO:995 and a VL nucleotide sequence having SEQ ID NO:999, a VH nucleotide sequence having SEQ ID NO:1001 and a VL nucleotide sequence having SEQ ID NO:1005, a VH nucleotide sequence having SEQ ID NO:1003 and a VL nucleotide sequence having SEQ ID NO:1007, a VH nucleotide sequence having SEQ ID NO:1009 and a VL nucleotide sequence having SEQ ID NO:1011, These antibodies include an antibody having a VH nucleotide sequence having SEQ ID NO:1013 and a VL nucleotide sequence having SEQ ID NO:1015, as well as an antibody having a VH nucleotide sequence having SEQ ID NO:1017 and a VK nucleotide sequence having SEQ ID NO:1019, a VH nucleotide sequence having SEQ ID NO:1020 and a VL nucleotide sequence having SEQ ID NO:1022.

[0055] Exemplary anti-influenza antibodies include a VH amino acid sequence having SEQ ID NO:982 and a VL amino acid sequence having SEQ ID NO:984, a VH amino acid sequence having SEQ ID NO:986 and a VL amino acid sequence having SEQ ID NO:988, a VH amino acid sequence having SEQ ID NO:986 and a VL amino acid sequence having SEQ ID NO:990, a VH amino acid sequence having SEQ ID NO:992 and a VL amino acid sequence having SEQ ID NO:994, a VH amino acid sequence having SEQ ID NO:992 and a VL amino acid sequence having SEQ ID NO:996, a VH amino acid sequence having SEQ ID NO:998 and a VL amino acid sequence having SEQ ID NO:1000, a VH amino acid sequence having SEQ ID NO:998 and a VL amino acid sequence having SEQ ID NO:1002, a VH amino acid sequence having SEQ ID NO:1004 and a VL amino acid sequence having SEQ ID NO:1006, These antibodies include an antibody having a VH amino acid sequence having SEQ ID NO:1008 and a VL amino acid sequence having SEQ ID NO:1010, a VH amino acid sequence having SEQ ID NO:1012 and a VK amino acid sequence having SEQ ID NO:1014, and a VH amino acid sequence having SEQ ID NO:1016 and a VL amino acid sequence having SEQ ID NO:1018.

[0056] In other embodiments, the anti-influenza antibody comprises a heavy chain having three CDRs comprising the amino acid sequences of 1023, 1031, and 1039 and a light chain having three CDRs comprising the amino acid sequences of 1047, 1059, and 1071; a heavy chain having three CDRs comprising the amino acid sequences of 1023, 1032, and 1040 and a light chain having three CDRs comprising the amino acid sequences of 1048, 1060, and 1072; a heavy chain having three CDRs comprising the amino acid sequences of 1025, 1032, and 1040 and a light chain having three CDRs comprising the amino acid sequences of 1048, 1060, and 1072; a light chain having three CDRs comprising the amino acid sequences 1057, 1069 and 1081; a heavy chain having three CDRs comprising the amino acid sequences 1026, 1033 and 1041; a light chain having three CDRs comprising the amino acid sequences 1049, 1061 and 1073; a heavy chain having three CDRs comprising the amino acid sequences 1026, 1033 and 1041; a light chain having three CDRs comprising the amino acid sequences 1054, 1066 and 1078; a light chain having three CDRs comprising the amino acid sequences 1027, 1034 and 1042; a heavy chain having three CDRs comprising amino acid sequences 1050, 1062, and 1074; a heavy chain having three CDRs comprising amino acid sequences 1027, 1034, and 1042 and a light chain having three CDRs comprising amino acid sequences 1056, 1068, and 1080; a heavy chain having three CDRs comprising amino acid sequences 1028, 1035, and 1043 and a light chain having three CDRs comprising amino acid sequences 1051, 1063, and 1065; a heavy chain having three CDRs comprising the amino acid sequences 1029, 1037, and 1045 and a light chain having three CDRs comprising the amino acid sequences 1053, 1065, and 1077; or a heavy chain having three CDRs comprising the amino acid sequences 1030, 1038, and 1046 and a light chain having three CDRs comprising the amino acid sequences 1058, 1070, and 1082.

[0057] Influenza (78) Exemplary anti-influenza antibodies include a VH nucleotide sequence having SEQ ID NO:397 and a VL nucleotide sequence having SEQ ID NO:398, a VH nucleotide sequence having SEQ ID NO:399 and a VL nucleotide sequence having SEQ ID NO:400, L Nucleotide sequences, VH nucleotide sequence having SEQ ID NO:401 and VH nucleotide sequence having SEQ ID NO:402 Lnucleotide sequences, a VH nucleotide sequence having SEQ ID NO:403 and a VL nucleotide sequence having SEQ ID NO:404, or a VH nucleotide sequence having SEQ ID NO:405 and a VL nucleotide sequence having SEQ ID NO:406, or a VH nucleotide sequence having SEQ ID NO:407 and a VL nucleotide sequence having SEQ ID NO:408, or a VH nucleotide sequence having SEQ ID NO:409 and a VL nucleotide sequence having SEQ ID NO:410, or a VH nucleotide sequence having SEQ ID NO:411 and a VL nucleotide sequence having SEQ ID NO:412, or a VH nucleotide sequence having SEQ ID NO:413 and a VL nucleotide sequence having SEQ ID NO:414, or a VH nucleotide sequence having SEQ ID NO:415 and a VL nucleotide sequence having SEQ ID NO:416, or a VH nucleotide sequence having SEQ ID NO:417 and a VL nucleotide sequence having SEQ ID NO:418, or a VH nucleotide sequence having SEQ ID NO:419 and a VL nucleotide sequence having SEQ ID NO:420, or a VH nucleotide sequence having SEQ ID NO:421 and a VL nucleotide sequence having SEQ ID NO:422, or a VH nucleotide sequence having SEQ ID NO:423 and a VL nucleotide sequence having SEQ ID NO:424, or a VH nucleotide sequence having SEQ ID NO:425 and a VL nucleotide sequence having SEQ ID NO:426, or a VH nucleotide sequence having SEQ ID NO:427 and a VL nucleotide sequence having SEQ ID NO:428, or a VH nucleotide sequence having SEQ ID NO:429 and a VL nucleotide sequence having SEQ ID NO:430, or a VH nucleotide sequence having SEQ ID NO:431 and a VL nucleotide sequence having SEQ ID NO:432, or a VH nucleotide sequence having SEQ ID NO:433 and a VL nucleotide sequence having SEQ ID NO:434, or a VH nucleotide sequence having SEQ ID NO:435 and a VL nucleotide sequence having SEQ ID NO:436,a VH nucleotide sequence having SEQ ID NO:435 and a VL nucleotide sequence having SEQ ID NO:436, or a VH nucleotide sequence having SEQ ID NO:437 and a VL nucleotide sequence having SEQ ID NO:438, or a VH nucleotide sequence having SEQ ID NO:439 and a VL nucleotide sequence having SEQ ID NO:440, or a VH nucleotide sequence having SEQ ID NO:441 and a VL nucleotide sequence having SEQ ID NO:442, or a VH nucleotide sequence having SEQ ID NO:541 and a VL nucleotide sequence having SEQ ID NO:542, or a VH nucleotide sequence having SEQ ID NO:543 and a VL nucleotide sequence having SEQ ID NO:544, or a VH nucleotide sequence having SEQ ID NO:545 and a VL nucleotide sequence having SEQ ID NO:546, or a VH nucleotide sequence having SEQ ID NO:547 and a VL nucleotide sequence having SEQ ID NO:548, or a VH nucleotide sequence having SEQ ID NO:549 and a VL nucleotide sequence having SEQ ID NO:550. or a VH nucleotide sequence having SEQ ID NO: 551 and a VL nucleotide sequence having SEQ ID NO: 552, or a VH nucleotide sequence having SEQ ID NO: 553 and a VL nucleotide sequence having SEQ ID NO: 554, or a VH nucleotide sequence having SEQ ID NO: 555 and a VL nucleotide sequence having SEQ ID NO: 556, or a VH nucleotide sequence having SEQ ID NO: 557 and a VL nucleotide sequence having SEQ ID NO: 558, or a VH nucleotide sequence having SEQ ID NO: 559 and a VL nucleotide sequence having SEQ ID NO: 560, or a VH nucleotide sequence having SEQ ID NO: 561 and a VL nucleotide sequence having SEQ ID NO: 562, or a VH nucleotide sequence having SEQ ID NO: 563 and a VL nucleotide sequence having SEQ ID NO: 564, ora VH nucleotide sequence having SEQ ID NO:565 and a VL nucleotide sequence having SEQ ID NO:566, or a VH nucleotide sequence having SEQ ID NO:567 and a VL nucleotide sequence having SEQ ID NO:568, or a VH nucleotide sequence having SEQ ID NO:569 and a VL nucleotide sequence having SEQ ID NO:570, or a VH nucleotide sequence having SEQ ID NO:571 and a VL nucleotide sequence having SEQ ID NO:572, or a VH nucleotide sequence having SEQ ID NO:573 and a VL nucleotide sequence having SEQ ID NO:574, or a VH nucleotide sequence having SEQ ID NO:575 and a VL nucleotide sequence having SEQ ID NO:576, or a VH nucleotide sequence having SEQ ID NO:577 and a VL nucleotide sequence having SEQ ID NO:578, or a VH nucleotide sequence having SEQ ID NO:579 and a VL nucleotide sequence having SEQ ID NO:580, or a VH nucleotide sequence having SEQ ID NO:581 and a VL nucleotide sequence having SEQ ID NO:582. or a VH nucleotide sequence having SEQ ID NO: 583 and a VL nucleotide sequence having SEQ ID NO: 584, or a VH nucleotide sequence having SEQ ID NO: 585 and a VL nucleotide sequence having SEQ ID NO: 586, or a VH nucleotide sequence having SEQ ID NO: 587 and a VL nucleotide sequence having SEQ ID NO: 588, or a VH nucleotide sequence having SEQ ID NO: 589 and a VL nucleotide sequence having SEQ ID NO: 590, or a VH nucleotide sequence having SEQ ID NO: 591 and a VL nucleotide sequence having SEQ ID NO: 592, or a VH nucleotide sequence having SEQ ID NO: 593 and a VL nucleotide sequence having SEQ ID NO: 594, or a VH nucleotide sequence having SEQ ID NO: 595 and a VL nucleotide sequence having SEQ ID NO: 596, orThe antibodies include an antibody having a VH nucleotide sequence having SEQ ID NO:597 and a VL nucleotide sequence having SEQ ID NO:598, or a VH nucleotide sequence having SEQ ID NO:599 and a VL nucleotide sequence having SEQ ID NO:600.

[0058] Exemplary anti-influenza antibodies include a VH amino acid sequence having SEQ ID NO:469 and a VL amino acid sequence having SEQ ID NO:470, a VH amino acid sequence having SEQ ID NO:471 and a VL amino acid sequence having SEQ ID NO:472, L Polypeptide sequences, VH amino acid sequence having SEQ ID NO:473 and VH amino acid sequence having SEQ ID NO:474 Lamino acid sequence, a VH amino acid sequence having SEQ ID NO:475 and a VL amino acid sequence having SEQ ID NO:476, or a VH nucleotide sequence having SEQ ID NO:477 and a VL nucleotide sequence having SEQ ID NO:478, a VH amino acid sequence having SEQ ID NO:479 and a VL amino acid sequence having SEQ ID NO:480, a VH amino acid sequence having SEQ ID NO:481 and a VL amino acid sequence having SEQ ID NO:482, a VH amino acid sequence having SEQ ID NO:483 and a VL amino acid sequence having SEQ ID NO:484, a VH amino acid sequence having SEQ ID NO:485 and a VL amino acid sequence having SEQ ID NO:486, a VH amino acid sequence having SEQ ID NO:487 and a VL amino acid sequence having SEQ ID NO:488, a VH amino acid sequence having SEQ ID NO:489 and a VL amino acid sequence having SEQ ID NO:490, a VH amino acid sequence having SEQ ID NO:491 and a VL amino acid sequence having SEQ ID NO:492 a VH amino acid sequence having SEQ ID NO: 492, a VH amino acid sequence having SEQ ID NO: 493 and a VL amino acid sequence having SEQ ID NO: 494, a VH amino acid sequence having SEQ ID NO: 495 and a VL amino acid sequence having SEQ ID NO: 496, a VH amino acid sequence having SEQ ID NO: 497 and a VL amino acid sequence having SEQ ID NO: 498, a VH amino acid sequence having SEQ ID NO: 499 and a VL amino acid sequence having SEQ ID NO: 500, a VH amino acid sequence having SEQ ID NO: 501 and a VL amino acid sequence having SEQ ID NO: 502, a VH amino acid sequence having SEQ ID NO: 503 and a VL amino acid sequence having SEQ ID NO: 504, a VH amino acid sequence having SEQ ID NO: 505 and a VL amino acid sequence having SEQ ID NO: 506, a VH amino acid sequence having SEQ ID NO: 507 and a VL amino acid sequence having SEQ ID NO: 508, The VH amino acid sequence having SEQ ID NO:509 and the VL amino acid sequence having SEQ ID NO:510,a VH amino acid sequence having SEQ ID NO:511 and a VL amino acid sequence having SEQ ID NO:512, a VH amino acid sequence having SEQ ID NO:513 and a VL amino acid sequence having SEQ ID NO:514, a VH amino acid sequence having SEQ ID NO:515 and a VL amino acid sequence having SEQ ID NO:516, a VH amino acid sequence having SEQ ID NO:517 and a VL amino acid sequence having SEQ ID NO:518, a VH amino acid sequence having SEQ ID NO:519 and a VL amino acid sequence having SEQ ID NO:520, a VH amino acid sequence having SEQ ID NO:521 and a VL amino acid sequence having SEQ ID NO:522, a VH amino acid sequence having SEQ ID NO:523 and a VL amino acid sequence having SEQ ID NO:524, a VH amino acid sequence having SEQ ID NO:525 and a VL amino acid sequence having SEQ ID NO:526, a VH amino acid sequence having SEQ ID NO:527 and a VL amino acid sequence having SEQ ID NO:528 a VH amino acid sequence having SEQ ID NO: 537 and a VL amino acid sequence having SEQ ID NO: 538; a VH amino acid sequence having SEQ ID NO: 539 and a VL amino acid sequence having SEQ ID NO: 540; a VH amino acid sequence having SEQ ID NO: 601 and a VL amino acid sequence having SEQ ID NO: 602; a VH amino acid sequence having SEQ ID NO: 603 and a VL amino acid sequence having SEQ ID NO: 604; a VH amino acid sequence having SEQ ID NO:605 and a VL amino acid sequence having SEQ ID NO:606; a VH amino acid sequence having SEQ ID NO:607 and a VL amino acid sequence having SEQ ID NO:608;a VH amino acid sequence having SEQ ID NO: 617 and a VL amino acid sequence having SEQ ID NO: 618; a VH amino acid sequence having SEQ ID NO: 619 and a VL amino acid sequence having SEQ ID NO: 620; a VH amino acid sequence having SEQ ID NO: 621 and a VL amino acid sequence having SEQ ID NO: 622; a VH amino acid sequence having SEQ ID NO: 623 and a VL amino acid sequence having SEQ ID NO: 624; a VH amino acid sequence having SEQ ID NO: 625 and a VL amino acid sequence having SEQ ID NO: 626; a VH amino acid sequence having SEQ ID NO:625 and a VL amino acid sequence having SEQ ID NO:626, a VH amino acid sequence having SEQ ID NO:627 and a VL amino acid sequence having SEQ ID NO:628, a VH amino acid sequence having SEQ ID NO:629 and a VL amino acid sequence having SEQ ID NO:630, a VH amino acid sequence having SEQ ID NO:631 and a VL amino acid sequence having SEQ ID NO:632, a VH amino acid sequence having SEQ ID NO:633 and a VL amino acid sequence having SEQ ID NO:634, a VH amino acid sequence having SEQ ID NO:635 and a VL amino acid sequence having SEQ ID NO:636, a VH amino acid sequence having SEQ ID NO:637 and a VL amino acid sequence having SEQ ID NO:638, a VH amino acid sequence having SEQ ID NO:639 and a VL amino acid sequence having SEQ ID NO:640, a VH amino acid sequence having SEQ ID NO:641 and a VL amino acid sequence having SEQ ID NO:642 a VL amino acid sequence having SEQ ID NO:642, a VH amino acid sequence having SEQ ID NO:643 and a VL amino acid sequence having SEQ ID NO:644,The antibodies include antibodies having a VH amino acid sequence having SEQ ID NO:645 and a VL amino acid sequence having SEQ ID NO:646, a VH amino acid sequence having SEQ ID NO:647 and a VL amino acid sequence having SEQ ID NO:648, a VH amino acid sequence having SEQ ID NO:649 and a VL amino acid sequence having SEQ ID NO:650, a VH amino acid sequence having SEQ ID NO:651 and a VL amino acid sequence having SEQ ID NO:652, a VH amino acid sequence having SEQ ID NO:653 and a VL amino acid sequence having SEQ ID NO:654, a VH amino acid sequence having SEQ ID NO:655 and a VL amino acid sequence having SEQ ID NO:656, a VH amino acid sequence having SEQ ID NO:657 and a VL amino acid sequence having SEQ ID NO:658, and a VH amino acid sequence having SEQ ID NO:659 and a VL amino acid sequence having SEQ ID NO:660.

[0059] In other embodiments, the anti-influenza antibody comprises a heavy chain having three CDRs comprising the amino acid sequences SEQ ID NOs: 1, 37, 73, respectively, and a light chain having three CDRs comprising the amino acid sequences 109, 145, 181, respectively; or a heavy chain having three CDRs comprising the amino acid sequences 2, 38, 74, respectively, and a light chain having three CDRs comprising the amino acid sequences 110, 146, 182, respectively; or a heavy chain having three CDRs comprising the amino acid sequences 3, 39, 75, respectively, and a light chain having three CDRs comprising the amino acid sequences 111, 147, 183, respectively; or a heavy chain having three CDRs comprising the amino acid sequences 4, 40, 76, respectively. a heavy chain having three CDRs comprising amino acid sequences 112, 148, and 184, respectively, and a light chain having three CDRs comprising amino acid sequences 5, 41, and 77, respectively, and a light chain having three CDRs comprising amino acid sequences 113, 149, and 185, respectively, or a heavy chain having three CDRs comprising amino acid sequences 6, 42, and 78, respectively, and a light chain having three CDRs comprising amino acid sequences 114, 150, and 186, respectively, or a heavy chain having three CDRs comprising amino acid sequences 7, 43, and 79, respectively. and a light chain having three CDRs each comprising the amino acid sequences 115, 151, 187, or a heavy chain having three CDRs each comprising the amino acid sequences 8, 44, 80 and a light chain having three CDRs each comprising the amino acid sequences 116, 152, 188, or a heavy chain having three CDRs each comprising the amino acid sequences 9, 45, 81 and a light chain having three CDRs each comprising the amino acid sequences 117, 153, 189, or a heavy chain having three CDRs each comprising the amino acid sequences 10, 46, 82 and a light chain having three CDRs each comprising the amino acid sequences 117, 153, 189, a light chain having three CDRs comprising the sequences 118, 154, 190, or a heavy chain having three CDRs comprising the amino acid sequences 11, 47, 83, respectively, and a light chain having three CDRs comprising the amino acid sequences 119, 155, 191, respectively, or a heavy chain having three CDRs comprising the amino acid sequences 12, 48, 84, respectively, and a light chain having three CDRs comprising the amino acid sequences 120, 156, 192, respectively, or a heavy chain having three CDRs comprising the amino acid sequences 13, 49, 85, respectively, and a light chain having three CDRs comprising the amino acid sequences 121, 157,a heavy chain having three CDRs comprising the amino acid sequences 14, 50, 86, respectively, and a light chain having three CDRs comprising the amino acid sequences 122, 158, 194, respectively, or a heavy chain having three CDRs comprising the amino acid sequences 15, 51, 87, respectively, and a light chain having three CDRs comprising the amino acid sequences 123, 159, 195, respectively, or a heavy chain having three CDRs comprising the amino acid sequences 16, 52, 88, respectively, and a light chain having three CDRs comprising the amino acid sequences 124, 160, 196, respectively; or a heavy chain having three CDRs each comprising the amino acid sequences 17, 53, 89 and a light chain having three CDRs each comprising the amino acid sequences 125, 161, 197, or a heavy chain having three CDRs each comprising the amino acid sequences 18, 54, 90 and a light chain having three CDRs each comprising the amino acid sequences 126, 162, 198, or a heavy chain having three CDRs each comprising the amino acid sequences 19, 55, 91 and a light chain having three CDRs each comprising the amino acid sequences 127, 163, 199, or a heavy chain having three CDRs each comprising the amino acid sequences 20, 56, a heavy chain having three CDRs comprising amino acid sequences 21, 57, 93, respectively, and a light chain having three CDRs comprising amino acid sequences 129, 165, 201, respectively; a heavy chain having three CDRs comprising amino acid sequences 22, 58, 94, respectively, and a light chain having three CDRs comprising amino acid sequences 130, 166, 202, respectively; or a heavy chain having three CDRs comprising amino acid sequences 23, 59, 95, respectively, and a light chain having three CDRs comprising amino acid sequences 24, 59, 96, respectively. and a light chain having three CDRs each comprising the amino acid sequences 131, 167, and 203, or a heavy chain having three CDRs each comprising the amino acid sequences 24, 60, and 96 and a light chain having three CDRs each comprising the amino acid sequences 132, 168, and 204, or a heavy chain having three CDRs each comprising the amino acid sequences 25, 61, and 95 and a light chain having three CDRs each comprising the amino acid sequences 133, 169, and 205, or a heavy chain having three CDRs each comprising the amino acid sequences 26, 62, and 96 and a light chain having three CDRs each comprising the amino acid sequences 134, 170, and 171,a heavy chain having three CDRs comprising the amino acid sequences 27, 63, 97, respectively, and a light chain having three CDRs comprising the amino acid sequences 135, 171, 207, respectively; or a heavy chain having three CDRs comprising the amino acid sequences 28, 64, 98, respectively, and a light chain having three CDRs comprising the amino acid sequences 136, 172, 208, respectively; or a heavy chain having three CDRs comprising the amino acid sequences 29, 65, 99, respectively, and a light chain having three CDRs comprising the amino acid sequences 137, 173, 209, respectively; or a heavy chain having three CDRs each containing the amino acid sequences 30, 66, and 100 and a light chain having three CDRs each containing the amino acid sequences 138, 174, and 210, or a heavy chain having three CDRs each containing the amino acid sequences 31, 67, and 101 and a light chain having three CDRs each containing the amino acid sequences 139, 175, and 211, or a heavy chain having three CDRs each containing the amino acid sequences 32, 68, and 102 and a light chain having three CDRs each containing the amino acid sequences 140, 176, and 212, or a heavy chain having three CDRs each containing the amino acid sequences 33, 69, and 103 and a light chain having three CDRs each comprising the amino acid sequences 141, 177, and 213, respectively; or a heavy chain having three CDRs each comprising the amino acid sequences 34, 70, and 104, respectively, and a light chain having three CDRs each comprising the amino acid sequences 142, 178, and 214, respectively; or a heavy chain having three CDRs each comprising the amino acid sequences 35, 71, and 105, respectively, and a light chain having three CDRs each comprising the amino acid sequences 143, 179, and 215, respectively; or a heavy chain having three CDRs each comprising the amino acid sequences 36, 72, and 106, respectively, and a light chain having three CDRs each comprising the amino acid sequences 36, 72, and 106, respectively. a light chain having three CDRs each containing the amino acid sequences 144, 180, and 216, or a heavy chain having three CDRs each containing the amino acid sequences 217, 247, and 277 and a light chain having three CDRs each containing the amino acid sequences 307, 337, and 367, or a heavy chain having three CDRs each containing the amino acid sequences 218, 248, and 278 and a light chain having three CDRs each containing the amino acid sequences 308, 338, and 368, or a heavy chain having three CDRs each containing the amino acid sequences 219, 249, and 279 and a light chain having three CDRs each containing the amino acid sequence 309,a light chain having three CDRs comprising amino acid sequences 220, 250, 280, respectively, and a light chain having three CDRs comprising amino acid sequences 310, 340, 370, respectively; a heavy chain having three CDRs comprising amino acid sequences 221, 251, 281, respectively, and a light chain having three CDRs comprising amino acid sequences 311, 341, 371, respectively; or a heavy chain having three CDRs comprising amino acid sequences 222, 252, 282, respectively, and a light chain having three CDRs comprising amino acid sequences 312, 342, 372, respectively. a heavy chain having three CDRs each containing the amino acid sequences 223, 253, and 283 and a light chain having three CDRs each containing the amino acid sequences 313, 343, and 373; a heavy chain having three CDRs each containing the amino acid sequences 224, 254, and 284 and a light chain having three CDRs each containing the amino acid sequences 314, 344, and 374; or a heavy chain having three CDRs each containing the amino acid sequences 225, 255, and 285 and a light chain having three CDRs each containing the amino acid sequences 315, 345, and 375. or a heavy chain having three CDRs each comprising the amino acid sequences 226, 256, 286 and a light chain having three CDRs each comprising the amino acid sequences 316, 346, 376, or a heavy chain having three CDRs each comprising the amino acid sequences 227, 257, 287 and a light chain having three CDRs each comprising the amino acid sequences 317, 347, 377, or a heavy chain having three CDRs each comprising the amino acid sequences 228, 258, 288 and a light chain having three CDRs each comprising the amino acid sequences 318, 348, 378, or a heavy chain having three CDRs each comprising the amino acid sequences 229, 259, 289 and a light chain having three CDRs each comprising the amino acid sequences 319, 349, 379, or a heavy chain having three CDRs each comprising the amino acid sequences 230, 260, 290 and a light chain having three CDRs each comprising the amino acid sequences 320, 350, 380, or a heavy chain having three CDRs each comprising the amino acid sequences 231, 261, 291 and a light chain having three CDRs each comprising the amino acid sequences 321, 351, 381, or a heavy chain having three CDRs each comprising the amino acid sequences 232, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333,a heavy chain having three CDRs comprising the amino acid sequences 233, 263, and 293, respectively, and a light chain having three CDRs comprising the amino acid sequences 323, 353, and 383, respectively; a heavy chain having three CDRs comprising the amino acid sequences 234, 273, and 294, respectively, and a light chain having three CDRs comprising the amino acid sequences 324, 354, and 384, respectively; or a heavy chain having three CDRs comprising the amino acid sequences 235, 274, and 295, respectively. a heavy chain having three CDRs each comprising the amino acid sequences 325, 355, and 385, or a heavy chain having three CDRs each comprising the amino acid sequences 236, 275, and 296, and a light chain having three CDRs each comprising the amino acid sequences 326, 356, and 386, or a heavy chain having three CDRs each comprising the amino acid sequences 237, 276, and 297, and a light chain having three CDRs each comprising the amino acid sequences 327, 357, and 387, or a heavy chain having three CDRs each comprising the amino acid sequences 237, 277, and 298, and a light chain having three CDRs each containing the amino acid sequences 328, 358, and 388, or a heavy chain having three CDRs each containing the amino acid sequences 238, 278, and 299 and a light chain having three CDRs each containing the amino acid sequences 329, 359, and 389, or a heavy chain having three CDRs each containing the amino acid sequences 239, 279, and 300 and a light chain having three CDRs each containing the amino acid sequences 330, 360, and 390, or a heavy chain having three CDRs each containing the amino acid sequences 240, 280, and 301 and a light chain having three CDRs each containing the amino acid sequences 330, 360, and 390, a light chain having three CDRs comprising the sequences 331, 361, 391, or a heavy chain having three CDRs comprising the amino acid sequences 241, 281, 302, respectively, and a light chain having three CDRs comprising the amino acid sequences 332, 362, 392, respectively, or a heavy chain having three CDRs comprising the amino acid sequences 242, 282, 303, respectively, and a light chain having three CDRs comprising the amino acid sequences 333, 363, 393, respectively, or a heavy chain having three CDRs comprising the amino acid sequences 243, 283, 304, respectively, and a light chain having three CDRs comprising the amino acid sequences 334, 364,a light chain having three CDRs containing the amino acid sequences 244, 284, and 305, respectively, and a light chain having three CDRs containing the amino acid sequences 335, 365, and 395, respectively; or a heavy chain having three CDRs containing the amino acid sequences 245, 285, and 306, respectively, and a light chain having three CDRs containing the amino acid sequences 336, 366, and 396, respectively.

[0060] Other anti-influenza antibodies include those having the amino acid or nucleic acid sequences shown in Table 1 below.

[0061] Table 1A: Nucleic acid sequences of the variable regions of antibody 3I14 TIFF2024163140000001.tif60152

[0062] Table 1B: Amino acid sequence of the variable region of antibody 3I14 TIFF2024163140000002.tif37152

[0063] (Table 1C) Antibody 3I14V L Nucleic acid sequence of the variable region of D94N TIFF2024163140000003.tif25152

[0064] (Table 1C) Antibody 3I14V L Amino acid sequence of the variable region of D94N TIFF2024163140000004.tif15152

[0065] 3I14 and 3I14V L The amino acid sequences of the complementarity determining regions of the heavy and light chains of the D94N neutralizing influenza antibody are shown in Table 2 below.

[0066] (Table 2) TIFF2024163140000005.tif32148

[0067] Other binding domains than scFvs, such as, by way of non-limiting example, camelid single domain antibody fragments or receptor ligands, antibody binding domains, antibody hypervariable loops or CDRs, can also be used for predetermined targeting of lymphocytes.

[0068] In preferred embodiments, the transmembrane domain further comprises a stalk region between the extracellular ligand-binding domain and the transmembrane domain. As used herein, the term "stalk region" generally refers to any oligopeptide or polypeptide that functions to link the transmembrane domain to the extracellular ligand-binding domain. In particular, the stalk region is used to provide increased flexibility and accessibility to the extracellular ligand-binding domain. The stalk region may comprise up to 300 amino acids, preferably 10-100 amino acids, and more preferably 25-50 amino acids. The stalk region may be derived from all or a portion of a naturally occurring molecule, such as all or a portion of the extracellular region of CD8, CD4, or CD28, or all or a portion of an antibody constant region. Alternatively, the stalk region may be a synthetic sequence corresponding to a naturally occurring stalk sequence, or may be a completely synthetic stalk sequence. In a preferred embodiment, the stalk region is a portion of the human CD8 alpha chain.

[0069] The signal transduction domain or intracellular signal transduction domain of the CAR of the present invention is responsible for the intracellular signal that activates immune cells and immune responses after the extracellular ligand binding domain binds to the target.In other words, the signal transduction domain is responsible for activating at least one of the normal effector functions of the immune cells that express the CAR.For example, the effector function of T cells can be cytolytic activity or helper activity, including cytokine secretion.Therefore, the term "signal transduction domain" refers to the part of a protein that transmits effector signal function and allows the cell to perform a specific function.

[0070] The signaling domain contains two different classes of cytoplasmic signal sequences: those that initiate antigen-dependent primary activation and those that act in an antigen-independent manner to provide secondary or costimulatory signals. Primary cytoplasmic signal sequences can contain signal motifs known as immunoreceptor tyrosine-based activation motifs or ITAMs. ITAMs are well-defined signal motifs found in the cytoplasmic tails of various receptors that function as binding sites for tyrosine kinases of the syk / zap70 class. Examples of ITAMs used in the present invention can include, but are not limited to, those derived from TCR zeta, FcR gamma, FcR beta, FcR epsilon, CD3 gamma, CD3 delta, CD3 epsilon, CD5, CD22, CD79a, CD79b, and CD66d. In a preferred embodiment, the signaling domain of the CAR can contain the CD3 zeta signaling domain or the cytoplasmic domain of the Fc epsilon RI beta or gamma chain. In another preferred embodiment, the signaling domain is provided by CD3 zeta and costimulation is provided by CD28 and a tumor necrosis factor receptor (TNFr), such as 4-1BB or OX40.

[0071] In certain embodiments, the intracellular signaling domain of the CAR of the present invention comprises a costimulatory signal molecule. In some embodiments, the intracellular signaling domain comprises two, three, four, or more costimulatory molecules in tandem. Costimulatory molecules are cell surface molecules other than antigen receptors or their ligands that are required for an effective immune response.

[0072] A "costimulatory ligand" refers to a molecule on an antigen-presenting cell that specifically binds to a cognate costimulatory molecule on a T cell, thereby providing a signal that mediates a T cell response, including, but not limited to, activation of proliferation, differentiation, etc., in addition to the primary signal provided by, for example, the binding of a peptide-loaded MHC molecule to the TCR / CD3 complex. Costimulatory ligands include CD7, B7-1 (CD80), B7-2 (CD86), PD-L1, PD-L2, 4-1BBL, OX40L, inducible costimulatory ligand (ICOS-L), intracellular adhesion molecules (ICAMs), CD30L, CD40, CD70, CD83, HLA-G, MICA, M1CB, HVEM, lymphotoxin beta receptor, 3 / TR6, ILT3, ILT4, agonists or antibodies that bind to Toll ligand receptors, and Costimulatory ligands may include, but are not limited to, ligands that specifically bind to B7-H3. Costimulatory ligands also include antibodies that specifically bind to costimulatory molecules present on T cells, such as, but not limited to, ligands that specifically bind to CD27, CD28, 4-IBB, OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LTGHT, NKG2C, B7-H3, and CD83.

[0073] A "costimulatory molecule" refers to a cognate binding partner on a T cell that specifically binds to a costimulatory ligand, thereby mediating a costimulatory response by the cell, such as, but not limited to, proliferation. Costimulatory molecules include, but are not limited to, MHC class 1 molecules, BTLA, and Toll ligand receptors. Examples of costimulatory molecules include ligands that specifically bind to CD27, CD28, CD8, 4-1BB (CD137), OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, and CD83, and the like. In another specific embodiment, the signaling domain is a TNFR-associated factor 2 (TRAF2) binding motif, which is the intracytoplasmic tail of the costimulatory TNFR member family. The cytoplasmic tails of costimulatory TNFR family members contain a TRAF2-binding motif consisting of a major conserved motif (P / S / A)X(Q / E)E) or a minor motif (PXQXXD), where X is any amino acid. TRAF proteins are recruited to the intracellular tails of many TNFRs in response to receptor trimerization.

[0074] The distinguishing features of suitable transmembrane polypeptides include their ability to be expressed on the surface of immune cells, particularly lymphocytes or natural killer (NK) cells, and their ability to interact with each other to direct the cellular response of immune cells to a predetermined target cell. The different transmembrane polypeptides of the CAR of the present invention, including extracellular ligand binding domains and / or signaling domains, are involved in signal transduction after binding to target ligands and interact to induce an immune response. The transmembrane domain can be derived from either natural or synthetic sources. The transmembrane domain can be derived from any membrane-bound or transmembrane protein.

[0075] As used herein, the term "portion" refers to any subset of the molecule, such as a shorter polypeptide. Alternatively, functional variants of a polypeptide's amino acid sequence can be prepared by mutations in the DNA encoding the polypeptide. Such variants or functional variants include, for example, deletions from, or insertions or substitutions of, residues within the amino acid sequence. Any combination of deletions, insertions, and substitutions can also be made to arrive at a final construct, particularly one that exhibits specific anti-target cell immune activity, as long as the final construct possesses the desired activity. The function of the CAR of the present invention in a host can be detected in an assay suitable for demonstrating the signaling ability of the CAR upon binding to a specific target. Such assays are available to those skilled in the art. For example, assays including measuring calcium ion release, intracellular tyrosine phosphorylation, inositol phosphate turnover, or the resulting increases in interleukin (IL) 2, interferon gamma, GM-CSF, IL-3, and IL-4 production allow for the detection of signaling pathways induced by target binding.

[0076] cell Embodiments of the present invention include cells expressing a CAR (i.e., CARTS). The cells can be any type of cell, including immune cells capable of expressing a CAR for cancer therapy or cells harboring an expression vector encoding a CAR, such as bacterial cells. As used herein, the terms "cell," "cell line," and "cell culture" can be used interchangeably. All of these terms also encompass their progeny, which are any and all subsequent generations. It is understood that all progeny may not be identical due to intentional or unintentional mutations. In the context of expression of heterologous nucleic acid sequences, a "host cell" refers to a eukaryotic cell capable of replicating a vector and / or expressing a heterologous gene encoded by a vector. A host cell can be or has been used as a recipient of a vector. A host cell can be "transfected" or "transformed," which refer to the process by which foreign nucleic acid is transferred or introduced into the host cell. Transformed cells include the primary cell of interest and its progeny. As used herein, the terms "engineered" and "recombinant" or host cell are intended to refer to a cell into which a foreign nucleic acid sequence, such as a vector, has been introduced. Thus, recombinant cells can be distinguished from naturally occurring cells that do not contain recombinantly introduced nucleic acids. In embodiments of the invention, the host cells are T cells, including cytotoxic T cells (TCs, also known as cytotoxic T lymphocytes, CTLs, T killer cells, cytolytic T cells, CD8+ T cells, or killer T cells); NK cells and NKT cells are also encompassed by the invention.

[0077] Some vectors may utilize control sequences that allow them to replicate and / or express in both prokaryotic and eukaryotic cells. Those skilled in the art will further understand the conditions for incubating all of the above host cells to maintain them and allow replication of the vector. The techniques and conditions for large-scale production of vectors and production of nucleic acids encoded by the vectors and their cognate polypeptides, proteins, or peptides are also understood and known.

[0078] The cells can be autologous, syngeneic, allogeneic and in some instances even xenogeneic.

[0079] In many situations, one skilled in the art may wish to be able to kill modified CTLs when one wishes to terminate treatment, when cells become neoplastic, in studies where the presence and subsequent absence of cells is of interest, or other times. To this end, one skilled in the art may provide for the expression of a particular gene product, e.g., an inducible suicide gene, that can kill the modified cells under controlled conditions.

[0080] Armed CARTS The present invention further includes CARTS engineered to secrete one or more polypeptides. The polypeptides can be, for example, antibodies or cytokines. Preferably, the antibodies are specific for CAIX, GITR, PD-L1, PD-L2, PD-1, or CCR4.

[0081] Armed CARTS have the advantage of simultaneously secreting the polypeptide at the target site, for example, the tumor site.

[0082] Armed CART can be constructed by including the nucleic acid encoding the polypeptide of interest after the intracellular signaling domain.Preferably, an internal ribosome entry site (IRES) is placed between the intracellular signaling domain and the polypeptide of interest.Those skilled in the art can understand that multiple IRES sequences can be used in series to express two or more polypeptides.

[0083] In one embodiment, the methods and compositions described herein provide second-generation, target-specific anti-CAIX CAR T cells armed with the ability to secrete anti-PD-L1 IgG in the RCC environment to address T cell exhaustion. A human anti-CAIX CAR containing a CD28 costimulatory domain was selected based on its killing activity and low immunogenicity in human cRCC xenografts in mice. Anti-CAIX CART cells secreting anti-PD-L1 IgG1 or IgG4 were extensively compared with unrelated anti-BCMA CARs or anti-CAIX CARs, both secreting irrelevant anti-SARS IgG1. We demonstrated stable CAR expression and high proliferation of all CART cells. Anti-CAIX CART cells were capable of clonal expansion upon contact with CAIX+ RCC cells and were activated to release high levels of IFN-γ and IL-2, which may enhance tumor suppression. These anti-CAIX CART cells were also able to secrete high levels of anti-PD-L1 IgG1 or IgG4, which specifically interacted with PD-L1 in vitro and in vivo to induce downregulation of the exhaustion markers PD-1, Tim-3, and Lag-3. These results indicate that anti-PD-L1 antibodies secreted into the tumor microenvironment can reverse T cell exhaustion and promote the antitumor activity of anti-CAIX CART cells. These anti-CAIX CART cells, primarily those secreting anti-PD-L1, were also able to suppress the proliferation of CAIX+ RCC cells, slow tumor growth, and reduce tumor size and weight in an NSG orthotopic mouse model of RCC. In addition, anti-CAIX CART cells secreting the IgG1 isotype of anti-PD-L1 were also able to induce ADCC in vitro and increase the number of human NK cells infiltrating tumor sites in vivo. To determine the ability of NK cells to recognize the IgG1 isotype of anti-PD-L1 in vivo, only two mice in each group were injected with human NK cells 2 days before euthanasia. Because our previous experiments with this mouse model showed that these cells persist in the blood for only a few days, human NK cell injection was not performed at the beginning of treatment.

[0084] In one embodiment, mice were injected with CART cells without the addition of interleukins to avoid affecting the therapeutic effect of CART cells alone.

[0085] In another embodiment, CART cells can be maintained by the use of cytokines such as IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21.

[0086] Cytokines that share the γc receptor, such as IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21, are important for the development and maintenance of memory T cells. Among these, IL-21 promotes a less differentiated phenotype, thereby increasing tumor-specific CD8 T cells and enhancing their antitumor efficacy in a mouse melanoma model compared with IL-2 or IL-15.

[0087] In certain embodiments, the CART cells are maintained with IL-21.

[0088] Although CAIX is also physiologically expressed in some tissues, its overexpression in many tumors, particularly cRCC, makes it a consistent marker for the development of cancer-targeted systemic therapies.

[0089] In one embodiment, the anti-CAIX scFv within the CAR recognizes the catalytic domain of CAIX, which is located in the central part of the protein, which may enhance its specificity for sites of high CAIX expression.

[0090] The selection of CD28 as the costimulatory domain for the CAR presented herein was based on the fact that CD28 CARs result in vigorous proliferative responses and improved effector function, whereas 4-1BB-based CARs induce a more gradual accumulation of T cells that may be responsible for less immediate effects. In one embodiment, CD28 is replaced by 41BB in the CAR construct.

[0091] T cell exhaustion is common in cancer, and these T cells exhibit low proliferation and cytokine production capacity, associated with a high apoptosis rate and expression of inhibitory receptors such as PD-1, Tim-3, and Lag3. A new strategy to prevent T cell exhaustion involves that of the PD-1 / PD-L1 axis.

[0092] The methods and compositions provided herein provide anti-CAIX CART cells that secrete anti-PD-L1 IgG1 and IgG4, which reverse T cell exhaustion and improve the efficacy of CART cells in treating cRCC in vitro and in vivo.

[0093] Introduction of constructs into CTLs The expression vector encoding the CAR can be introduced as one or more DNA molecules or constructs, which can include at least one marker that allows for selection of host cells containing the construct(s).

[0094] Constructs can be prepared by conventional methods or other convenient means, in which genes and regulatory regions can be isolated, ligated if appropriate, cloned in a suitable cloning host, and analyzed by restriction or sequencing. In particular, PCR can be used to isolate individual fragments containing all or part of the functional unit, into which one or more mutations can be introduced, if appropriate, using primer repair, ligation, in vitro mutagenesis, etc. Once a construct is complete and has been demonstrated to have the correct sequence, it can then be introduced into CTLs by any convenient means. For cell infection or transduction, constructs can be packaged into non-replicating defective viral genomes, such as adenovirus, adeno-associated virus (AAV), or herpes simplex virus (HSV), or other vectors, including retroviral or lentiviral vectors. Constructs can contain viral sequences for transfection, if desired. Alternatively, constructs can be introduced by fusion, electroporation, biolistics, transfection, lipofection, etc. Host cells can be grown and expanded in culture prior to introduction of the construct, followed by appropriate treatment for introduction and integration of the construct. The cells are then expanded and screened for the marker present in the construct. Various vectors that may be suitably used include hprt, neomycin resistance, thymidine kinase, hygromycin resistance, etc.

[0095] In some cases, if the construct is desired to be integrated into a specific locus, it can have a target site for homologous recombination. For example, using materials and methods for homologous recombination known in the art, an endogenous gene can be knocked out and replaced with a gene encoded by the construct (at the same locus or elsewhere). For homologous recombination, those skilled in the art can use either OMEGA or O-vectors. For example, see Thomas and Capecchi, Cell (1987) 51, 503-512; Mansour, et al., Nature (1988) 336, 348-352; and Joyner, et al., Nature (1989) 338, 153-156.

[0096] The construct can be introduced as a single DNA molecule encoding at least CAR and optionally another gene, or as separate DNA molecules with one or more genes. Other genes include, for example, genes encoding therapeutic molecules or suicide genes. The constructs can be introduced simultaneously or sequentially, each with the same or different markers.

[0097] Vectors containing useful elements that can be used to prepare construct DNA stocks and to perform transfections, such as bacterial or yeast replication origins, selectable and / or amplifiable markers, promoter / enhancer elements for expression in prokaryotes or eukaryotes, etc., are well known in the art and many are commercially available.

[0098] How to use The cells according to the invention can be used to treat cancer, viral infection or autoimmune disorders in a patient in need thereof. In another embodiment, the isolated cells according to the invention can be used in the manufacture of a medicament for treating cancer, viral infection or autoimmune disorders in a patient in need thereof.

[0099] The present invention is based on a method of treating a patient in need thereof, comprising at least one of the steps of: (a) providing a chimeric antigen receptor cell according to the present invention; and (b) administering the cell to the patient.

[0100] Treatment can be ameliorative, curative, or preventative. It can be either part of an autoimmunotherapy or part of an allogeneic immunotherapy treatment. Autologous means that the cells, cell lines, or cell populations used to treat a patient are derived from the patient or from a human leukocyte antigen (HLA)-matched donor. Allogeneic means that the cells or cell populations used to treat a patient are derived from a donor, not from the patient.

[0101] The present invention is particularly suited to allogeneic immunotherapy insofar as T cells, typically obtained from a donor, can be transformed into non-alloreactive cells. This can be done under standard protocols and replicated as many times as necessary. The resulting modified T cells can be pooled and administered to one or more patients, thus making them available as an "off-the-shelf" therapeutic product.

[0102] The cells that can be used in the disclosed methods are described in the previous section. The treatment can be used to treat patients diagnosed with cancer, viral infection, autoimmune disorders, or graft-versus-host disease (GvHD). Cancers that can be treated include tumors that are not or have not yet substantially been vascularized, and tumors that are vascularized. Cancers can include non-solid tumors (e.g., hematological tumors, such as leukemia and lymphoma) or solid tumors. Cancer types that can be treated using the CAR of the present invention include, but are not limited to, carcinomas, blastomas, and sarcomas, as well as certain leukemias or lymphoid malignancies, benign and malignant tumors, and malignant tumors, such as sarcomas, carcinomas, and melanomas. Adult tumors / cancers and pediatric tumors / cancers are also included.

[0103] It may be treatment in combination with one or more treatments for cancer selected from the group consisting of antibody therapy, chemotherapy, cytokine therapy, dendritic cell therapy, gene therapy, hormone therapy, laser phototherapy and radiation therapy.

[0104] According to a preferred embodiment of the present invention, the treatment can be performed on patients undergoing immunosuppressive treatment. Indeed, the present invention is preferably based on cells or cell populations that have been rendered resistant to at least one immunosuppressant by inactivation of a gene encoding a receptor for such an immunosuppressant. In this aspect, the immunosuppressive treatment should favor the selection and expansion of T cells according to the present invention in the patient.

[0105] In a further embodiment, the cell composition of the present invention is administered to a patient in combination with (e.g., before, simultaneously with, or after) bone marrow transplantation, T cell depletion therapy using any chemotherapeutic agent, such as fludarabine, external beam radiation therapy (XRT), cyclophosphamide, or antibodies, such as OKT3 or CAM PATH. In another embodiment, the cell composition of the present invention is administered after B cell depletion therapy, such as a drug that reacts with CD20, such as Rituxan. For example, in one embodiment, the subject may undergo standard treatment using high-dose chemotherapy followed by peripheral blood stem cell transplantation. In a specific embodiment, after transplantation, the subject receives an infusion of the expanded immune cells of the present invention. In a further embodiment, the expanded cells are administered before or after surgery. The modified cells obtained by any one of the methods described herein may, in certain aspects of the invention, be used to treat a patient in need thereof against host-versus-graft (HvG) rejection and graft-versus-host disease (GvHD), and therefore, within the scope of the present invention is a method of treating a patient in need thereof against host-versus-graft (HvG) rejection and graft-versus-host disease (GvHD), comprising the step of treating the patient by administering to the patient an effective amount of modified cells comprising an inactivated TCR alpha and / or TCR beta gene.

[0106] Cell administration The present invention is particularly suited to allogeneic immunotherapy, insofar as T cells, typically obtained from a donor, can be transformed into non-alloreactive cells. This can be done under standard protocols and replicated as many times as necessary. The resulting modified T cells can be pooled and administered to one or more patients, thus making them available as an "off-the-shelf" therapeutic product.

[0107] Depending on the nature of the cells, cells can be introduced into a host organism, e.g., a mammal, in a wide variety of ways. In certain embodiments, cells can be introduced into the tumor site, while in alternative embodiments, the cells are targeted to the cancer or modified to target the cancer. The number of cells used depends on many circumstances, the purpose of introduction, the viability of the cells, the protocol used, such as the number of administrations, the proliferation potential of the cells, the stability of the recombinant construct, etc. Cells can be applied as a dispersion and are usually injected at or near the site of interest. Cells can be contained in a physiologically acceptable medium.

[0108] In some embodiments, the cells are encapsulated to inhibit immune recognition and introduced into the tumor site.

[0109] The cells may be administered as desired. A variety of protocols may be used, depending on the desired response, the mode of administration, the viability of the cells, and the number of cells present. The number of administrations will depend, at least in part, on the factors described above.

[0110] Administration of cells or cell populations according to the present invention can be carried out in any convenient manner, including by aerosol inhalation, injection, digestion, infusion, implantation, or transplantation. The compositions described herein can be administered to patients by subcutaneous, intradermal, intratumoral, intranodal, intramedullary, intramuscular, intravenous, or intralymphatic injection, or intraperitoneal. In one embodiment, the cell compositions of the present invention are preferably administered by intravenous injection.

[0111] The administration of cells or cell populations is at 10 per kg body weight, including all integer values ​​of cell number within that range.4 ~10 9 cells, preferably 10 per kg body weight 5 ~10 6 The administration of cells may consist of administering a single dose of cells. The cells or cell population may be administered in one or more doses. In another embodiment, an effective amount of cells is administered in a single dose. In another embodiment, an effective amount of cells is administered in two or more doses over a period of time. The timing of administration is within the discretion of the administering physician and depends on the clinical condition of the patient. The cells or cell population may be derived from any source, such as a blood bank or donor. While individual needs vary, determining the optimal range of effective amounts of a particular cell type for a particular disease or condition is within the skill of the art. An effective amount refers to an amount that provides a therapeutic or prophylactic benefit. The dose administered will depend on the age, health, and weight of the recipient, the type of concurrent treatment, if any, the frequency of treatment, and the nature of the desired effect.

[0112] It should be understood that the system is subject to many variables, such as cellular response to the ligand, expression efficiency and, if appropriate, secretion levels, activity of the expressed product, the individual needs of the patient which may vary with time and environment, loss of cells or the rate of loss of cellular activity as a result of expression activity of individual cells, etc. Thus, even if there are common cells that can be administered to the entire population for each individual patient, it is expected that each patient will be monitored for the appropriate dose for that individual, and such patient monitoring practices are routine in the art.

[0113] Nucleic Acid-Based Expression Systems The CAR of the present invention can be expressed from an expression vector. Recombinant techniques for producing such expression vectors are well known in the art.

[0114] vector The term "vector" is used to refer to a carrier nucleic acid molecule into which a nucleic acid sequence can be inserted for introduction into a cell where it can be replicated. A nucleic acid sequence can be "exogenous," meaning that it is foreign to the cell into which the vector is introduced or that the sequence is homologous to a sequence in the cell but is located in a location within the host nucleic acid where the sequence is not normally found. Vectors include plasmids, cosmids, viruses (bacteriophages, animal viruses, and plant viruses), and artificial chromosomes (e.g., YACs). Those skilled in the art are well versed in the techniques of constructing vectors through standard recombinant techniques (see, for example, Maniatis et al., 1988 and Ausubel et al., 1994, both of which are incorporated herein by reference).

[0115] The term "expression vector" refers to any type of genetic construct containing a nucleic acid encoding an RNA that can be transcribed. In some instances, the RNA molecule is then translated into a protein, polypeptide, or peptide. In other instances, these sequences are not translated, for example, in the production of antisense molecules or ribozymes. Expression vectors can contain a variety of "control sequences," which represent nucleic acid sequences required for the transcription, and possibly translation, of an operably linked coding sequence in a particular host cell. In addition to control sequences that govern transcription and translation, vectors and expression vectors can contain nucleic acid sequences that perform other functions as well, as described below.

[0116] Promoters and enhancers A "promoter" is a regulatory sequence, a region of a nucleic acid sequence that controls the initiation and rate of transcription. It can contain genetic elements to which regulatory proteins and molecules, such as RNA polymerase and other transcription factors, can bind to initiate transcription of a particular nucleic acid sequence. The phrases "operably located," "operably linked," "under control," and "under transcriptional control" mean that the promoter is in the correct functional location and / or orientation relative to a nucleic acid sequence to control the initiation and / or expression of that sequence.

[0117] A promoter typically contains a sequence that functions to position the start site for RNA synthesis. The most well-known example is the TATA box, but in some promoters lacking a TATA box, such as the promoters of the mammalian terminal deoxynucleotidyl transferase gene and the SV40 late gene, additional elements overlapping the start site itself help fix the start position. Additional promoter elements regulate the frequency of transcription initiation. Typically, these are located in the region 30-110 bp upstream of the start site, but many promoters have been shown to contain functional elements downstream of the start site as well. To place a coding sequence "under the control" of a promoter, one skilled in the art places the 5' end of the transcription start site of the transcriptional reading frame "downstream" (i.e., 3') of the selected promoter. This "upstream" promoter stimulates transcription of the DNA and promotes expression of the encoded RNA.

[0118] Spacing between promoter elements is often flexible, so that promoter function is preserved even when elements are inverted or moved relative to one another. In the tk promoter, spacing between promoter elements can be increased to 50 bp apart before activity begins to decline. Depending on the promoter, individual elements appear to function either cooperatively or independently to activate transcription. Promoters may or may not be used in combination with "enhancers," which refer to cis-acting regulatory sequences involved in the transcriptional activation of a nucleic acid sequence.

[0119] A promoter may be one naturally associated with a nucleic acid sequence and may be obtained by isolating the 5' prime non-coding sequence located upstream of its coding segment and / or exons. Such a promoter may be referred to as "endogenous." Similarly, an enhancer may be naturally associated with a nucleic acid sequence and may be located downstream or upstream of that sequence. Alternatively, certain advantages may be obtained by placing a coding nucleic acid segment under the control of a recombinant or heterologous promoter, which refers to a promoter not normally associated with a nucleic acid sequence in its natural environment. A recombinant or heterologous enhancer also refers to an enhancer not normally associated with a nucleic acid sequence in its natural environment. Such promoters or enhancers may include promoters or enhancers of other genes, as well as promoters or enhancers isolated from any other virus or prokaryotic or eukaryotic cell, and promoters or enhancers that are not "naturally occurring," i.e., contain different elements of different transcriptional regulatory regions and / or mutations that alter expression. For example, promoters most widely used in recombinant DNA construction include the lactamase (penicillinase), lactose, and tryptophan (trp) promoter systems. In addition to synthetic production of promoter and enhancer nucleic acid sequences for the compositions disclosed herein, the sequences can be produced using nucleic acid amplification techniques, including recombinant cloning and / or PCR™ (see U.S. Patent Nos. 4,683,202 and 5,928,906, each of which is incorporated herein by reference). Furthermore, it is contemplated that control sequences that direct transcription and / or expression of sequences in non-nuclear organelles, such as mitochondria, chloroplasts, etc., can also be used.

[0120] It is usually important to use a promoter and / or enhancer that effectively induces expression of the DNA segment in the organ, cell type, tissue, organ, or organism selected for expression. Those skilled in the art of molecular biology are generally familiar with the use of promoter, enhancer, and cell type combinations for protein expression (see, for example, Sambrook et al. 1989, incorporated herein by reference). The promoter used may be constitutive, tissue-specific, inducible, and / or useful under conditions suitable for inducing high-level expression of the introduced DNA segment, for example, conditions advantageous for large-scale production of recombinant proteins and / or peptides. The promoter may be heterologous or endogenous.

[0121] Furthermore, any promoter / enhancer combination can also be used to induce expression. The use of T3, T7, or SP6 cytoplasmic expression systems is another possible embodiment. Eukaryotic cells can support cytoplasmic transcription from certain bacterial promoters if the appropriate bacterial polymerase is provided, either as part of the delivery complex or as an additional gene expression construct.

[0122] The identification of tissue-specific promoters or elements and assays to characterize their activity are well known to those of skill in the art.

[0123] Specific initiation signals may also be required for efficient translation of the coding sequence. These signals include the ATG initiation codon or adjacent sequences. Exogenous translational control signals, including the ATG initiation codon, may need to be provided. One of ordinary skill in the art can readily determine this and provide the necessary signals.

[0124] In certain embodiments of the present invention, the use of internal ribosome entry site (IRES) elements is used to generate multigenic or polycistronic messages, which may be used in the present invention.

[0125] A vector may contain a multiple cloning site (MCS), a nucleic acid region containing multiple restriction enzyme sites, any of which can be used to digest the vector in conjunction with standard recombinant techniques. "Restriction enzyme digestion" refers to the catalytic cleavage of a nucleic acid molecule by an enzyme that functions only at specific locations within the nucleic acid molecule. Many of these restriction enzymes are commercially available. The use of such enzymes is widely understood by those skilled in the art. Often, vectors can be linearized or fragmented using a restriction enzyme that cuts within the MCS so that exogenous sequences can be ligated to the vector. "Ligation" refers to the process of forming phosphodiester bonds between two nucleic acid fragments, which may or may not be contiguous with each other. Restriction enzymes and techniques related to ligation reactions are well known to those skilled in the art of recombinant technology.

[0126] Splice sites, termination signals, origins of replication and selectable markers may also be used.

[0127] Plasmid vectors In certain embodiments, it is contemplated that a plasmid vector will be used to transform a host cell. Generally, plasmid vectors containing replicon and control sequences derived from a species compatible with the host cell are used in connection with these hosts. The vector usually has a replication site and marking sequences capable of providing phenotypic selection in transformed cells. In a non-limiting example, E. coli is often transformed using derivatives of pBR322, a plasmid derived from an E. coli species. pBR322 contains genes for ampicillin and tetracycline resistance, thus providing a simple means for identifying transformed cells. pBR plasmids or other microbial plasmids or phages must also contain, or be modified to contain, a promoter that can be used by the microorganism for expression of its own proteins, for example.

[0128] Additionally, phage vectors containing replicon and control sequences compatible with the host microorganism can be used as transforming vectors in connection with these hosts. For example, phage lambda GEM™ 11 can be utilized to generate recombinant phage vectors that can be used to transform host cells, such as E. coli LE392.

[0129] Additional useful plasmid vectors include the pIN vectors (Inouye et al., 1985) and the pGEX vectors used to generate glutathione S-transferase (GST) soluble fusion proteins for subsequent purification and isolation or cleavage. Other suitable fusion proteins are those containing galactosidase, ubiquitin, etc.

[0130] Bacterial host cells, such as E. coli, containing the expression vector are grown in any of a number of suitable media, such as LB. Expression of the recombinant protein in a particular vector can be induced by contacting the host cells with an agent specific for the particular promoter, such as by adding IPTG to the medium or by switching to a higher incubation temperature, as will be understood by those skilled in the art. After culturing the bacteria for an additional period, usually 2-24 hours, the cells are harvested by centrifugation and washed to remove residual medium.

[0131] viral vectors The ability of certain viruses to infect cells or enter cells through receptor-mediated endocytosis, integrate into the host cell genome, and stably and efficiently express viral genes makes them attractive candidates for transferring foreign nucleic acids into cells (e.g., mammalian cells). The element of the present invention can be a viral vector encoding one or more CARs of the present invention. Non-limiting examples of viral vectors that can be used to deliver the nucleic acids of the present invention are described below.

[0132] Adenovirus vectors A specific nucleic acid delivery method uses adenoviral expression vectors. Adenoviral vectors are known to have a low payload capacity for integration into genomic DNA, but this feature is offset by the high gene transfer efficiency afforded by these vectors. "Adenoviral expression vector" is meant to include a construct containing sufficient adenoviral sequences to (a) support packaging of the construct and (b) ultimately express the tissue- or cell-specific construct cloned therein. Knowledge of the genetic organization and nature of adenoviruses allows the replacement of large segments of adenoviral DNA with up to 7 kb of foreign sequence (Grunhaus and Horwitz, 1992).

[0133] AAV vectors Nucleic acid can be introduced into cells by adenovirus-mediated transfection. High transfection efficiency has been reported in cell systems using adenovirus-based systems (Kelleher and Vos, 1994; Cotten et al., 1992; Curiel, 1994). Adeno-associated virus (AAV) has a high integration rate and can infect non-dividing cells, making it an attractive vector system for use in the cells of the present invention, as it is useful for gene delivery to mammalian cells, for example, in tissue culture (Muzyczka, 1992) or in vivo. AAV has a wide host range for infectivity (Tratschin et al., 1984; Laughlin et al., 1986; Lebkowski et al., 1988; McLaughlin et al., 1988). Details regarding the production and use of rAAV vectors are described in US Pat. Nos. 5,139,941 and 4,797,368, each of which is incorporated herein by reference.

[0134] Retroviral vectors Retroviruses are useful as delivery vectors because of their ability to integrate genes into the host genome, transfer large amounts of foreign genetic material, infect a wide range of species and cell types, and be packaged in specialized cell lines (Miller, 1992).

[0135] To construct a retroviral vector, a nucleic acid (e.g., one encoding a desired sequence) is inserted into the viral genome, replacing specific viral sequences to generate a replication-defective virus. To produce virions, packaging cell lines containing the gag, pol, and env genes but lacking the long-term repeat (LTR) and packaging elements are constructed (Mann et al., 1983). When a recombinant plasmid containing a cDNA along with retroviral long-term repeat (LTR) and packaging sequences is introduced into a specialized cell line (e.g., by calcium phosphate precipitation), the packaging sequences package the RNA transcripts of the recombinant plasmid into viral particles, which are then secreted into the culture medium (Nicolas and Rubenstein, 1988; Temin, 1986; Mann et al., 1983). The medium containing the recombinant retrovirus is then collected, optionally concentrated, and used for gene transfer. Retroviral vectors can infect a wide variety of cell types. However, integration and stable expression require host cell division (Paskind et al., 1975).

[0136] Lentiviruses are complex retroviruses that contain common retroviral genes gag, pol, and env, as well as other genes with regulatory or structural functions. Lentiviral vectors are well known in the art (see, for example, Naldini et al., 1996; Zufferey et al., 1997; Blomer et al., 1997; U.S. Patent Nos. 6,013,516 and 5,994,136). Some examples of lentiviruses include human immunodeficiency viruses (HIV-1, HIV-2) and simian immunodeficiency viruses (SIV). Lentiviral vectors are created by multiple attenuation of HIV toxic genes, such as the deletion of genes env, vif, vpr, vpu, and nef, making the vector biologically safe.

[0137] Recombinant lentiviral vectors can infect non-dividing cells and can be used for gene transfer and expression of nucleic acid sequences both in vivo and ex vivo. For example, recombinant lentiviruses capable of infecting non-dividing cells are described in U.S. Patent No. 5,994,136, which is incorporated herein by reference, in which suitable host cells are transfected with two or more vectors carrying packaging functions, i.e., gag, pol, env, and rev and tat. Those skilled in the art can target recombinant viruses by linking the envelope protein to an antibody or a specific ligand that targets a receptor on a specific cell type. For example, by inserting a sequence of interest (including a regulatory region) into a viral vector together with another gene encoding a ligand for a receptor on a specific target cell, the vector becomes target-specific.

[0138] Other viral vectors Other viral vectors can also be used as vaccine constructs in the present invention. Vectors derived from viruses such as vaccinia virus (Ridgeway, 1988; Baichwal and Sugden, 1986; Coupar et al., 1988), Sindbis virus, cytomegalovirus, and herpes simplex virus can be used. They offer various attractive features for various mammalian cells (Friedmann, 1989; Ridgeway, 1988; Baichwal and Sugden, 1986; Coupar et al., 1988; Horwich et al., 1990).

[0139] Delivery using modified viruses The nucleic acid to be delivered can be housed within an infectious virus engineered to express a specific binding ligand. The viral particle will then specifically bind to the target cell's cognate receptor and deliver its contents to the cell. A new approach designed to enable specific targeting of retroviral vectors has been developed based on the chemical modification of retroviruses by chemically adding lactose residues to the viral envelope. This modification can achieve specific infection of hepatocytes through sialoglycoprotein receptors.

[0140] Another approach to targeting recombinant retroviruses using biotinylated antibodies against retroviral envelope proteins and against specific cellular receptors was also designed. The antibodies were linked through the biotin moiety by using streptavidin (Roux et al., 1989). Using antibodies against major histocompatibility complex class I and class II antigens, they demonstrated in vitro infection of various human cells bearing those surface antigens with ecotropic viruses (Roux et al., 1989).

[0141] Vector delivery and cell transformation Suitable nucleic acid delivery methods for cell transfection or transformation are known to those skilled in the art. Such methods include, but are not limited to, direct delivery of DNA, for example, by ex vivo transfection, by injection, etc. Through the application of techniques known in the art, cells can be stably or transiently transformed.

[0142] Ex vivo transformation Methods for transfecting eukaryotic cells and tissues removed from an organism in an ex vivo situation are known to those skilled in the art. Thus, it is contemplated that cells or tissues can be removed and transfected ex vivo with the nucleic acid of the present invention. In certain aspects, transplanted cells or tissues can be introduced into an organism. In a preferred aspect, the nucleic acid is expressed in the transplanted cells.

[0143] Kits of the Invention Any of the compositions described herein can be included in a kit. In a non-limiting example, the kit can include one or more cells for use in cell therapy and / or reagents for generating one or more cells for use in cell therapy with a recombinant expression vector. The components of the kit can be provided in suitable containers.

[0144] Some components of the kit may be packaged either in aqueous medium or in lyophilized form. The kit's storage means typically includes at least one vial, test tube, flask, bottle, syringe, or other container into which the components may be placed, preferably appropriately subdivided. If there are two or more components in the kit, the kit will also typically include a second, third, or other additional container into which the additional components may be individually placed. However, various combinations of components may be contained in vials. The kits of the present invention also typically include a means for containing the components in close confinement for commercial sale. Such containers may include injection- or blow-molded plastic containers into which the desired vials are retained.

[0145] When the components of the kit are provided in one and / or more liquid solutions, the liquid solution is an aqueous solution, with a sterile aqueous solution being particularly useful. In some instances, the containing means may itself be a syringe, pipette, and / or other such similar device from which the formulation may be applied to an infected area of ​​the body, injected into an animal, and / or even applied together and / or mixed with the other components of the kit.

[0146] However, the components of the kit may be provided in the form of a dry powder. When reagents and / or components are provided as a dry powder, the powder can be reconstituted by adding a suitable solvent. It is envisioned that the solvent may also be provided in a separate container. The kit may also include a second container for containing a sterile, pharmaceutically acceptable buffer and / or other diluent.

[0147] In certain embodiments of the present invention, the cells used in cell therapy are provided as a kit, and in some cases, the cells are essentially the only component of the kit.The kit can include reagents and materials for producing desired cells.In certain embodiments, the reagents and materials include primers for amplifying desired sequences, nucleotides, appropriate buffers or buffering reagents, salts, etc., and in some cases, the reagents include vectors and / or DNA encoding CAR and / or regulatory elements therefor as described herein.

[0148] In certain embodiments, the kit includes one or more devices suitable for extracting one or more samples from an individual. The device may be a syringe, a scalpel, or the like.

[0149] In some examples of the present invention, the kit includes, in addition to the cell therapy aspect, a second cancer therapy, such as chemotherapy, hormonal therapy, and / or immunotherapy. The kit may be specialized for an individual's particular cancer and may include each second cancer therapy for that individual.

[0150] Combination therapy In certain embodiments of the present invention, the clinical aspects of the methods of the present invention are used in combination with other drugs effective in treating hyperproliferative diseases, such as anti-cancer drugs. "Anticancer" drugs can negatively affect cancer in a subject by, for example, killing cancer cells, inducing apoptosis in cancer cells, slowing the growth rate of cancer cells, reducing the incidence or number of metastases, reducing tumor size, inhibiting tumor growth, reducing the blood supply to tumors or cancer cells, promoting an immune response to cancer cells or tumors, preventing or inhibiting the progression of cancer, or extending the lifespan of a subject with cancer. More generally, these other compositions can be provided in a combined amount effective to kill cells or inhibit cell proliferation. This process can include simultaneously contacting the expression construct and the drug or multiple elements with cancer cells. This can be achieved by contacting cells with a single composition or pharmaceutical formulation containing both drugs, or by simultaneously contacting cells with two separate compositions or formulations, one containing the expression construct and the other containing the second drug.

[0151] Tumor cells that are resistant to chemotherapy and radiotherapy agents are a major challenge in clinical oncology.One of the goals of current cancer research is to find ways to improve the effectiveness of chemotherapy and radiotherapy by combining it with other treatments.In the context of the present invention, it is assumed that cell therapy can be used in conjunction with chemotherapy, radiotherapy or immunotherapy intervention as well as proapoptotic or cell cycle regulator.

[0152] Alternatively, the treatment of the present invention may precede or follow the treatment of the other agent by intervals ranging from minutes to weeks. In embodiments in which the other agent and the present invention are administered separately to an individual, one skilled in the art would typically ensure that no significant time elapses between the delivery of each agent and the treatment of the present invention, allowing the agent and the treatment to continue to exert their beneficial combined effect on the cells. In such instances, one skilled in the art would contemplate contacting the cells with both modalities within about 12 to 24 hours of each other, more preferably within about 6 to 12 hours of each other. However, in some circumstances, it may be desirable to significantly extend the treatment period, allowing several days (2, 3, 4, 5, 6, or 7) to several weeks (1, 2, 3, 4, 5, 6, 7, or 8) between administrations.

[0153] It is contemplated that cycles of treatment may be repeated as necessary. It is also contemplated that various standard therapies and surgical interventions may be applied in combination with the cell therapy of the present invention.

[0154] chemotherapy Cancer therapy also includes a variety of combination therapies with both compound-based and radiation-based treatments. Combination chemotherapy includes, for example, Abraxane, altretamine, docetaxel, herceptin, methotrexate, novantrone, zoladex, cisplatin (CDDP), carboplatin, procarbazine, mechlorethamine, cyclophosphamide, camptothecin, ifosfamide, melphalan, chlorambucil, busulfan, nitrosurea, dactinomycin, daunorubicin, doxorubicin, bleomycin, plicomycin, mitomycin, etoposide (VP16), tamoxifen, raloxifene, estrogen receptor binding agents, taxol, gemcitabine, navelbine, farnesyl protein transferase inhibitors, transplatinum, 5-fluorouracil, vincristine, vinblastine, and methotrexate, or analog or derivative variants of any of the above, and combinations thereof.

[0155] In certain embodiments, chemotherapy is administered to the individual in combination with the present invention, eg, before, during and / or after the administration of the present invention.

[0156] Radiation therapy Other commonly used DNA-damaging agents include gamma rays, X-rays, and / or what are commonly known as direct delivery of radioisotopes to tumor cells. Other forms of DNA-damaging agents, such as microwaves and UV radiation, are also contemplated. All of these agents are believed to cause widespread damage to DNA, DNA precursors, DNA replication and repair, and chromosome assembly and maintenance. X-ray doses range from daily doses of 50-200 roentgens over prolonged periods (3-4 weeks) to single doses of 2000-6000 roentgens. Dose ranges for radioisotopes vary and depend on the half-life of the isotope, the strength and type of radiation produced, and uptake by neoplastic cells.

[0157] The terms "contacting" and "exposing," as applied to a cell, are used herein to refer to the process of delivering a therapeutic construct and a chemotherapeutic or radiotherapeutic agent to or placing them directly adjacent to a target cell. To achieve cell death or stasis, both agents are delivered to the cell in a combined amount effective to kill the cell or prevent it from dividing.

[0158] immunotherapy Immunotherapy is typically based on the use of immune effector cells and molecules to target and destroy cancer cells. The immune effector can be, for example, an antibody specific to some marker on the surface of tumor cells. The antibody can function alone as an effector of a therapeutic agent, or it can actually induce other cells to cause cell death. Antibodies can also be linked to drugs or toxins (chemotherapeutic agents, radionuclides, ricin A chain, cholera toxin, pertussis toxin, etc.) and used solely as targeting agents. Alternatively, the effector can be a lymphocyte bearing a surface molecule that interacts either directly or indirectly with the tumor cell target. Various effector cells include cytotoxic T cells and NK cells.

[0159] The immunotherapy of the treatment of the present invention described herein can therefore be used as part of a combination therapy in combination with the cell therapy of the present invention. General approaches to combination therapy are discussed below. Typically, tumor cells must have some marker that can be targeted, i.e., not present on most other cells. Many tumor markers exist, any of which may be suitable for targeting in the present invention. Common tumor markers include PD-1, PD-L1, CTLA4, carcinoembryonic antigen, prostate-specific antigen, urinary tumor-associated antigen, fetal antigen, tyrosinase (p97), gp68, TAG-72, HMFG, sialyl Lewis antigen, MucA, MucB, PLAP, estrogen receptor, laminin receptor, erbB, and p155.

[0160] gene In yet another embodiment, the secondary treatment is gene therapy in which a therapeutic polynucleotide is administered before, after, or simultaneously with the clinical aspects of the invention. A variety of expression products are encompassed by the invention, including inducers of cell proliferation, inhibitors of cell proliferation, or regulators of programmed cell death.

[0161] surgery Approximately 60% of cancer patients will undergo some type of surgery, including preventative, diagnostic or staging, curative and palliative surgery. Curative surgery is a cancer treatment that may be used in combination with other therapies, such as the treatment of the present invention, chemotherapy, radiation therapy, hormone therapy, gene therapy, immunotherapy and / or alternative therapies.

[0162] Curative surgery includes resection, which physically removes, excises, and / or destroys all or a portion of cancerous tissue. Tumor resection refers to the physical removal of at least a portion of a tumor. In addition to tumor resection, surgical treatments include laser surgery, cryosurgery, electrosurgery, and microsurgery (Mohs surgery). It is further contemplated that the present invention may be used in combination with the removal of superficial cancers, pre-cancers, or incidental amounts of normal tissue.

[0163] When all or part of cancer cells, tissue or tumor is removed, cavity can be formed in the body.Treatment can be achieved by perfusion, direct injection or local application to the area where additional anti-cancer therapy is performed.Such treatment can be repeated, for example, every 1, 2, 3, 4, 5, 6 or 7 days, or every 1, 2, 3, 4 and 5 weeks, or every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 months.These treatments can also be performed with different dosages.

[0164] Other drugs It is contemplated that other agents may be used in combination with the present invention to improve the therapeutic efficacy of treatment. These additional agents include immunomodulators, agents that affect cell surface receptor upregulation and GAP junctions, cytostatic and differentiation agents, inhibitors of cell adhesion, or agents that increase the sensitivity of hyperproliferative cells to apoptosis-inducing agents. Immunomodulators include tumor necrosis factor, interferon alpha, beta, and gamma, IL-2 and other cytokines, F42K and other cytokine analogs, or MIP-1, MIP-1 beta, MCP-1, RANTES, and other chemokines. It is further contemplated that upregulation of cell surface receptors or their ligands, such as Fas / Fas ligand, DR4, or DR5 / TRAIL, enhances the apoptosis-inducing ability of the present invention by establishing an autocrine or paracrine effect on hyperproliferative cells. Increasing intracellular signals by increasing the number of GAP junctions will enhance the anti-hyperproliferative effect on adjacent hyperproliferative cell populations. In other embodiments, cytostatic or differentiation agents may be used in combination with the present invention to improve the anti-hyperproliferative effect of treatment. It is believed that cell adhesion inhibitors can improve the effect of the present invention. Examples of cell adhesion inhibitors include focal adhesion kinase (FAK) inhibitors and lovastatin. It is also envisioned that other agents that increase the sensitivity of hyperproliferative cells to apoptosis, such as antibody c225, can be used in combination with the present invention to improve the effect of treatment. [Example]

[0165] Example 1: Materials and Methods Cells, culture media, and reagents. Human CAIX+ renal cell carcinoma cell lines sk-rc-52, sk-rc-09, and CAIX- sk-rc-59 were obtained from Dr. Gerd Ritter at Memorial Sloan-Kettering Cancer Center, New York. They were cultured at 37°C under 5% CO2 in complete R-10 medium containing RPMI 1640 medium (Life Technologies) supplemented with 10% FCS, 2 mmol / L L-glutamine, 100 U / ml penicillin, and 100 μg / ml streptomycin (Sigma). Primary human T cells were maintained in R-10 medium containing 10% human serum and 100 IU / ml recombinant human interleukin-2 (IL-2) (Chiron). Human embryonic kidney cell line 293T (ATCC) and mouse fibroblast NIH3T3 cells (ATCC) were grown in D-10 complete medium (Life Technologies) containing DMEM medium containing 10% FCS, 100 U / ml penicillin, and 100 μg / ml streptomycin (Sigma). Leukopacks obtained from the Children's Hospital Boston blood bank were collected from healthy volunteers who provided written informed consent.

[0166] In one embodiment, human ccRCC cell lines, Skrc52, which is initially CAIX+ / PD-L1-, and Skrc59, which is initially CAIX- / PD-L1+, were obtained from Dr. Gerd Ritter (Memorial Sloan-Kettering Cancer Center, New York). These cells were cultured in RPMI 1640 medium (Life Technologies) supplemented with 10% (v / v) heat-inactivated fetal bovine serum (FBS, Gibco), 100 IU / ml penicillin, and 100 μg / ml streptomycin. 293T (CRL-11268, ATCC) and Lenti-X 293T (Clontech) cells were grown in DMEM medium (Life Technologies) supplemented with 10% FBS, 100 IU / ml penicillin, and 100 μg / ml streptomycin. All cell lines used in this project were transduced with luciferase via lentiviral transduction and maintained at 37°C under 5% CO2. Skrc52 cells were selected for CAIX- / PD-L1- and CAIX+ / PD-L1- cell populations by fluorescence-activated cell sorting (FACS). Skrc59 cells were engineered to express high levels of human CAIX, and CAIX+ / PD-L1+ were selected by FACS sorting.

[0167] Cloning of anti-PD-L1 scFv-Fc IgG1 and IgG4 into a bicistronic lentiviral vector encoding an anti-CAIX second-generation CAR

[0168] The anti-PD-L1 antibody (Ab) used to construct CART cells was previously selected using a 27 billion-member human scFv phage display library against full-length PD-L1 in the form of paramagnetic proteoliposomes (manuscript in preparation). The DNA sequence encoding the anti-PD-L1 scFv (clone 42)-Fc IgG1 or IgG4 was codon-optimized and synthesized to include 5' NdeI and 3' ClaI restriction sites to allow for further scFv-Fc cloning to replace ZsGreen in the lentiviral vector pHAGE-eIFα signal-scFvG36 (anti-CAIX)-C9 tag-linker-CD28-CD3ζ-IRES-ZsGreen (e.g., CD28z) (Genewiz). This original anti-CAIX vector was previously constructed and published (21). For the cloning of a negative control, we first replaced the anti-PD-L1 scFv with an anti-severe acute respiratory syndrome (SARS) scFv (clone 11A) in an IgG1-Fc lentiviral vector containing an anti-CAIX G36 scFv CAR. The DNA sequence encoding the anti-SARS scFv was amplified using the MluI forward primer: TIFF2024163140000006.tif4128 and XbaI reverse primer The plasmid pHAGE CMV-anti-SARS(11A)scFv-Fc-CD28-gp41-IRES-ZsGreen was amplified by PCR using TIFF2024163140000007.tif4128 to insert 5' MluI and 3' XbaI restriction sites for further cloning. The final pHAGE-eIFα-scFv G36(anti-CAIX)-C9 tag-linker-CD28-CD3ζ-IRES-anti-SARS(11A)IgG1 was used as a negative control. We also replaced the anti-CAIX scFv with anti-B cell maturation antigen (BCMA) scFv in the anti-SARS IgG1-containing CAR construct by double digestion of pHAGE-eIFα-A716scFv(anti-BCMA)-C9 tag-linker-CD28-CD3ζ-IRES-ZsGreen and pHAGE-eIFα-G36scFv(anti-CAIX)-C9 tag-linker-CD28-CD3ζ-IRES-anti-SARS(11A)IgG1 with NcoI and NotI. After the cloning process, we obtained four main plasmids for initiating lentivirus production: an anti-CAIX CAR capable of expressing anti-PD-L1 IgG1 (anti-CAIX / anti-PD-L1 IgG1), an anti-CAIX CAR capable of expressing anti-PD-L1 IgG4 (anti-CAIX / anti-PD-L1 IgG4), an anti-CAIX CAR capable of expressing an irrelevant anti-SARS Ab (anti-CAIX / anti-SARS IgG1), and an anti-BCMA CAR capable of expressing an irrelevant anti-SARS Ab (anti-BCMA / anti-SARS IgG1).

[0169] Isolation of scFv and conversion of scFv to scFv-Fc. CAIX-specific scFv antibodies were isolated from a non-immune human scFv phage library as previously reported and deposited in GenBank under accession numbers GQ903548–GQ903561. 23The scFv-encoding DNA fragment was excised from pFarber phagemid at the SfiI / NotI sites and subcloned into the mammalian expression vector pcDNA3.1-F105L-hinge-stuffer, which contains a human IgG1 F105 leader sequence and a human IgG1 hinge-CH2-CH3 Fc portion expressing the scFv-Fc antibody. The scFv-Fc plasmid was transiently transfected into 293T cells using Lipofectamine 2000 (Invitrogen), and the expressed antibody was purified using Sepharose Protein A beads (Amersham Bioscience). Specific binding to CAIX was tested by staining with the phage scFv antibody or scFv converted to the scFv-Fc format by incubation with CAIX-expressing 293T and sk-rc-52 cell lines and with CAIX-negative 293T and sk-rc-59 cell lines. In these experiments, an unrelated anti-HIV CCR5 antibody (clone A8) 25 or anti-SARS antibodies (11A) 24 and fluorescently conjugated secondary antibody alone was used as a negative control.

[0170] Construction of scFv-CD8-TCRζ and scFv-CD28-TCRζ constructs. The DNA constructs Pz1, scFv-CD8-TCRζ and P28z, scFv-CD28-TCRζ in the phagemid vector pSL1180 were obtained from Dr. Michel Sadelain at Memorial Sloan Kettering Cancer Center, New York. In Pz1, the scFv and TCRζ intracellular domains are attached to the N- and C-termini of the human CD8 α chain, respectively. Similarly, in P28z, the scFv and TCRζ sequences are attached to the N- and C-termini of human CD28, respectively. The amino acid sequence of human CD8α is 71 residues long, consisting of 47 (aa 137-183), 23 (aa 184-206), and 2 (aa 207-208) residues in the CD8α extracellular, hinge, transmembrane, and cytoplasmic domains, respectively. The CD28 sequence in P28z is 107 residues long, consisting of 40 (aa 114-153), 23 (aa 154-176), and 44 (aa 177-220) residues in the CD28 extracellular, transmembrane, and cytoplasmic domains, respectively. The human CD3ζ intracellular domain, common to both CARs, consists of 112 amino acids (aa 52-163).

[0171] A nucleic acid sequence encoding an internal C9 tag (a nine-amino acid peptide from human rhodopsin, TETSQVAPA) with a GGGGS linker was amplified by PCR and fused upstream of the CD8-TCRζ and CD28-TCRζ sequences using a 5' NotI and 3' PacI site. The primers used for cloning the chimeric TCRζ constructs were: TIFF2024163140000008.tif18142 (forward primer for CD8 construct, italics indicate NotI site, capital letters indicate C9 tag sequence, underline indicates GGGGS linker), TIFF2024163140000009.tif12128 (forward primer for CD28 construct) and reverse primers for both constructs TIFF2024163140000010.tif5128, PacI sites are in italics. These DNA fragments encode functional features arranged according to the following sequence: NotI-C9 tag (TETSQVQPQ)-GGGGS-CD8 or CD28-TCRζ-PacI. Chimeric TCR constructs tagged with the internal C9 peptide were cloned into the pcDNA3.1-F105L-hinge-stuffer vector containing the anti-CXCR4 scFv-Fc, clone 48, using the NotI and PacI restriction sites. With this design, we inserted the chimeric TCR receptor construct to replace the Fc partial fragment. Anti-CAIX scFv (clone G36) and anti-CCR5 scFv (as an irrelevant scFv control, clone A8) antibody fragments were then cloned in place of the anti-CXCR4 scFv at the SfiI / NotI sites to generate a CAIX-specific chimeric TCR construct.

[0172] The lentiviral vector pHAGE-CMV-DsRed-IRES-ZsGreen and four HIV helper plasmids, pHDM-Hgpm2 (HIV gag-pol), pMD-tat, pRC / CMV-rev, and Env VSV-G pseudotype, were obtained from Dr. Richard Mulligan at the Virus Production Core of the Harvard Gene Therapy Initiative in Boston. The CMV promoter in pHAGE-CMV-IRES-ZsGreen was replaced with the EF1α promoter from the pSIN lentiviral vector at the SpeI / NotI sites. G36, one of five scFv-Fc antibodies that exhibit high affinity for CAIX+ cells and high ADCC exclusively against CAIX+ tumor cells, was cloned into the pHAGE-EF1α lentiviral vector at AscI / BamHI, replacing the first cassette of the DsRed protein.

[0173] Lentivirus production and transduction of human primary T cells. Lentivirus was produced by transient transfection of 293T cells with five plasmids using Lipofectamine 2000 according to the manufacturer's instructions (Invitrogen). Cells were grown in 15 cm Petri dishes (Nalge Nunc) to 80% confluence and transfected with 30 μg of total plasmid DNA. The vector-plasmid ratio (pHDM-Hgpm2 (HIV gag-pol): pMD-tat: pRC / CMV-rev: Env VSV-G pseudotype) was 20:1:1:1:2. After changing to D-10 medium, viral supernatant was collected on day 3, filtered through a 0.45 μm filter, and concentrated by ultracentrifugation (Beckman Coulter, Fullerton, CA) at 16,500 rpm (48,960 x g, Beckman SW28 rotor) and 4°C for 90 minutes. The virus pellet was resuspended in R-10 medium and kept frozen at -80°C.

[0174] In one embodiment, lentivirus was produced by transient transfection of five plasmids into 293T cells using polyethyleneimine (PEI). Briefly, 293T cells at 80% confluence in 15 cm plates (Nalge Nunc) were transfected with 30 μg of five plasmids: 5 μg of each of the construct plasmids pHDH-Hgpm2 (HIV gag-pol), pMD-tat, pRC / CMV-rev, and Env VSV-G, and 10 μg of the main plasmid containing the CAR (anti-CAIX / anti-PD-L1 IgG1, anti-CAIX / anti-PD-L1 IgG4, anti-CAIX / anti-SARS IgG1, or anti-BCMA / anti-SARS IgG1). The viral supernatant was concentrated using a Lenti-X Concentrator (Clontech) according to the manufacturer's instructions and kept frozen at -80°C.

[0175] Human PBMCs were isolated by Ficoll density gradient separation and activated with 2 μg / ml PHA (Sigma) and 100 IU / ml human IL-2 for 4 days. Cells were infected with two or three rounds of lentiviral transduction at a multiplicity of infection (MOI) of 10-20 in the presence of 10 μg / ml DEAE. Three days after transduction, transduced T cells were harvested for in vitro phenotypic and functional analysis or expanded for in vivo experiments.

[0176] Selection, activation, and lentivector transduction of CD8+ T cells. Blood collars collected from healthy volunteers who provided written informed consent were obtained from the blood bank at Brigham and Women's Hospital (Boston, MA). Human peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll-Paque PLUS (GE Healthcare, NJ). CD8+ cells were isolated from PBMCs using Dynabeads from CD8 Positive Isolation (Life Technologies). These cells were cultured in RPMI 1640 medium (Life Technologies) containing 10% heat-inactivated fetal bovine serum, 20 mM HEPES, 100 IU / ml penicillin, and 100 μg / ml streptomycin. 50 IU / ml IL-21 (Peprotech) was added to the medium every 2 days. Assays to determine whether IL-2 or IL-21 was the best cytokine for inducing anti-CAIX CART cell proliferation were performed using 50 IU / mL of each cytokine. CD8+ T cells were activated with Dynabeads Human T-Activator CD3 / CD28 (Life Technologies) at a 1:1 ratio. The cells were transduced with lentivirus at a multiplicity of infection of 20 and 10 μg / mL diethylaminoethyl ester. All assays were performed in triplicate and with T cells from three different healthy donors.

[0177] Flow cytometry analysis. Transduction efficiency of human primary T cells was assessed by reporter gene (ZsGreen) expression. CAIX-Fc protein was expressed from a pcDNA3.1 plasmid encoding CAIX amino acids 38–397, followed by the human IgG1 hinge, CH2, and CH3 domains, with the CAIX signal peptide (aa1–37) replaced by an Ig leader sequence. Expression of the scFv (G250) in transduced T cells was examined by staining the cells with 1 μg of CAIX-Fc protein followed by an APC-conjugated mouse anti-human IgG antibody (Jackson ImmunoResearch). Furthermore, expression of the internal rhodopsin nanopeptide (TETSQVAPA) C9 tag in the scFv domain of the TCR construct in transduced T cells was detected by staining with 5 μg of mouse 1D4 antibody followed by an APC-conjugated goat anti-mouse IgG antibody (Jackson ImmunoResearch). For analysis, subsets of human cells in cultures during clonal expansion experiments were stained with fluorescently conjugated mouse anti-human antibodies (Invitrogen) against CD3 (clone S4.1), CD4 (clone S3.5), or CD8 (clone 3B5). For all cell stainings, 500,000 cells were stained with the antibody at the recommended concentration according to the manufacturer's instructions. Isotype-matched control antibodies were used in each sample, and cells were analyzed using a FACSCalibur cytometer (Beckton-Dickinson).

[0178] In one embodiment, transduction of 293T cells or CD8+ T cells was confirmed by FACS analysis of anti-CAIX or anti-BCMA expression. Cells were stained with 10 μg / mL human CAIX-Fc or human BCMA-mouse-Fc (AB Bioscience) produced in our laboratory, followed by development with 1:250 APC-conjugated mouse anti-human IgG Ab (Southern Biotech) or goat anti-mouse IgG Ab (Biolegend), respectively. CountBright™ Absolute Counting Beads (Molecular Probes) were used for proliferation and clonal expansion assays. All samples were analyzed using an LSR Fortessa or FACSCalibur (BD Bioscience), and data were analyzed using FlowJo software. To analyze the T cell exhaustion state of CART cells, they were cultured for 5 days in the presence of IL-21 50 U / mL (Peprotech) and Dynabeads Human T Activator CD3 / CD28. After this period, CART cells were cocultured with Skrc-59 CAIX+ PD-L1+ cells for 2 days to stimulate exhaustion. 1 x 106 CART cells from this assay and tumor-infiltrating lymphocytes (TILs) recovered from the in vivo assay were stained with FITC-conjugated anti-human PD-1, PE-conjugated anti-human Tim3, PerCP / Cy5.5-conjugated anti-human Lag3 antibody (Biolegend), and Pacific Blue-conjugated anti-human CD45 and analyzed by FACS. To verify the expression levels of CAIX and PD-L1 in the different RCC cell lines used in this project, we used 10 μg / mL anti-human CAIX mAb (clone G36) and 10 μg / mL biotinylated mouse anti-human PD-L1 (Biolegend), both of which were generated in our laboratory. Primary antibodies were detected with 1:250 APC-conjugated anti-human Ab and PE-conjugated avidin, respectively, and analyzed by FACS.

[0179] ADCC and cytotoxicity assays of lentivirally transduced T cells. Cytotoxicity assays were performed using the DELFIA EuTDA Cytotoxicity Kit (Perkin Elmer, Boston, MA) according to the manufacturer's instructions. Briefly, target tumor cells were labeled with a fluorescent ligand (BATDA) for 30 minutes at 37°C and transfected at 1 x 10 4 Labeled cells were added to each well of a 96-well U-bottom plate. For antibody-dependent cellular cytotoxicity (ADCC) assays, a panel of anti-CAIX scFv-Fc antibodies or an irrelevant scFv-Fc antibody was added separately at 1 μg / ml or 5 μg / ml. Assays were prepared with effector cell (human PBMC) to target cell (E:T) ratios of 50:1, 25:1, and 12.5:1. For T cell cytotoxicity assays, different effector cell (untransduced or transduced T cells) to target cell (E:T) ratios were prepared (100:1, 50:1, and 25:1). Cultures were incubated at 37°C in a humidified atmosphere with 5% CO2 for 4 hours. After spinning the plate at 500 x g for 5 minutes, 20 μl of supernatant was transferred to a flat-bottom plate. 200 μl of europium solution was added, and the fluorescence emitted from the cells was read using a fluorometer (Victor™, PerkinElmer). A control for spontaneous release was prepared by culturing labeled cells alone, and a control for maximum release was made by adding lysis buffer (provided in the kit) to labeled cells.

[0180] ELISA, ELISPOT assay, and Western blot. For cytokine secretion, RCC cell lines sk-rc-52 (CAIX+) or sk-rc-59 (CAIX-) were cultured at 1 x 10 per well of a 24-well plate. 6 The seeds were sown overnight to give 1 x 10 6Untransduced or transduced T cells were seeded. Before coculture with tumor cells, T cells were washed twice with PBS to remove human IL-2. After overnight incubation, supernatants were collected and analyzed for IL-2 and IFN-γ by ELISA (e-Bioscience). To detect T cells in the IFN-γ ELISPOT assay (e-Bioscience), membranes were developed using AEC substrate solution, and the number of spots was counted using an ELISPOT plate reader (CTL Cellular Technology).

[0181] For Western blots, preparation of untransduced and transduced T cells was as described. 50 One million cells were prepared in non-reducing and reducing buffer (0.1 M dithiothreitol) and run on a 10-20% polyacrylamide gradient gel (Invitrogen). Proteins were transferred to a polyvinylidene fluoride transfer membrane (NEN Life Science Products, Boston, MA) overnight at 100 V and 4°C. The membrane was incubated with a 1:2000 primary antibody, anti-human ζ chain monoclonal antibody 8D3 (BD ​​Pharmingen, San Diego, CA), followed by a 1:3000 secondary antibody, horseradish peroxidase (Caltag). Immunodetection was performed using the ECL Plus Western Blot Detection System (GE Healthcare, Piscataway, NJ) and x-ray film exposure.

[0182] Detection of IgG secreted by CART cells using ELISA. Total IgG levels secreted into the medium of transduced cells were detected using a Human IgG ELISA Quantitation Set (Bethyl Laboratories). Anti-PD-L1 Ab secreted by transduced CD8+ CART cells was purified using Protein A Sepharose beads (GE Healthcare) and biotinylated using EZ-Link Sulfo-NHS-LC-Biotin (Thermo Scientific). These antibodies were incubated with 5 μg / mL human PD-L1 produced in our laboratory that had been pre-immobilized to a MaxiSorp plate (Nunc) for 2 hours at room temperature. Biotinylated antibodies were detected by incubation with streptavidin-HRP for 1 hour and developed using SureBlue™ TMB Peroxidase Substrate and TMB Stop Solution (KPL). Absorbance was read at λ = 450 nm.

[0183] Proliferation, clonal expansion and cytokine secretion after contact with tumor cells. Tumor cells were irradiated (3,000 rads) and plated at 2.5 x 10 per well. 5 1 x 10 cells were seeded for one week of culture. 6 T cells were cultured in a medium containing R-10 and 100 IU / ml human IL-2. To maintain appropriate density, T cells were split and restimulated weekly with tumor cells. The number of T cells was counted every 3 or 4 days for 2 weeks. The expression rates of ZsGreen by transduced T cells and T cell subsets were determined weekly by fluorescence-activated cell sorting (FACS). To study cytokine secretion after tumor cell contact, T cells exposed to irradiated tumor cells for 1 or 2 weeks were washed and incubated overnight with fresh tumor cells. Culture supernatants were collected 24 hours later for analysis.

[0184] Clonal expansion of CAIX+ CART cells In one embodiment, Skrc52 CAIX+ / PD-L1- and Skrc52 CAIX- / PD-L1- cells were irradiated with 3,000 rads and plated at 2.5 x 10 per well. 5 1 x 10 seeds were sown. 6 T cells were added every two days in culture medium containing 50 IU / ml of human IL-21. T cells were split to maintain appropriate density and restimulated with tumor cells weekly. T cell numbers were counted by FACS once a week for 3 weeks.

[0185] Effect of anti-CAIX CART cells secreting anti-PD-L1 antibody on RCC cell viability and antibody-dependent cellular cytotoxicity (ADCC). 2.5 x 103 Skrc59 CAIX+ / PD-L1+ and Skrc52 CAIX- / PD-L1- cells were plated overnight in a 96-well plate. Four days after transduction, CART cells were added to RCC cells at effector cell:tumor cell (E:T) ratios of 25:1, 50:1, and 100:1 and incubated overnight. CART cells were removed, and tumor cell viability was assayed using MTT (Life Technologies). For ADCC assays, RCC cells were incubated with 50 μL of CART cell supernatant adjusted to 500 ng / mL of anti-PD-L1 IgG1, anti-PD-L1 IgG4, or anti-SARS IgG1 Abs for 1 hour at 37°C. Cells were then incubated with NK cells at 12.5:1, 25:1, or 50:1 for 4 hours at 37° C. Lactate dehydrogenase (LDH) was measured in the supernatants by CytoTox 96® Non-Radioactive Cytotoxicity Assay (Promega).

[0186] ELISA assay to detect IL-2 and IFNγ released by functional CAR T cells. For cytokine secretion analysis, 2.5 x 103 Skrc59 CAIX+ / PD-L1+ or Skrc52 CAIX- / PD-L1- RCC cells were seeded overnight in 96-well plates, followed by the addition of CAR-transduced T cells at 5:1, 25:1, and 50:1 concentrations and overnight incubation. Supernatants were removed and analyzed for IL-2 and IFNγ secretion using the Human IFNγ or Human IL-2 ELISA Ready-SET-Go-Kit (eBioscience).

[0187] Orthotopic renal cell carcinoma model construction and CART cell therapy. 5 x 10 4 Passaged Skrc59 CAIX+ / PD-L1+ cells were suspended in 10 μL of culture medium, diluted 1:1 with Matrigel™ (Life Technologies), and injected into the left kidney capsule of 6-8 week-old male NSG mice (N=35). One week later, tumor engraftment was confirmed by bioluminescence (BLI) imaging using a Xenogen IVIS imaging system (Life Technologies). 1.0 x 107 of each CAR T cell (anti-BCMA CAR / anti-SARS IgG1, anti-CAIX CAR / anti-SARS IgG1, anti-CAIX CAR / anti-PD-L1 IgG1, and anti-CAIX CAR / anti-PD-L1 IgG4) or untransduced T cells were injected intravenously into the tail vein (day 0); N=6 mice per group. Tumor BLI was quantified 7, 14, 23, and 30 days after CAR T cell injection. 2.5 x 10 6A second injection of CAR or non-transduced T cells was administered on day 17. Mice were sacrificed 30 days after tumor implantation by standard CO2 inhalation, and tumors were collected and weighed. Kidney tumors from all mice were bisected, and one half was fragmented into small pieces and digested with 0.5 U / mL collagenase and 1.0 mg / mL DNAse for TIL extraction, which was analyzed by FACS for the expression of exhaustion markers and the percentage of CAR T cells. The other half was fixed in 10% buffered formaldehyde and subjected to immunohistochemistry for different markers. Two days before euthanasia, two mice from each group were injected with 4.5 x 106 NK cells. Tumor-resident NK cells were stained with APC-anti-CD56 Ab and analyzed by FACS. Animal experiments were performed in accordance with the guidelines of the DFCI Animal Care Committee.

[0188] Tumor formation and T cell therapy. In one experiment, given the immune rejection and rapid in vivo growth characteristics of sk-rc-52 in 6- to 8-week-old female BALB / c nude mice, 5 million cells were subcutaneously inoculated into the mice, collected, and expanded in vitro. This cell line was then passaged two more times in nude mice, and the passaged cells were expanded for further experiments (subclone 4-1). In therapeutic experiments, 5 million sk-rc-59 and 7.5 million passaged sk-rc-52 cells were subcutaneously inoculated into opposite flanks of nude mice to achieve comparable tumor growth rates. After 7 days, tumors grew to approximately 6 mm in size, and 50 million untransduced or transduced T cells were intravenously injected. The mice were also treated with 20,000 IU of human IL-2 via intraperitoneal injection every two days. Tumor size was measured bidimensionally with calipers, and the average diameter of two tumors is reported here. Animal experiments were conducted in accordance with the guidelines of the Dana Farber Cancer Institute Animal Care Committee. 3 When the tumor size reached 100 mg / kg, the mice were sacrificed and the tumors were collected.

[0189] Immunohistochemistry and immunofluorescence staining. For in vitro testing of transduced T cells, cultured T cells were washed twice with PBS and resuspended in 2 μM Far Red DDAO-SE CellTrasE dye (Molecular Probe) in PBS for 15 min at 37°C. Cells were then washed twice with culture medium and cytospun onto glass slides. CART cells co-expressing ZsGreen and pre-stained with Far Red were observed using a confocal microscope (Zeiss) at the Harvard NeuroDiscovery Center's Optical Imaging Core facility.

[0190] To test the killing effect of transduced T cells in the tumor bed in situ, tumors were prepared as frozen sections for use with the ApopTag Peroxidase In Situ Apoptosis Detection Kit (Millipore). Frozen sections were incubated with TdT enzyme (Millipore) for 1 hour. Rabbit anti-DIG (Dako) was added and incubated for 30 minutes, followed by Cy3-conjugated anti-rabbit antibody (Invitrogen) for 30 minutes. Sections were mounted with DAPI antifade mounting medium, and fluorescent images were examined using a confocal microscope.

[0191] Xenograft tumors and mouse spleens were collected, fixed in 10% formalin / PBS solution, and provided to the Harvard Medical School, Rodent Histopathology Core Facility. Before staining, paraffin-embedded sections were dewaxed with xylene and rehydrated through graded alcohols. Immunohistochemical staining was performed by incubating with anti-human granzyme B antibody (Dako, clone GrB-7 (1:200)) as the primary antibody for 1 hour, followed by incubation with secondary anti-rabbit antibody (Pierce) or anti-mouse antibody (Dako) for 30 minutes. Sections were developed with DAB substrate and counterstained with hematoxylin.

[0192] In one embodiment, fixed tumors were paraffin-embedded, sectioned at 4 micrometers, placed on slides, and prepared for IHQ. The tissues were stained with anti-human Ki67 (Vector, VP-K451), PD-L1 (Clone 405.9A11, produced in Dr. Gordon Freeman's laboratory), granzyme B (Abcam, ab4059), or NCAM (CD56) (Abcam, ab133345) antibodies, followed by secondary HRP-conjugated anti-rabbit Ab or HRP-avidin. Slides were developed with DAB and counterstained with hematoxylin. Images were captured under an Olympus BX51 microscope using a DP71 digital camera (Olympus) and analyzed with DP Controller Software (Olympus). Image quantification was performed using the IHC Profiler Plugin for ImageJ Software as described in Varghese F, Bukhari AB, Malhotra R, De A. IHC Profiler: an open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples. PloS one. 2014;9;e96801.

[0193] statistical analysis Statistical significance was determined using a two-tailed Student's t-test.

[0194] Statistical analyses for Figures 16-23 are representative of at least three experiments unless otherwise stated. Statistical significance of the data was assessed using ANOVA and Tukey post-hoc tests. P<0.05 was considered significant. Statistical analyses were performed using IBM SPSS Statistics software, version 20.

[0195] Example 2: Killing via ADCC of anti-CAIX antibodies and selection of CAR targeting moieties We previously reported a panel of high-affinity human anti-CAIX antibodies that differed in terms of their epitope mapping, expression levels, and ability to internalize CAIX. 23 Our first objective was to investigate the antitumor activity of five of these anti-CAIX single-chain antibodies as candidates for CAR construction. To test ADCC through anti-CAIX mAbs, we converted the scFvs into scFv-Fc (hIgG1) minibodies. 23 We found that all scFv-Fc exhibited antigen-specific tumor lysis. Specific lysis ranged from 40 to 57% for the tumor cell line sk-rc-09, which exhibits high CAIX+ expression, and 46 to 60% for the tumor cell line sk-rc-52, which exhibits moderate CAIX+ expression, against a background of <5% lysis for the CAIX- tumor cell line sk-rc-59. Negative control scFv-Fc, such as anti-CXCR4 48-Fc, also exhibited specific lysis. 23 and anti-SARS 11A-Fc 24 Only background levels of cell lysis were observed against scFvG36 (Figure 1). Based on ADCC killing and other reported analyses, scFvG36 was selected for further evaluation as a CAR targeting moiety.

[0196] Construction and expression of CAIX-specific chimeric receptors. Two generations of anti-CAIX CARs were constructed: a first-generation G36 CD8 CAR with scFv G36 linked to the truncated extracellular, hinge, and transmembrane domains and signaling domain of CD8, TCRζ (G36-CD8z). To deliver a costimulatory signal, a second-generation CD28 CAR was generated consisting of scFv G36 fused to the truncated extracellular, transmembrane, and intracellular domains of CD28 and the signaling domain of TCRζ (G36-CD28z) (Figure 2A). An unrelated second-generation CD28 CAR was generated by using an anti-HIV CCR5 (clone A8) scFv instead. 25To detect the expression of these constructs, a human rhodopsin C9 tag was inserted between the scFv and the CD8 or CD28 domain, respectively, followed by an IRES sequence followed by ZsGreen expression. Highly concentrated virus stocks with comparable levels were obtained among the different constructs, which were tested by cotransfection of the vector plasmids into 293T cells (data not shown).

[0197] For transduction, peripheral blood lymphocytes were stimulated for 3 days using PHA mitogen. Concentrated lentiviral supernatant was used to infect human primary T cells in the presence of the cationic reagent DEAE, which improves transduction rates by 1.5-2-fold compared to polybrene (data not shown). Transduction rates of primary T cells ranged from 17% to 45% as measured by ZsGreen expression in FACS analysis. A representative experiment demonstrating approximately 25% ZsGreen expression by primary CART cells after lentiviral transduction is shown in the left column of Figure 2B. CAIX-Fc fusion protein can bind to G36-CD8z and -CD28z CART cells, but not to control A8-CD28z CART cells (Figure 2B, center column). C9 tag expression was detected at approximately one-third the level of CAIX-Fc protein (Figure 2B, right column), which may be related to the finding that mAb 1D4 preferentially recognizes the rhodopsin nanopeptide C9 when presented as a carboxy-terminal polypeptide sequence relative to internal polypeptide sequences (data not shown). Transduced cells cultured in vitro for 6 weeks maintained their ZsGreen expression.

[0198] In Western blots under reducing conditions, the G36 and A8 CD28z CARs migrated at a molecular weight of approximately 53 kDa, compared with 16 kDa for endogenous TCRζ. The G36-CD8z CAR migrated at a molecular weight of approximately 48 kDa. Under non-reducing conditions, these two CD28z CARs formed homodimers (Figure 2C; data for CD8z CAR not shown).

[0199] Example 3: Enhanced cytokine secretion by transduced T cells upon contact with CAIX+ tumors We conducted a study to compare the reported superior efficacy of second-generation G36-CD28z CART cells, which incorporate the signaling element of the costimulatory molecule CD28 to circumvent MHC presentation and improve T cell effector function, with first-generation G36-CD8z CART cells. As shown in Figure 3A, after overnight incubation with CAIX+ sk-rc-52 cells, only low levels of type I cytokines IL-2, IFNγ, and IL-17 were observed in control A8 CD28z CART cells or LAK cells alone. In contrast, both first- and second-generation G36-expressing CART cells exhibited high levels of cytokine secretion, with second-generation G36-CD28z CART cells secreting greater amounts of type I cytokines than first-generation G36-CD8z CART cells, reflecting their higher activation state. Specifically, G36-CD28z CART cells secreted 6.5-fold, 2.3-fold, and 4-fold more IL-2, IFNγ, and IL-17, respectively, than G36-CD8z CART cells. The specificity of the induction of cytokine secretion by these two G36 CART cells is observed due to their minimal stimulation with CAIX-sk-rc-59 cells.

[0200] In Elispot studies, G36-CD28z CART cells became highly IFN-γ-producing cells after interaction with CAIX+ sk-rc-52 tumor cells (Figure 3B). Upon interaction with CAIX+ sk-rc-52 tumor cells, G36-CD28z CART cells generated 6-fold more spots than G36-CD8z CART cells and 12-fold more spots than those observed after interaction with CAIX- sk-rc-59 tumor cells. Similarly, G36-CD28z CART cells had more granzyme B-secreting spots after contact with CAIX+ tumor cells compared with G36-CD8z CART cells and control T cells. T cells stimulated with PMA and ionomycin produced the most IFN-γ- and granzyme B-secreting T cells. These studies demonstrate both the specificity and high productivity of G36-CD28z CART cells activated by contact with CAIX+ tumor cells.

[0201] Example 4: Specific cytotoxicity through CAR signaling in transduced T cells To further evaluate the killing activity of different G36 CART cells, an in vitro cytotoxicity assay was established. Using different effector-to-target ratios, G36-CD28z CART cells and their twice-in vivo passaged subclone 4-1 showed the most cytolysis of the CAIX tumor sk-rc-52 (Figure 3C). At a high effector-to-target ratio of over 25:1, G36-CD28z CART cells exhibited 2- to 3-fold higher cytotoxicity than G36-CD8z CART cells. At a low effector-to-target ratio of 5:1, G36-CD28z CART cells exhibited 8- to 9-fold higher lysis than G36-CD8z CART cells. However, G36-CD28z CART cells still exhibited good cytotoxicity, demonstrating greater than 60% tumor lysis, even at an effector-to-target ratio of 100:1. Irrelevant A8-CD28z CART cells and control T cell LAKs showed background nonspecific tumor lysis with approximately 20% lysis when using E:T ratios up to 100: 1. In all cases with CAIX-tumor sk-rc-59, both transduced and untransduced T cells showed background lysis.

[0202] Example 5: Improved in vitro proliferation of CART cells in the presence of long-term CAIX+ tumors Apart from enhanced cytokine secretion and cytotoxicity during short-term contact with CAIX+ tumor cells, the incorporation of the CD28 costimulatory molecule into the CAR constructs demonstrated improved proliferation during long-term contact with antigen-specific tumor cells. Untransduced and transduced (approximately 20%) T cells were mixed with freshly irradiated tumor cells weekly in the presence of 100 units / ml of human IL-2. To test different levels of antigen stimulation for a given amount of T cells, we used tumor cell-to-T cell ratios of 1:8, 1:4, and 1:2. T cell numbers were counted by trypan elimination, and the CAR cell fraction was examined by flow cytometry. The numbers of transduced and untransduced T cells were maintained in culture with CAIX- sk-rc-59 tumor cells (Figure 4A, bottom). The lack of baseline proliferation of control T cells is likely due to the high amounts of inhibitory cytokines secreted by the tumor cell line. In contrast, after 2 weeks of culture with CAIX+ sk-rc-52 tumor cells, at a 1:8 ratio, the population of G36-CD28z CART cells increased 30-fold, while G36-CD8z CART cells expanded 17-fold. At a 1:4 ratio, the number of G36-CD28z CART cells increased 19-fold, while G36-CD8z CART cells expanded 4-fold. Neither G36-CD28z nor G36-CD8z CART cells were able to proliferate in the presence of large amounts of tumor cells. Irrelevant A8-CD28z CART cells and control LAK T cells showed no proliferation in the presence of tumor cells (Figure 4A, top).

[0203] Proliferating T cells were also collected to examine their enrichment upon exposure to CAIX+ tumor cells. Exposure to CAIX- tumors did not alter the percentage of any CART cells within this population. However, exposure to CAIX+ sk-rc-52 tumor cells resulted in enrichment of both G36 CART cell populations. For G36-CD28z CART cells, the positive population was enriched from 18% on day 0 to 52% on day 8 and 88% on day 16. Expression of G36-CD8z CART cells was enriched from 19% on day 0 (similar to T cells alone) to 32% on day 8 and 72% on day 16. No expansion of A8-CD28z CART cells was observed during the 2-week study (Figure 4B). The percentage of CD8 cells remained constant throughout the 16-day study under all conditions (Figure 4C).

[0204] Example 6: Sustained effector function of CART cells after recontact with tumor Transduced T cells exposed to irradiated tumor cells for 1 or 2 weeks were also tested for cytokine secretion after 24 hours of exposure to fresh, non-irradiated tumor cells. After 1 or 2 weeks of exposure to CAIX+ tumors (sk-rc-52), G36-CD28z and G36-CD8z CART cells exhibited similar levels of IFN-γ secretion, although costimulatory signals via the G36-CD28z CAR resulted in 2- to 2.5-fold greater IFN-γ secretion than those observed with the G36-CD8z CAR (Table 1). Regarding IL-2 secretion, 2-week tumor exposure of G36-CD28z and G36-CD8z CART cells resulted in greater IL-2 secretion than 1-week exposure. G36-CD28z CART cells produced 5-fold more IL-2 than G36-CD8z CART cells after 1 week of exposure and 2.5-fold more IL-2 after 2 weeks of exposure. Additionally, G36-CD28z CART cells exposed to tumor cells for 2 weeks secreted 3.3-fold more IL-2 than those exposed to tumor cells for 1 week, and G36-CD8z CART cells secreted 6.8-fold more IL-2 after 2 weeks compared with 1 week of tumor exposure. These results indicate that the transduced CART cells were not exhausted and maintained functional activity after a second tumor challenge. Treatment of A8-CD28z, LAK, and G36 CART cells with CAIX-sk-rc59 cells resulted in background levels of IFN-γ and IL-2 secretion.

[0205] Example 7: Suppression of tumor formation by CART cells We next tested the ability of CART cells to inhibit tumor growth in nude mice inoculated with sk-rc-52 tumor cells in the left flank and sk-rc-59 tumor cells in the right flank, which were established to produce similar tumor curves. Seven days after tumor implantation, when typical tumor sizes were approximately 6x6 mm, 50 million G36-CD28z CART cells, A8-CD28z CART cells, or untransduced T cells (LAK) were injected intravenously. Adoptive T cell therapy was performed in two separate experiments, with group sizes of n=7 in the first study and n=8 in the second study, using high-dose IL-2 (2x10) administered intraperitoneally. 5To compare tumor growth and the effects of cell therapy, T cell treatment was not included.

[0206] In the first study, treated and untreated CAIX- sk-rc-59 tumors (within the four study groups) had a mean size of 6.09 ± 0.02 mm on day 4 and 9.29 ± 0.12 mm on day 25. They showed the same tumor growth rates in the control and T cell-treated groups. Untreated CAIX+ tumors that did not receive T cells showed tumor sizes similar to CAIX- tumors, with mean sizes of 6.09 ± 0.13 mm on day 4 and 9.15 ± 0.11 mm on day 25. However, tumor sizes in G36-CD28z CART cell-treated mice showed a statistically significant reduction in size compared with mice without T cell treatment at every time point examined during the 25-day study (Figure 5). G36-CD28z CART treatment also resulted in greater tumor size reductions than those seen in A8-CD28z CART cell and LAK-treated mice at days 7 (p<0.05) and 25 (p<0.001), as calculated by two-tailed t-tests. In a second study, tumor sizes in G36-CD28z CART cell-treated mice were significantly smaller than those in mice without T cell treatment throughout the 29-day experiment. G36-CD28z CART cell-treated mice also had smaller tumors than those seen in A8-CD28z CART cell and LAK-treated mice, p<0.01 from days 8 to 26 and p<0.001 at day 29 (Figure 5).

[0207] Partial regression of a CAIX+ tumor was considered when its tumor size was less than 30% of the volume of a control CAIX- tumor in the same mouse given the same T cells. Partial tumor regression was observed in a high percentage of cases using G36-CD28z CART cells (10 of 15 (67%)) but was minimal with the irrelevant target A8-CD28z CART cells (1 of 15 (7%)) and activated T cell LAK (2 of 15 (13%)) (Table 2). The frequency of partial regression responses was found to be statistically significant in mice treated with G36-CD28z CART cells versus control A8-CD28z CART cells and LAK, with p<0.001 and p<0.005 by Fisher's test, respectively.

[0208] Example 8: In situ cytotoxicity by CART cells Samples of the total population of transduced T cells used in the in vivo studies were pre-stained with Far Red dye, and CART cells expressing ZsGreen protein within that population were analyzed by confocal microscopy. These results, similar to our FACS analysis, indicated a transduction efficiency of approximately 30% (Figure 6A).

[0209] To provide evidence that treatment of CAIX+ sk-rc-52 tumor cells with G36-CD28z CART cells in vivo resulted in apoptotic death, tumor sections were stained by Tunnel assay. Three days after adoptive T cell treatment, Tunnel staining revealed apoptotic tumor cells (red) at the tumor margin (Figure 6B, bottom row) and within the tumor bed (Figure 6B, center row). Apoptotic tumor cells lost DAPI nuclear staining. A ZsGreen-expressing CART cell interacting with two apoptotic tumor cells is shown in the magnified graph (Figure 6B, bottom row).

[0210] Due to limitations of the fluorescent signal, ZsGreen-expressing CART cells could not be observed in gross tissue sections. Therefore, 3 days after treatment with G36-CD28z CART cells or LAK, tumors were harvested and sections were also stained with granzyme B antibody to identify activated T cells. In Figure 6C, dark brown staining areas indicate granzyme B+ T cells, which are observed infiltrating CAIX+ sk-rc-52 tumor sections (Figure 6C, upper left). These granzyme B+ T cells were observed at the periphery of the tumor (Figure 6C, upper left (a) and center) and within the tumor (Figure 6C, upper left (b) and bottom). Tumors with necrotic areas, as shown in the H&E-stained slides (indicated by n in Figure 6C, center right and bottom), are located near the granzyme B+ T cells. In contrast, CAIX+ sk-rc-52 tumors treated with control activated T cells (LAK) (Figure 7) did not exhibit granzyme B+ T cells. Similarly, CAIX- sk-rc-59 tumors treated with G36-CD28z CART cells (Figure 8) or LAK (Figure 9) showed low background staining, and the tumors were proliferative. As a positive control for granzyme B staining, CART cells were locally injected into established sk-rc-52 tumors in mice. One day later, the mice were sacrificed, and tumor tissue was excised for this staining (Figure 10).

[0211] Table 1. Cytokine secretion after 1 or 2 weeks of contact with tumor cells * TIFF2024163140000011.tif67152 * Transduced T cells were incubated with irradiated tumor cells for 1 or 2 weeks, then harvested, washed, and incubated overnight with fresh, non-irradiated tumor cells. After 24 hours, supernatants were collected for cytokine analysis. In T cell cultures that did not interact with tumor cells, only background levels of cytokines were detected: <50 pg / ml IFN-γ and <10 pg / ml IL-2.

[0212] Table 2. Frequency of partial regression of CAIX+ tumors with G36-CD28z CART cells TIFF2024163140000012.tif35152 Mice from the experiments reported in Figure 5 (experiment 1, n = 7 and experiment 2, n = 8) were scored for response on day 10. A partial response was defined as tumor regression to less than 30% of the volume of the control tumor (same T cell treatment in the same mouse bearing sk-rc-52 in the left flank and control tumor sk-rc-59 in the right flank). Fisher test results - * G36-CD28z vs. LAK; ** G36-CD28z vs. A8-CD28z; NS - no statistically significant relationship between the number of tumors and the partial response between LAK- and A8-CD28z-transduced T cells.

[0213] Example 9: Anti-carbonic anhydrase IX chimeric antigen receptor T cells releasing anti-PD-L1 antibodies reverse cellular exhaustion and regress renal cell carcinoma in a humanized mouse model Characterization of anti-CAIX CAR T cells secreting anti-PDL1 IgG1 or IgG4

[0214] To develop a novel CAR therapy for CAIX+ RCC, we engineered a bicistronic lentiviral vector to express an anti-CAIX (G36) scFv linked to CD28 and CD3-ζ signaling domains (G36-CD28z CAR in the first cassette and anti-PD-L1 IgG1 or IgG4 in the second expression cassette following an IRES site) (Figure 16A). The anti-PD-L1 IgG sequence was inserted into the lentiviral vector to prevent T cell exhaustion, which we anticipate may improve the efficacy of G36-CD28z CAR T cells (Figure 16B). As a control, we used an anti-CAIX CAR or anti-BCMA CAR containing an irrelevant anti-SARS IgG1 mAb in the second cassette. Lentiviruses generated from these constructs were transduced into CD8 T cells and cultured in the presence of IL-21, resulting in CART cells that exhibited slightly improved proliferation than observed with IL-2 (Figures 21A and 21B) while maintaining the same specific killing activity against CAIX+ RCC (Figures 21C and 21D). The percentages of CAIX and PD-L1 expression in all RCC lines used in our experiments are shown in Figure 22.

[0215] The function of CAR T cells is shown in Figure 23, where all CAR-transduced CD8 T cells were able to proliferate in the presence of IL-21 and anti-CD8 / CD28 beads (Figures 23A and 23B) and achieved transduction levels of 65–90% after 4 days (Figure 23C). Fourteen days after transduction, we assessed stable, long-term expression of the integrated lentiviral CARs (Figure 16C), which remained at approximately 25–50% for all CARs. Total IgG levels secreted by CD8 T cells were also determined, ranging from approximately 300–650 ng / mL after 4 days (Figure 16D). The binding specificity of anti-PD-L1 IgG1 and IgG4 antibodies to human PD-L1 was also confirmed (Figure 16E). The levels of biotinylated anti-PD-L1 IgG1 and IgG4 were significantly lower than total IgG, which could be explained by the fact that a portion of the IgG was lost during the purification process. The ability of anti-CAIX CART cells to undergo clonal expansion in the presence of CAIX+ RCC cells was confirmed (Figures 16F and 16G). Anti-CAIX CART cells are unable to significantly proliferate in the presence of CAIX- RCC cells.

[0216] Effector activity of anti-CAIX CART cells. All anti-CAIX CART cells were able to induce a 50-70% reduction in survival of Skrc59 CAIX+ / PD-L1+ cells, indicating that anti-PD-L1 IgG1 and IgG4 secreted by some CART cells did not increase cell death under these assay conditions (Figure 17A). Anti-CAIX CART cells induced IL-2 and IFNγ release in the presence of CAIX+ / PD-L1+ cells, indicating specific activation of anti-CAIX CART cells (Figures 17C and 17E, respectively). For anti-CAIX CART cells secreting anti-PD-L1 IgG, a unique differential effect was seen with the IgG1 isoform, which was able to induce approximately 60% ADCC in CAIX+ / PD-L1+ RCC cells when incubated with natural killer (NK) cells (Figure 17G). In the presence of CAIX- / PD-L1- cells, no effect on cell survival, cytokine secretion, or ADCC was observed for any of the CART cells (Figures 17B, 17D, 17F, and 17H).

[0217] Anti-CAIX CART cells secreting anti-PD-L1 antibodies can reduce T cell exhaustion in vitro. After induction of exhaustion, we found a 50% reduction in the exhaustion markers Lag-3, Tim3, and PD-1 in the anti-PD-L1 IgG1 and IgG4 anti-CAIX CART groups compared with parental anti-CAIX or irrelevant anti-BCMA CART cells (Figures 18A, 18B, and 18C, respectively). At this time point, the killing activity of anti-CAIX CART cells without anti-PD-L1 was retested in Skrc59 CAIX / PD-L1 cells. As can be seen in Figure 18D, anti-CAIX CART cells lost their killing activity against CAIX / PD-L1 RCC in vitro to a level similar to that of the irrelevant CAR group, confirming that the anti-CAIX CART cells were anergic. In contrast, RCC survival was reduced by 25–50% in the anti-CAIX CAR anti-PD-L1 IgG1 and IgG4 CART groups, thereby providing evidence that checkpoint blockade induced by the presence of secreted anti-PD-L1 IgG can reduce T-cell exhaustion.

[0218] Anti-CAIX CART cells secreting anti-PD-L1 antibodies can further reduce tumor growth in an orthotopic mouse model of human RCC. Using NSG mice, an orthotopic RCC model was established by injecting Skrc-59 CAIX+PD-L1+luciferase+ positive RCC cells under the kidney capsule, followed by an i.v. injection of 1.0x107 CART or non-transduced T cells on day 0 and a low dose (2.5x107) on day 17. 6Repeated treatments with the same cells (number of cells) were performed. We did not treat mice with systemic IL-2 to maintain CART cell proliferation to avoid any bias this molecule might have on tumor growth. The data in Figures 19A–19C demonstrate that all three CAIX CART cell groups exhibited reduced RCC growth compared with irrelevant BCMA CART cells or untransduced cells over the experimental period, and the significant antitumor effect of anti-CAIX CART cells secreting anti-PD-L1 IgG1 or IgG4 became evident on days 23 and 30 (Figures 19A and 19B). However, even 1 week after intravenous treatment with CART cells, we observed that tumors were 2–3 times smaller in the anti-PD-L1-secreting CART cells compared with the parental anti-CAIX CART cells and the two control groups (Figure 24A). We also analyzed the survival of CD45+ T cells in mouse blood to assess their survival in this passive transfer model. On day 8, we observed that the amount of human T cells in the PBMCs was only 10-15% (Figure 24B). For this reason, we decided to expand the CAR T cells in vitro for a second tail blood injection on day 17. One week after the second injection (day 23), the anti-PD-L1 IgG1 and IgG4 groups had tumors 15-fold smaller than the control group and 5-fold smaller than the anti-CAIX CAR T cells that do not secrete anti-PD-L1 (Figure 19C and Figure 24A). On day 30, the group of mice treated with CAR T cells secreting anti-PD-L1 antibodies had tumors 5-fold smaller than the control group (Figure 19C and Figure 24A). The weight of tumors excised from mice treated with CAR T cells secreting anti-PD-L1 antibodies was also lower, which was particularly noticeable in the anti-PD-L1 IgG4 antibody group (Figures 19B and 19D).

[0219] Analysis of tumor infiltration of CART cells and evidence that anti-CAIX CART cells secreting anti-PD-L1 antibodies can reverse T cell exhaustion. Analysis of resected tumors showed approximately 10% TILs in all groups (Figure 24C).

[0220] One of the most significant effects observed with anti-CAIX CAR cells secreting anti-PD-L1 IgG1 or IgG4 antibodies in vivo was their ability to reduce the expression of exhaustion markers PD-1, Tim-3, and Lag-3. As shown in Figure 20A, we observed an approximately 40–50% reduction in the expression of these markers in TILs compared to treatment with untransduced control cells at day 30. An approximately 30–70% reduction was also observed compared to anti-CAIX CAR cells that did not secrete anti-PD-L1 antibodies, providing evidence that locally secreted antibodies are effective in reducing T cell exhaustion.

[0221] The effector activity of CART cells in vivo and their influence on RCC growth were evaluated by immunohistochemical detection of granzyme B, the tumor proliferation marker Ki67, and the tumor immunosuppressive protein PD-L1 in TILs (Figures 20B and 20C). Granzyme B staining demonstrated the effector activity of CD8+ cells, indicated by an increased percentage of strongly positively stained cells, especially in RCC tumors treated with anti-CAIX CART cells secreting anti-PD-L1 IgG4 (Figures 20B and 20C). PD-L1 expression was dramatically reduced in tumors treated with anti-CAIX-CART cells, which was more pronounced in the anti-CAIX / anti-PD-L1 IgG-secreting group (Figures 20B and 20C). Ki67 expression was significantly reduced in the anti-CAIX / anti-PD-L1 IgG-secreting group, which can be visualized in the total DAB pixel count graph. However, when evaluating the intensity of positive nuclear staining (Ki67 IHC quantification graph), we note that anti-CAIX / anti-PD-L1 IgG4 showed the lowest intensity of Ki67 expression (Figures 20B and 20C). When quantifying nuclear proteins such as Ki67, the DAB staining pattern should be limited to the nucleus and the threshold function in ImageJ should be used to select the positively stained area for quantification. For this reason, negative cells are not present in the Ki67 IHC quantification graph (Figure 20C), and DAB pixel counts are also shown to evaluate total Ki67 staining, including negative cells (Figure 20C).

[0222] Anti-CAIX CART cells secreting anti-PD-L1 IgG1 antibody can direct NK cells to tumors. Tumors from mice treated with anti-CAIX / anti-PD-L1 IgG1, which received NK cell injections 2 days before euthanasia, showed 40% more intratumoral NK cells, as detected by anti-CD56 staining by FACS, compared with anti-BCMA / anti-SARS IgG1 (Figure 25A). Increased NK cells in the anti-CAIX / anti-PD-L1 IgG1 group were also detected and quantified by IHC (Figure 25B). Very few NK cells were also detected in the group treated with CART cells secreting nonspecific IgG1 Ab.

[0223] Other Aspects While the present invention has been described with reference to its detailed description, the above description is intended to be illustrative and not limiting on the scope of the invention, which is defined by the appended claims. Other aspects, advantages, and modifications are within the scope of the appended claims.

[0224] References TIFF2024163140000013.tif114148TIFF2024163140000014.tif210148TIFF20241631400 00015.tif217149TIFF2024163140000016.tif210148TIFF2024163140000017.tif203149 TIFF2024163140000018.tif203149TIFF2024163140000019.tif210149TIFF20241631400 00020.tif217148TIFF2024163140000021.tif210149TIFF2024163140000022.tif232148

[0225] Sequence information SEQUENCE LISTING <110> Dana-Farber Cancer Institute, Inc. <120> CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF <150> US 62 / 094,625 <151> 2014-12-19 <150> US 62 / 252,083 <151> 2015-11-06 <160> 1664 <170> PatentIn version 3.5 <210> 1 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 1 Gly Gly Pro Phe Ser Ser Tyr Ala 1 5 <210> 2 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 2 Gly Gly Ile Phe Ser Ser Tyr Ala 1 5 <210> 3 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 3 Gly Gly Thr Phe Ser Ser Tyr Ala 1 5 <210> 4 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 4 Gly Val Thr Phe Ser Ser Tyr Ala 1 5 <210> 5 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 5 Gly Val Thr Phe Ser Ser Tyr Ala 1 5 <210> 6 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 6 Gly Val Thr Phe Ser Ser Tyr Ala 1 5 <210> 7 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 7 Gly Gly Thr Phe Ser Ser Tyr Ala 1 5 <210> 8 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 8 Gly Gly Thr Phe Ser Ser Tyr Ala 1 5 <210> 9 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 9 Gly Gly Thr Phe Ser Ser Tyr Ala 1 5 <210> 10 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 10 Gly Val Thr Phe Ser Ser Tyr Ala 1 5 <210> 11 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 11 Gly Val Thr Phe Arg Ser Tyr Ala 1 5 <210> 12 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 12 Gly Gly Thr Phe Ser Ser Tyr Ala 1 5 <210> 13 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 13 Gly Gly Pro Phe Ser Ser Tyr Ala 1 5 <210> 14 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 14 Gly Gly Thr Phe Ser Ser Tyr Ala 1 5 <210> 15 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 15 Gly Gly Thr Phe Ser Ser Tyr Ala 1 5 <210> 16 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 16 Gly Val Thr Phe Ser Ser Tyr Ala 1 5 <210> 17 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 17 Gly Val Thr Phe Ser Ser Tyr Ala 1 5 <210> 18 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 18 Gly Val Thr Phe Ser Ser Tyr Ala 1 5 <210> 19 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 19 Gly Gly Pro Phe Ser Ser Tyr Ala 1 5 <210> 20 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 20 Gly Gly Pro Phe Ser Ser Tyr Ala 1 5 <210> 21 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 21 Gly Val Thr Phe Ser Ser Tyr Ala 1 5 <210> 22 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 22 Gly Gly Thr Phe Ser Ser Tyr Ala 1 5 <210> 23 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 23 Gly Gly Thr Phe Ser Ser Tyr Ala 1 5 <210> 24 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 24 Gly Val Thr Phe Ser Ser Tyr Ala 1 5 <210> 25 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 25 Gly Val Thr Phe Ser Ser Tyr Ala 1 5 <210> 26 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 26 Gly Val Thr Phe Ser Ser Tyr Ala 1 5 <210> 27 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 27 Gly Gly Thr Phe Ser Ser Tyr Ala 1 5 <210> 28 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 28 Gly Gly Ile Phe Ser Ser Tyr Ala 1 5 <210> 29 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 29 Gly Gly Thr Phe Ser Ser Tyr Ala 1 5 <210> 30 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 30 Gly Gly Thr Phe Ser Ser Tyr Ala 1 5 <210> 31 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 31 Gly Gly Thr Phe Ser Ser Tyr Ala 1 5 <210> 32 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 32 Gly Gly Thr Phe Ser Ser Tyr Ala 1 5 <210> 33 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 33 Gly Gly Thr Phe Ser Ser Tyr Ala 1 5 <210> 34 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 34 Gly Val Thr Phe Arg Ser Tyr Ala 1 5 <210> 35 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 35 Gly Gly Thr Phe Ser Ser Tyr Ala 1 5 <210> 36 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 36 Gly Val Thr Phe Ser Ser Tyr Ala 1 5 <210> 37 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 37 Ile Ser Pro Met Phe Gly Thr Ala 1 5 <210> 38 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 38 Ile Ser Pro Ile Phe Gly Thr Ala 1 5 <210> 39 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 39 Ile Ser Pro Ile Phe Gly Thr Ala 1 5 <210> 40 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 40 Ile Ser Pro Ile Phe Gly Thr Ala 1 5 <210> 41 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 41 Ile Met Pro Met Phe Gly Thr Ala 1 5 <210> 42 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 42 Ile Ser Pro Leu Phe Gly Thr Ala 1 5 <210> 43 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 43 Ile Ser Pro Ile Phe Gly Thr Ala 1 5 <210> 44 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 44 Ile Ser Pro Ile Phe Gly Thr Ala 1 5 <210> 45 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 45 Ile Ser Pro Met Phe Gly Thr Ala 1 5 <210> 46 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 46 Ile Ser Pro Ile Phe Gly Thr Ala 1 5 <210> 47 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 47 Ile Ser Gly Ile Phe Gly Thr Ala 1 5 <210> 48 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 48 Ile Ser Pro Met Phe Gly Thr Ala 1 5 <210> 49 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 49 Ile Ser Gly Ile Phe Gly Thr Ala 1 5 <210> 50 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 50 Ile Ser Pro Ile Phe Gly Thr Ala 1 5 <210> 51 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 51 Ile Ser Pro Ile Phe Gly Thr Ala 1 5 <210> 52 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 52 Ile Ser Pro Met Phe Gly Thr Ala 1 5 <210> 53 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 53 Ile Thr Pro Met Phe Gly Thr Ala 1 5 <210> 54 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 54 Ile Ser Pro Leu Phe Gly Thr Ala 1 5 <210> 55 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 55 Ile Ser Pro Met Phe Gly Thr Ala 1 5 <210> 56 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 56 Ile Ser Pro Leu Phe Gly Thr Ala 1 5 <210> 57 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 57 Ile Ser Pro Met Phe Gly Thr Ala 1 5 <210> 58 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 58 Ile Ser Pro Leu Phe Gly Thr Ala 1 5 <210> 59 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 59 Ile Ser Pro Ile Phe Gly Thr Ala 1 5 <210> 60 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 60 Ile Ser Pro Ile Phe Gly Thr Ala 1 5 <210> 61 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 61 Ile Ser Pro Leu Phe Gly Thr Ala 1 5 <210> 62 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 62 Ile Ser Pro Ile Phe Gly Thr Ala 1 5 <210> 63 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 63 Ile Ser Pro Met Phe Gly Thr Ala 1 5 <210> 64 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 64 Ile Ser Pro Ile Phe Gly Thr Ala 1 5 <210> 65 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 65 Ile Thr Pro Ile Phe Gly Thr Ala 1 5 <210> 66 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 66 Ile Ser Pro Ile Phe Gly Thr Ala 1 5 <210> 67 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 67 Ile Ile Pro Ile Phe Gly Thr Ala 1 5 <210> 68 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 68 Ile Thr Pro Met Phe Gly Thr Ala 1 5 <210> 69 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 69 Ile Ser Ala Met Phe Gly Thr Ala 1 5 <210> 70 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 70 Ile Ile Pro Ile Phe Gly Thr Ala 1 5 <210> 71 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 71 Ile Thr Pro Met Phe Gly Thr Ala 1 5 <210> 72 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 72 Ile Ser Pro Met Phe Gly Thr Ala 1 5 <210> 73 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 73 Ala Arg Asp Asp Gly Tyr Ala Pro Ser Gly Gly Leu Arg Glu Phe Asp 1 5 10 15 Val <210> 74 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 74 Ala Arg Gly Arg Gly Ala Tyr Met Gly Pro Ser Met Asp Val 1 5 10 <210> 75 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 75 Ala Arg Gly Ala Arg Tyr Tyr Ala Gly Gly Tyr Phe Asp Val 1 5 10 <210> 76 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 76 Ala Arg Asp Ser Gly Asn Tyr Asp Gly Tyr Gly Pro Gly Ser Arg Phe 1 5 10 15 Asp Val <210> 77 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 77 Ala Arg Glu Arg Gly Ser Trp Ser Phe Gly Tyr Phe Asp Val 1 5 10 <210> 78 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 78 Ala Arg Ser Arg Thr Tyr Ala Asp Gly Arg Thr Phe Asp Val 1 5 10 <210> 79 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 79 Ala Arg Glu Leu Gly Tyr Leu Ala Gly Ser Pro Ser Pro Gly Phe Asp 1 5 10 15 Tyr <210> 80 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 80 Ala Arg Ser Arg Arg Tyr Trp Ala Asp Gly Gly Phe Asp Tyr 1 5 10 <210> 81 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 81 Ala Arg Glu Gly Gly Tyr Ser Pro Gly Gly Val Asp Phe Asp Tyr 1 5 10 15 <210> 82 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 82 Ala Arg Gly Thr Thr Tyr Ser Thr Ala Arg Tyr Phe Asp Val 1 5 10 <210> 83 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 83 Ala Arg Ser Pro Ala Tyr Tyr Phe Gly Pro Asn Met Asp Val 1 5 10 <210> 84 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 84 Ala Arg Ser Ser Arg Tyr Ala Pro Ser Asp Ser Thr Asn Phe Asp Gln 1 5 10 15 <210> 85 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 85 Ala Arg Gly Asp Arg Phe Tyr Val Gly Glu Arg Phe Asp Val 1 5 10 <210> 86 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 86 Ala Arg Gly Gly Gly Val Gly Arg Ile Trp Ile Ala Gly Tyr Gly Phe 1 5 10 15 Asp Gln <210> 87 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 87 Ala Arg Gly Pro Gly Tyr His Pro Ala Gly Ala Ser Gly Gln Phe Phe 1 5 10 15 Asp Leu <210> 88 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 88 Ala Arg Gly Arg Gly Tyr Ala Pro Asp Ala Leu Thr Asn Phe Asp Val 1 5 10 15 <210> 89 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 89 Ala Arg Gly Arg Gly Tyr Ile Ala Val Ala Gly Asp Met Asp Val 1 5 10 15 <210> 90 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 90 Ala Arg Gly Asp Ala Tyr Tyr Val Gly Gly Gly Ala Arg Pro Phe Asp 1 5 10 15 Leu <210> 91 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 91 Ala Arg Gly Tyr Ser Tyr Tyr Pro Gly Gly Gly Gly Gly Arg Asn Phe 1 5 10 15 Asp Tyr <210> 92 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 92 Ala Arg Ala Pro Thr Tyr Tyr Ala Ser Arg Asp Ser Tyr Asn Phe Asp 1 5 10 15 Tyr <210> 93 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 93 Ala Arg Asp Thr Thr Tyr Ile Ala Gly Gly His Phe Asp Val 1 5 10 <210> 94 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 94 Ala Arg Ala Ser Gly Tyr Phe Thr Gly Trp Gly Thr Phe Asp Tyr 1 5 10 15 <210> 95 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 95 Ala Arg Gly Arg Tyr Tyr Tyr Thr Val Gly Val Tyr Asp Val 1 5 10 <210> 96 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 96 Ala Arg Gly Gly Gly Tyr Ser Ala Asp Gly Gly Ala Gly Asn Asn Thr 1 5 10 15 Ile Phe Asp Val 20 <210> 97 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 97 Ala Arg Glu Arg Gly Tyr Thr Val Gly Gly Gly Gly Met Asp Val 1 5 10 15 <210> 98 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 98 Ala Arg Glu Tyr Leu Gly Asp Asp Tyr Ser Ser Gly Ser Tyr Phe Asp 1 5 10 15 Val <210> 99 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 99 Ala Arg Glu Ser Gly Tyr Ser Gly Thr Gly Gln Phe Asp Val 1 5 10 <210> 100 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 100 Ala Arg Ser Gly Gly Tyr Tyr Asp Tyr Gly Val Gly Tyr Asp Gln 1 5 10 15 <210> 101 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 101 Ala Arg Ser Gly Gly Tyr Ser Pro Ser Ile Gly Gly Phe Asp Val 1 5 10 15 <210> 102 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 102 Ala Arg Gly Pro Gly Tyr Asp Pro Ser Ser Leu Arg Gly Phe Asp Val 1 5 10 15 <210> 103 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 103 Ala Arg Gly Glu Glu Ala Tyr Tyr Asp Leu 1 5 10 <210> 104 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 104 Ala Arg Gly Thr Ser Tyr Leu Pro Gly Arg Ser Gly Phe Asp Val 1 5 10 15 <210> 105 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 105 Ala Arg Gly Arg Gly Tyr Asp Pro Ser Val Gly Gly Phe Asp Val 1 5 10 15 <210> 106 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 106 Ala Arg Asp Ser Thr Pro Ser Val Thr Ser Ser Leu Tyr Arg Ile Pro 1 5 10 15 Ala Phe Asp Val 20 <210> 107 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 107 Ala Arg Gly Pro Gly Tyr Tyr Pro Asp Ser Asn Asn Tyr Asp Leu 1 5 10 15 <210> 108 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 108 Ala Arg Gly Gly Thr Tyr Ser Pro Gly Gly Thr Tyr Phe Asp Val 1 5 10 15 <210> 109 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 109 Arg Ser Val Leu Tyr Ser Ser Asn Asn Lys Asn Tyr 1 5 10 <210> 110 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 110 Asn Ile Gly Ser Lys Ser 1 5 <210> 111 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 111 Gln Thr Val Ser Asn Tyr 1 5 <210> 112 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 112 Ser Ser Asn Ile Gly Ser Asn Thr 1 5 <210> 113 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 113 His Ile Gly Ser Lys Ser 1 5 <210> 114 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 114 Ser Ser Asp Val Gly Gly Tyr Asn His 1 5 <210> 115 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 115 Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 <210> 116 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 116 Ser Ser Asn Met Gly Arg Asn Thr 1 5 <210> 117 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 117 Ser Gly Ser Ile Ala Ser Thr Tyr 1 5 <210> 118 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 118 Ser Gly Ser Ile Ala Ser Asn Tyr 1 5 <210> 119 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 119 Ser Ser Asn Ile Gly Ala Gly Tyr Asp 1 5 <210> 120 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 120 Ser Gly Ser Ile Ala Ser Asn Tyr 1 5 <210> 121 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 121 Asp Ile Gly Ser Lys Ser 1 5 <210> 122 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 122 Ser Gly Ser Val Ser Thr Ser Asn Tyr 1 5 <210> 123 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 123 Ser Asn Asn Val Gly Asn Gln Gly 1 5 <210> 124 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 124 Arg Ser Leu Phe Asp Ser Ser Asp Asn Lys Asn Tyr 1 5 10 <210> 125 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 125 Arg Ser Val Leu Tyr Ser Ser Asn Asn Lys Asn Tyr 1 5 10 <210> 126 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 126 Ser Ser Asn Ile Gly Val Asn Tyr 1 5 <210> 127 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 127 Ser Ser Asn Ile Gly Ser Asn Thr 1 5 <210> 128 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 128 Gln Ser Val Asp Arg Gly Tyr 1 5 <210> 129 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 129 Ser Ser Asp Ile Gly Ala Tyr Asn Tyr 1 5 <210> 130 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 130 Ala Leu Pro Lys Gln Tyr 1 5 <210> 131 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 131 Ser Asp Asn Val Gly Asn Gln Gly 1 5 <210> 132 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 132 Asn Asn Asn Val Gly Asn Gln Gly 1 5 <210> 133 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 133 Ser Ser Asp Val Gly Ala His Asn Phe 1 5 <210> 134 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 134 Gln Ser Val Asp Ser His 1 5 <210> 135 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 135 Thr Ser Asn Val Gly Arg Asn Thr 1 5 <210> 136 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 136 Arg Ser Asn Ile Gly Ser Asn Thr 1 5 <210> 137 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 137 Arg Ser Asn Ile Gly Arg Asn Thr 1 5 <210> 138 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 138 Ser Asn Asn Val Gly Asn Gln Gly 1 5 <210> 139 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 139 Gln Ser Val Ser Ser Phe 1 5 <210> 140 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 140 Ala Leu Pro Lys Gln Tyr 1 5 <210> 141 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 141 Ser Gly Ser Ile Ala Ser Asn Tyr 1 5 <210> 142 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 142 Asn Gly Pro Ser Asn Tyr Ile 1 5 <210> 143 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 143 Gln Ser Val Ser Ser Ser Tyr 1 5 <210> 144 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 144 Ser Ser Asn Ile Gly Val Ser Phe 1 5 <210> 145 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 145 Trp Ala Ser 1 <210> 146 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 146 Asp Asp Ser 1 <210> 147 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 147 Ala Ala Ser 1 <210> 148 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 148 Ser Asn Asn 1 <210> 149 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 149 Ser Asn Asn 1 <210> 150 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 150 Asp Val Ser 1 <210> 151 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 151 Glu Val Thr 1 <210> 152 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 152 Asp Asn Asp 1 <210> 153 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 153 Glu Asp His 1 <210> 154 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 154 Glu Asp Asn 1 <210> 155 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 155 Asp Asn Ser 1 <210> 156 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 156 Glu Asp Asn 1 <210> 157 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 157 Asp Asp Ile 1 <210> 158 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 158 Ser Thr Asn 1 <210> 159 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 159 Arg Asn Asn 1 <210> 160 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 160 Trp Ala Ser 1 <210> 161 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 161 Trp Ala Ser 1 <210> 162 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 162 Arg Asn Asn 1 <210> 163 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 163 Ser Asn Asn 1 <210> 164 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 164 Gly Ala Ser 1 <210> 165 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 165 Glu Val Ser 1 <210> 166 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 166 Lys Asp Ser 1 <210> 167 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 167 Arg Asp Asn 1 <210> 168 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 168 Arg Asn Asn 1 <210> 169 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 169 Glu Val Asn 1 <210> 170 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 170 Gly Ala Ser 1 <210> 171 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 171 Asn Asp Asn 1 <210> 172 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 172 Ser Asn Asn 1 <210> 173 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 173 Ser Asn Asn 1 <210> 174 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 174 Lys Asn Asn 1 <210> 175 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 175 Asp Ala Ser 1 <210> 176 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 176 Lys Asp Thr 1 <210> 177 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 177 Glu Asp Asn 1 <210> 178 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 178 Leu Asn Ser Asp Gly Ser His 1 5 <210> 179 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 179 Gly Ala Ser 1 <210> 180 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 180 Arg Asp Asp 1 <210> 181 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 181 Gln Gln Tyr Tyr Ser Gly Ser Trp Thr 1 5 <210> 182 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 182 Gln Val Trp Asp Arg Ser Ser Asp His Val Val 1 5 10 <210> 183 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 183 Gln Gln Tyr Asp Asn Leu Pro Pro Val Thr 1 5 10 <210> 184 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 184 Ser Ala Trp Asp Asp Ser Leu Gly Gly Glu Val 1 5 10 <210> 185 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 185 Gln Val Trp Asp Ser Ser Asn Asp His Pro Val 1 5 10 <210> 186 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 186 Thr Ser Tyr Ala Gly Ser Asn Ser Leu Val 1 5 10 <210> 187 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 187 Ser Ser Tyr Ala Gly Gly Lys Trp Val 1 5 <210> 188 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 188 Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Val 1 5 10 <210> 189 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 189 Gln Ser Phe Asp Ala Ser Thr Leu Val 1 5 <210> 190 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 190 Gln Ser Tyr Asp Ser Asp Asn His Glu Val Ile 1 5 10 <210> 191 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 191 Gln Ser Tyr Asp Ser Ser Leu Ser Val Val Val 1 5 10 <210> 192 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 192 Gln Ser Tyr Asp Thr Ser Asn Arg Lys Val 1 5 10 <210> 193 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 193 Gln Val Trp Asp Thr Asn Ser Asp Pro Val Phe Val 1 5 10 <210> 194 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 194 Val Leu Tyr Met Gly Ser Gly Ile Ser Met 1 5 10 <210> 195 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 195 Ser Ala Trp Asp Ser Ser Leu Ser Ala Trp Val 1 5 10 <210> 196 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 196 Gln Gln Tyr Phe Ser Ser Pro Pro Ile Phe Thr 1 5 10 <210> 197 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 197 Gln Gln Tyr Tyr Ser Thr Pro Pro Thr 1 5 <210> 198 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 198 Gly Val Trp Asp Asp Ser Leu Asn Gly His Trp Val 1 5 10 <210> 199 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 199 Ala Ala Trp Asp Asp Ser Leu Lys Gly Arg Val 1 5 10 <210> 200 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 200 Gln Gln Tyr Gly Ser Ser Arg Leu Ser 1 5 <210> 201 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 201 Ser Ser Tyr Ala Gly Ser Asn Asn Val Val 1 5 10 <210> 202 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 202 Gln Ala Trp Asp Ser Ser Thr Ala Val 1 5 <210> 203 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 203 Ser Ala Trp Asp Ser Ser Leu Thr Ala Val Val 1 5 10 <210> 204 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 204 Ser Ala Trp Asp Ser Ser Leu Ser Ala Trp Val 1 5 10 <210> 205 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 205 Ala Ala Trp Asp Asp Ser Leu Asp Gly Pro Val 1 5 10 <210> 206 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 206 Gln Gln Arg Ser Met Trp Pro Leu Thr 1 5 <210> 207 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 207 Ser Ser Trp Asp Asp Asp Leu Asn Gly Pro Val 1 5 10 <210> 208 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 208 Gln Ser Tyr Asp Ser Ser Val Val 1 5 <210> 209 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 209 Ala Ala Trp Asp Val Ser Leu Asn Gly Gln Val 1 5 10 <210> 210 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 210 Ser Ala Trp Asp Ser Ser Leu Ser Asp Trp Val 1 5 10 <210> 211 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 211 Gln Gln Arg Phe Asn Trp Pro Pro Thr 1 5 <210> 212 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 212 Gln Ser Ala Asp Ala Ser Glu Asn Ser Val 1 5 10 <210> 213 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 213 Gln Ser Tyr Asp Thr Ser Asn Leu Val 1 5 <210> 214 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 214 Glu Thr Trp Asp Ser Asn Thr His Val Val 1 5 10 <210> 215 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 215 Gln Gln Val Asn Ser Phe Pro Arg Thr 1 5 <210> 216 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 216 Ser Ala Trp Asp Glu Ser Leu Ser Ser Val Leu 1 5 10 <210> 217 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 217 Gly Gly Thr Phe Ser Ser Tyr Ala 1 5 <210> 218 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 218 Gly Val Thr Phe Ser Ser Tyr Ala 1 5 <210> 219 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 219 Gly Gly Thr Phe Ser Ser Tyr Ala 1 5 <210> 220 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 220 Gly Gly Ile Phe Ser Ser Tyr Ala 1 5 <210> 221 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 221 Gly Val Ile Phe Ser Ser Tyr Ala 1 5 <210> 222 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 222 Gly Gly Thr Phe Ser Ser Tyr Ala 1 5 <210> 223 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 223 Gly Gly Thr Phe Ser Ser Tyr Ala 1 5 <210> 224 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 224 Gly Gly Pro Phe Arg Ser Tyr Ala 1 5 <210> 225 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 225 Gly Val Pro Phe Ser Ser Tyr Ala 1 5 <210> 226 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 226 Gly Val Thr Phe Ser Ser Tyr Ala 1 5 <210> 227 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 227 Gly Val Ile Phe Ser Ser Tyr Ala 1 5 <210> 228 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 228 Gly Val Thr Phe Ser Ser Tyr Ala 1 5 <210> 229 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 229 Gly Gly Thr Phe Ser Ser Tyr Ala 1 5 <210> 230 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 230 Gly Gly Thr Phe Ser Ser Tyr Ala 1 5 <210> 231 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 231 Gly Gly Pro Phe Ser Ser Tyr Ala 1 5 <210> 232 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 232 Gly Gly Ile Phe Ser Ser Tyr Ala 1 5 <210> 233 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 233 Gly Gly Ile Phe Arg Ser Tyr Ala 1 5 <210> 234 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 234 Gly Gly Thr Phe Ser Ser Tyr Ala 1 5 <210> 235 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 235 Gly Val Thr Phe Ser Ser Tyr Ala 1 5 <210> 236 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 236 Gly Gly Thr Phe Ser Ser Tyr Ala 1 5 <210> 237 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 237 Gly Gly Thr Phe Arg Ser Tyr Ala 1 5 <210> 238 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 238 Gly Gly Thr Phe Ser Ser Tyr Ala 1 5 <210> 239 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 239 Gly Gly Pro Phe Ser Ser Tyr Ala 1 5 <210> 240 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 240 Gly Val Thr Phe Ser Ser Tyr Ala 1 5 <210> 241 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 241 Gly Gly Thr Phe Ser Ser Tyr Ala 1 5 <210> 242 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 242 Gly Val Thr Phe Arg Ser Tyr Ala 1 5 <210> 243 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 243 Gly Gly Thr Phe Ser Ser Tyr Ala 1 5 <210> 244 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 244 Gly Val Thr Phe Ser Ser Tyr Ala 1 5 <210> 245 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 245 Gly Gly Pro Phe Ser Ser Tyr Ala 1 5 <210> 246 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 246 Gly Gly Ile Phe Ser Ser Tyr Ala 1 5 <210> 247 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 247 Ile Ile Thr Ile Phe Gly Thr Ala 1 5 <210> 248 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 248 Ile Ser Pro Ile Phe Gly Thr Ala 1 5 <210> 249 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 249 Ile Ser Ala Ile Phe Gly Thr Ala 1 5 <210> 250 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 250 Ile Thr Pro Ile Phe Gly Thr Ala 1 5 <210> 251 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 251 Ile Ser Pro Ile Phe Gly Thr Ala 1 5 <210> 252 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 252 Ile Ser Pro Ile Phe Gly Thr Ala 1 5 <210> 253 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 253 Ile Ile Thr Ile Phe Gly Thr Ala 1 5 <210> 254 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 254 Ile Ile Pro Ile Phe Gly Thr Ala 1 5 <210> 255 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 255 Ile Ser Pro Leu Phe Gly Thr Ala 1 5 <210> 256 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 256 Ile Ser Pro Met Phe Gly Thr Ala 1 5 <210> 257 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 257 Ile Ile Pro Ile Phe Gly Thr Ala 1 5 <210> 258 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 258 Ile Ser Pro Val Phe Gly Thr Ala 1 5 <210> 259 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 259 Ile Val Pro Leu Phe Gly Thr Ala 1 5 <210> 260 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 260 Ile Ile Pro Ile Phe Gly Thr Ala 1 5 <210> 261 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 261 Ile Ser Pro Ile Phe Gly Thr Ala 1 5 <210> 262 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 262 Ile Ser Ala Ile Phe Gly Thr Ala 1 5 <210> 263 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 263 Ile Ile Pro Met Phe Gly Thr Ala 1 5 <210> 264 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 264 Ile Asn Pro Ile Phe Gly Thr Ala 1 5 <210> 265 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 265 Ile Ser Pro Met Phe Gly Thr Ala 1 5 <210> 266 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 266 Ile Thr Pro Leu Phe Gly Thr Ala 1 5 <210> 267 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 267 Ile Met Pro Ile Phe Gly Thr Ala 1 5 <210> 268 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 268 Ile Ser Pro Met Phe Gly Thr Ala 1 5 <210> 269 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 269 Ile Ile Pro Ile Phe Gly Thr Ala 1 5 <210> 270 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 270 Ile Thr Pro Ile Phe Gly Thr Ala 1 5 <210> 271 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 271 Ile Ser Pro Met Phe Gly Thr Ala 1 5 <210> 272 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 272 Ile Ser Gly Ile Phe Gly Thr Ala 1 5 <210> 273 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 273 Ile Ser Pro Ile Phe Gly Thr Ala 1 5 <210> 274 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 274 Ile Ser Pro Met Phe Gly Thr Ala 1 5 <210> 275 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 275 Ile Ser Pro Met Phe Gly Thr Ala 1 5 <210> 276 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 276 Ile Ser Pro Ile Phe Gly Thr Ala 1 5 <210> 277 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 277 Ala Arg Gly Ala Thr Gly Phe Tyr Asp Val 1 5 10 <210> 278 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 278 Ala Arg Gly Arg Glu Tyr Tyr Ala Ser Asn Gly Asp Ser Phe Asp Val 1 5 10 15 <210> 279 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 279 Ala Arg Asp Leu Ser Arg Asp Ser Leu Asn Leu Pro Gly Ser Ser Pro 1 5 10 15 Gly Tyr Asp Leu 20 <210> 280 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 280 Ala Arg Gly Ser Gly Tyr Tyr Val Ala Ala Ser Gly Ala Phe Asp Val 1 5 10 15 <210> 281 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 281 Ala Arg Ser Arg Gly Tyr Ala Pro Gly Thr Ser Phe His Tyr Asp Val 1 5 10 15 <210> 282 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 282 Ala Arg Asp Gln Gly Gly Thr Arg Gly Asn Tyr Phe Asp Val 1 5 10 <210> 283 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 283 Ala Arg Gly Gly Gly Gly Arg Phe Asp Val 1 5 10 <210> 284 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 284 Ala Arg Gly Gly Val Tyr Ser Phe Asp Val 1 5 10 <210> 285 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 285 Ala Arg Gly Leu Gly Thr Tyr Ser Pro Ser Leu Tyr Pro Arg Gly Met 1 5 10 15 Asp Val <210> 286 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 286 Ala Arg Gly Arg Ala Tyr Leu Ser Val Arg Gly Ser Phe Asp Val 1 5 10 15 <210> 287 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 287 Ala Arg Gly Gly Ser Gly Ser Phe Asp Val 1 5 10 <210> 288 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 288 Ala Arg Ser Arg Gly Tyr Thr Val Ser Ser Leu Ala Gly Arg Tyr Phe 1 5 10 15 Asp Gln <210> 289 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 289 Ala Arg Gly Leu Gly Leu Tyr Phe Asp Val 1 5 10 <210> 290 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 290 Ala Arg Val Arg Gly Gly Tyr Gly Pro Tyr Gly Asp Phe Asp Val 1 5 10 15 <210> 291 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 291 Ala Arg Gly Arg Ser Tyr Ile Val Ser Val Ser Pro Gly Phe Asp Val 1 5 10 15 <210> 292 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 292 Ala Arg Asp Ser Gly Ile Ala Ser Gly Tyr Thr Ala Tyr Met Asp Tyr 1 5 10 15 <210> 293 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 293 Ala Arg Gly Ala Gly Ser Thr Phe Asp Val 1 5 10 <210> 294 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 294 Ala Arg Gly Glu Ser Ala Tyr Tyr Ser Arg Asn Tyr Asp Val 1 5 10 <210> 295 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 295 Ala Arg Gly Gly Gly Tyr Tyr Pro Ala Gly Val Gly Arg Tyr Asp Val 1 5 10 15 <210> 296 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 296 Ala Arg Gly Pro Thr Leu Tyr Ser Pro Pro Val Phe Asp Val 1 5 10 <210> 297 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 297 Ala Arg Gly Ala Gly Val Ser Ala Gly Pro Ser Trp Pro Phe Asp Val 1 5 10 15 <210> 298 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 298 Ala Arg Ser Arg Gly Tyr Asn Val Ala Ala Ser Phe Gly Phe Asp Val 1 5 10 15 <210> 299 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 299 Ala Arg Gly Thr Asp Tyr Ser Gly Tyr Arg Gly Phe Asp Val 1 5 10 <210> 300 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 300 Ala Arg Gly Gly Gly Val Phe Asp Val 1 5 <210> 301 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 301 Ala Arg Glu Gly Gly Tyr Ser Pro Gly Gly Val Asp Phe Asp Tyr 1 5 10 15 <210> 302 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 302 Ala Arg Ser Pro Ala Tyr Tyr Phe Gly Pro Asn Met Asp Val 1 5 10 <210> 303 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 303 Ala Arg Gly Pro Gly Tyr His Pro Ala Gly Ala Ser Gly Gln Phe Phe 1 5 10 15 Asp Leu <210> 304 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 304 Ala Arg Gly Arg Gly Tyr Ala Pro Asp Ala Leu Thr Asn Phe Asp Val 1 5 10 15 <210> 305 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 305 Ala Arg Gly Tyr Ser Tyr Tyr Pro Gly Gly Gly Gly Gly Arg Asn Phe 1 5 10 15 Asp Tyr <210> 306 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 306 Ala Arg Ser Gly Gly Tyr Tyr Asp Tyr Gly Val Gly Tyr Asp Gln 1 5 10 15 <210> 307 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 307 Ser Ser Asn Ile Gly Ser Asn Thr 1 5 <210> 308 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 308 Asn Ile Ala Thr Lys Ser 1 5 <210> 309 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 309 Asn Ile Ala Thr Lys Ser 1 5 <210> 310 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 310 Ile Asn Asn Val Gly Asp Gln Gly 1 5 <210> 311 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 311 Asn Ile Gly Ser Lys Ser 1 5 <210> 312 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 312 Ser Asn Asn Val Gly Asn Gln Gly 1 5 <210> 313 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 313 Thr Ser Asn Ile Gly Asn Asn Ala 1 5 <210> 314 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 314 Gly Ser Asn Val Gly Ser Asn Val 1 5 <210> 315 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 315 Ser Ser Asn Ile Gly Arg Asn Asp 1 5 <210> 316 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 316 Ser Ser Asn Ile Gly Ser Asn Thr 1 5 <210> 317 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 317 Ser Ser Asn Leu Gly Ser Asn Tyr 1 5 <210> 318 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 318 Glu Ser Leu Cys Ser Thr Cys 1 5 <210> 319 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 319 Thr Gly Ala Val Thr Ser Gly Tyr Tyr 1 5 <210> 320 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 320 Ser Ser Asn Ile Gly Ser His Ser 1 5 <210> 321 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 321 Ser Ser Asp Val Gly Gly Tyr Asn Tyr 1 5 <210> 322 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 322 Ser Leu Arg Thr Ser Tyr 1 5 <210> 323 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 323 Ser Ser Asn Ile Gly Ser Asn Thr 1 5 <210> 324 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 324 Ser Ser Asn Val Gly Asn Gln Gly 1 5 <210> 325 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 325 Gln Asn Val Leu Tyr Ser Ser Asn Asn Lys Asn Asn 1 5 10 <210> 326 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 326 Ser Gly Ser Val Ser Thr Thr Asn Tyr 1 5 <210> 327 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 327 Ser Asn Asn Val Gly Lys Gln Gly 1 5 <210> 328 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 328 Gln Tyr Ile Asp Arg Ser 1 5 <210> 329 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 329 Ser Gly Ser Val Ser Ser Phe Asn Tyr 1 5 <210> 330 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 330 Ser Ser Asn Ile Gly Asn Asn Ala 1 5 <210> 331 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 331 Ser Gly Ser Ile Ala Ser Thr Tyr 1 5 <210> 332 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 332 Ser Ser Asn Ile Gly Ala Gly Tyr Asp 1 5 <210> 333 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 333 Ser Asn Asn Val Gly Asn Gln Gly 1 5 <210> 334 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 334 Arg Ser Leu Phe Asp Ser Ser Asp Asn Lys Asn Tyr 1 5 10 <210> 335 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 335 Ser Ser Asn Ile Gly Ser Asn Thr 1 5 <210> 336 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 336 Arg Ser Asn Ile Gly Ser Asn Thr 1 5 <210> 337 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 337 Ser Asn Asn 1 <210> 338 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 338 His Asp Ser 1 <210> 339 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 339 Arg Asn Ser 1 <210> 340 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 340 Gly Ala Ser 1 <210> 341 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 341 Tyr Asp Ser 1 <210> 342 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 342 Arg Asn Asn 1 <210> 343 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 343 Ser Leu Asn 1 <210> 344 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 344 Arg Asn Asn 1 <210> 345 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 345 Gly Arg Asp 1 <210> 346 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 346 Ser Asn Asn 1 <210> 347 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 347 Arg Asn Ser 1 <210> 348 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 348 Gly Ala Thr 1 <210> 349 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 349 Ser Thr Ser 1 <210> 350 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 350 Gly Asn Ser 1 <210> 351 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 351 Glu Val Ser 1 <210> 352 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 352 Gln Ser Thr 1 <210> 353 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 353 Ser Asn Asn 1 <210> 354 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 354 Arg Asn Asp 1 <210> 355 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 355 Trp Ala Ser 1 <210> 356 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 356 Asn Thr Asn 1 <210> 357 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 357 Arg Asn Asn 1 <210> 358 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 358 Tyr Ala Ser 1 <210> 359 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 359 Asn Thr Asn 1 <210> 360 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 360 Tyr Asp Asp 1 <210> 361 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 361 Glu Asp His 1 <210> 362 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 362 Asp Asn Ser 1 <210> 363 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 363 Arg Asn Asn 1 <210> 364 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 364 Trp Ala Ser 1 <210> 365 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 365 Ser Asn Asn 1 <210> 366 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 366 Ser Asn Asn 1 <210> 367 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 367 Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Val 1 5 10 <210> 368 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 368 Ala Ala Trp Asp Asp Ser Leu Ser Gly Pro Trp Val 1 5 10 <210> 369 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 369 Ser Ala Trp Asp Ser Ser Leu Ser Asp Trp Val 1 5 10 <210> 370 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 370 Gln Gln Tyr Ser Ser Ser Pro Tyr Thr 1 5 <210> 371 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 371 Gln Leu Trp Asp His Thr Asn Ser His Val Val 1 5 10 <210> 372 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 372 Ser Ala Trp Asp Asn Thr Val Ser Gly Trp Val 1 5 10 <210> 373 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 373 Glu Ala Trp Asp Asp Ser Leu Ser Gly Pro Val 1 5 10 <210> 374 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 374 Ala Ala Trp Asp Asp Arg Leu Asn Gly Phe Val 1 5 10 <210> 375 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 375 Ala Ala Trp Asp Ala Ser Leu Met Ile Tyr Val 1 5 10 <210> 376 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 376 Ala Ala Trp Asp Asp Ser Leu Asn Gly Tyr Val 1 5 10 <210> 377 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 377 Ala Ala Trp Asp Asp Ser Leu Asn Gly Val Val 1 5 10 <210> 378 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 378 Gln Gln Tyr Gly Ser Ser Pro Gln Thr 1 5 <210> 379 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 379 Leu Leu Tyr Tyr Gly Gly Pro Trp Val 1 5 <210> 380 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 380 Ala Ala Trp Asp Asp Gly Leu Ser Gly Trp Val 1 5 10 <210> 381 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 381 Ala Ser Trp Asp Asp Ser Leu Asn Ala Tyr Val 1 5 10 <210> 382 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 382 Asn Ser Arg Gly Ser Gly Gly Asn Pro Tyr Val 1 5 10 <210> 383 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 383 Ala Ala Trp Asp Asp Ser Leu Asn Gly Arg Val 1 5 10 <210> 384 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 384 Ser Ala Trp Asp Asn Ser Leu Ser Ala Trp Val 1 5 10 <210> 385 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 385 Gln Gln Tyr Tyr Gly Lys Pro Phe Thr 1 5 <210> 386 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 386 Val Leu Tyr Met Gly Arg Gly Ile Tyr Val 1 5 10 <210> 387 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 387 Ser Ala Trp Asp Ser Ser Leu Ser Val Trp Val 1 5 10 <210> 388 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 388 His Gln Thr Ser Ser Leu Pro Trp Thr 1 5 <210> 389 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 389 Ala Leu Tyr Val Gly Gly Gly Ile Ser Val 1 5 10 <210> 390 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 390 Ala Ala Trp Asp Asp Ser Leu Ser Gly Pro Val 1 5 10 <210> 391 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 391 Gln Ser Phe Asp Ala Ser Thr Leu Val 1 5 <210> 392 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 392 Gln Ser Tyr Asp Ser Ser Leu Ser Val Val Val 1 5 10 <210> 393 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 393 Ser Ala Trp Asp Ser Ser Leu Ser Ala Trp Val 1 5 10 <210> 394 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 394 Gln Gln Tyr Phe Ser Ser Pro Pro Ile Phe Thr 1 5 10 <210> 395 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Polypeptide <400> 395 Ala Ala Trp Asp Asp Ser Leu Lys Gly Arg Val 1 5 10 <210> 396 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> ...

Claims

1. A chimeric antigen receptor (CAR) that contains an intracellular signaling domain, a transmembrane domain, and an extracellular domain.

2. The CAR of claim 1, wherein the transmembrane domain further comprises a stalk region located between the extracellular domain and the transmembrane domain.

3. The CAR of claim 1, wherein the transmembrane domain comprises CD28.

4. The CAR of claim 1, further comprising one or more additional costimulatory molecules located between the transmembrane domain and the intracellular signaling domain.

5. The CAR of claim 4, wherein the costimulatory molecule is CD28, 4-1BB, ICOS, or OX40.

6. The CAR of claim 1, wherein the intracellular signaling domain comprises a CD3 zeta chain.

7. The CAR of claim 1, wherein the extracellular domain is an antibody.

8. The CAR of claim 7, wherein the antibody is a Fab or scFV.

9. The CAR of claim 7, wherein the antibody is specific to BCMA, CD138, CCR4, PD-1, PDL-1, PD-L2, CXCR4, GITR, SARS virus, Flavivirus, MERS virus, influenza virus, or CAIX.

10. The nucleic acid encoding the CAR of any one of the preceding claims, further comprising a nucleic acid encoding a polypeptide located after the intracellular signaling domain.

11. The nucleic acid of claim 10, wherein the polypeptide is an antibody.

12. The nucleic acid of claim 11, wherein the antibody is an scFV.

13. 13. The nucleic acid of claim 12, wherein the antibody is specific to BCMA, CD138, CCR4, PD-1, PDL-1, PD-L2, CXCR4, GITR, SARS virus, Flavivirus, MERS virus, influenza virus, or CAIX.

14. A vector comprising the nucleic acid according to any one of claims 11 to 13.

15. A cell comprising the vector of claim 14.

16. A genetically engineered cell that expresses the chimeric antigen receptor of any one of claims 1 to 9 and retains it on its cell surface membrane.

17. 17. The genetically engineered cell of claim 16, which is a T cell or a NK cell.

18. T cells are CD4 + or CD8 + 20. The genetically engineered cell of claim 17,

19. CD4 + Cells and CD8 cells + 20. The genetically engineered cell of claim 18, comprising a mixed population of:

20. 17. The cell of claim 16, further engineered to express and secrete the polypeptide.

21. The cell of claim 20, wherein the expressed and secreted polypeptide is anti-PDL-1.

Citation Information

Patent Citations

  • Bispecific chimeric antigen receptors and therapeutic uses thereof

    WO2013123061A1

  • Compositions and methods for immunotherapy

    WO2014134165A1

  • Compositions and methods for treatment of cancer

    WO2017075537A1